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ABSTRACT 
Health economic evaluations are a systematic method of measuring and valuing the costs 
and effects of different health interventions. The cost-effectiveness of vaccines is particularly 
difficult to measure, as they are generally complicated by the infectious nature of the diseases. 
Using a scoping review framework, we gathered, summarised and described the evolution of 
published economic evaluations of vaccines in Canada. In recent years there has been a 
consistent increase in vaccine cost-effectiveness studies in Canada, with more studies adhering to 
Canadian economic evaluation guidelines. However, the two Canadian cost-effectiveness studies 
looking at universal chickenpox vaccination were conducted prior to the implementation of the 
program in Canada, and with limited knowledge of the actual cost or effectiveness of the 
vaccine. 
 We built an agent-based model (ABM) to aid in the understanding of chickenpox and 
shingles disease dynamics, to measure the cost-effectiveness of chickenpox vaccination and to 
help guide health policy decision-making. Chickenpox is a childhood disease caused by 
varicella-zoster virus (VZV), which can reactivate as shingles in adulthood. While natural 
waning of VZV cell-mediated immunity (CMI) can lead to shingles reactivation, one theory 
posits contact with a shingles or chickenpox case may boost an individual’s VZV-CMI (i.e. 
exogenous boosting), offering protection from shingles. Using the ABM, we tested several 
quantitative theories of VZV boosting, as well as the impact of chickenpox vaccination on 
shingles epidemiology. Our model highlighted the importance of not only knowing when, and if, 
the VZV exogenous boosting events occur but the duration an individual remains immune 
following a boosting event. 
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In Canada, there are eight different schedules, including diverse types of vaccines, ages 
of administration, number of doses for the chickenpox vaccine. Using the ABM we were able to 
test the effectiveness and cost-effectiveness of two main chickenpox vaccine schedules (schedule 
1- MMRV at 12 months and 4-6 years; schedule 2- MMRV at 12 months and 18 months). We 
found differences in effectiveness and costs between the two schedules were relatively minor, 
suggesting other considerations, such as the current vaccine strategy and public preference may 
play a bigger role in determining the most appropriate chickenpox vaccination schedule.  
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CHAPTER 1- INTRODUCTION 
Chickenpox is generally a self-limiting childhood disease caused by varicella-zoster virus 
(VZV). Following primary infection VZV can remain latent in the sensory ganglia for future 
reactivation as shingles. Reactivation of VZV is generally associated with a decrease of VZV 
cell-mediated immunity (CMI) (i.e. waning of natural immunity) due to aging and senescence. In 
parallel to the natural waning of VZV-CMI immunity, one theory posits boosting of immunity 
occurs on contact with a chickenpox or shingles infected individual (exogenous boosting) and 
this process may limit shingles reactivation. One area of interest is the association between 
chickenpox vaccine and shingles disease, especially as previous models have predicted a sharp 
increase in shingles incidence rates following the implementation of universal chickenpox 
vaccination and therefore the reduction of natural VZV boosting. Flexible and complex models 
like agent-based models (ABM) offer a platform to test research questions related to chickenpox 
vaccination and shingles, including measuring the impact of a variety of plausible assumptions 
about the waning and boosting of VZV immunity on disease outcomes. An ABM can also help 
examine policy-relevant research questions, including the most appropriate timing and 
scheduling for the two chickenpox vaccine doses currently offered as part of the routine 
vaccination schedule in Canada. Furthermore, as health sector budgets become increasingly 
strained it is also important for policy-makers to consider how to implement effective public 
health programs while keeping costs at a minimum. ABMs can be used to estimate the cost-
effectiveness of the chickenpox vaccine and of various vaccination schedules.  
1.1. Rationale and aims of this research 
1.1.1. Economic evaluations of vaccines  
At the most basic level, economic evaluations try to identify, measure and value the costs 
and consequences (inputs/outputs) of different interventions [1]. By measuring the associated 
costs and benefits, economic evaluations of vaccines aim to test whether a vaccination program 
is worth doing compared to another intervention (e.g. treatment), as well as compare the cost-
effectiveness of various implementation methods for the vaccination program [2]. However, 
testing whether a health intervention is worth doing compare with another health intervention 
can be difficult, and is based on a variety of factors, including cost, effects (e.g. life-years, 
quality adjusted life years) and/or willingness-to-pay. Often the widespread use, reimbursement 
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and overall recommendations for a vaccine are contingent on transparent and favourable cost-
effectiveness [3]. Therefore, most developed countries have committees or organizations that 
measure the cost-effectiveness of each new vaccine to inform vaccine decision-making [3].  
Economic evaluation of vaccines are often complicated by the fact that vaccination aim 
to prevent the spread of infectious diseases, and, as such, can have unintended population effects 
external to the individual-level protection afforded by the vaccine (i.e. externalities) [3,4]. 
Examples of possible externalities, or unintended consequences, of vaccination include herd 
immunity, shifting age of infection or strain replacement [3,4]. Therefore, economists must 
consider how both negative and positive externalities may impact the cost-effectiveness of a 
vaccine [3,4]. One method to measure the impact of externalities on disease outcomes is 
infectious disease modelling. Economic evaluations, specifically those focused on vaccination, 
are increasingly using modelling to estimate the costs and benefits of various health interventions 
[5]. As described by Kim et al. [6, p.434] “models are a simplified description of the underlying 
processes leading to disease and resource utilization and provide a formal framework to 
synthesize information from various sources”. In general, using infectious disease modelling to 
measure the cost-effectiveness of a vaccine is important, as it can: (i) predict the duration of 
immunity based on immune correlates of protection, (ii) discount costs and benefits, (iii) 
evaluate alternative vaccination strategies not tested in clinical trials, (iv) evaluate the long-term 
benefits of the intervention and (v) estimate the indirect consequences of vaccination [3]. The 
model needs to be dynamic to account for externalities; that is, the model must take into 
consideration the force of infection changing over time [3]. To aid in the development of relevant 
and accurate cost-effectiveness results, specific guidelines are available for the production of 
economic evaluations of vaccines and the models used to conduct these analyses [2,6].  
Model type (e.g. compartmental versus individual, dynamic versus static) is one of many 
decisions that needs to be made when conducting economic evaluation of vaccines; other 
decisions include the target population, study question, type of evaluation, comparator, 
perspective, and time horizon [2,4]. Consequently, there is the potential for a wide diversity in 
study design and quality of economic evaluations of vaccines being produced worldwide and in 
Canada. As a result of the foregoing, it is important to systematically gather, review and 
summarise Canadian economic evaluations on vaccines, with the goal of describing general 
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trends and gaps in the literature. Furthermore, a review of the literature can help identify novel 
and interesting research questions that address the identified gaps in the literature. 
1.1.2. Chickenpox and shingles 
Chickenpox is a childhood disease caused by VZV, which can reactivate as shingles 
following initial infection. In Canada, prior to chickenpox vaccination in 2001, chickenpox was 
very prevalent, with approximately 350,000 chickenpox cases per year, and 90% of children 
having the infection before age 12 [7]. Shingles is generally a more serious disease than 
chickenpox, causing significant radicular pain that lasts for a prolonged period, and a multitude 
of complications, including post-herpetic neuralgia (prolonged neurogenic pain), sight-
threatening eye infections and secondary bacterial infections [8].  
Reactivation of latent VZV in the form of shingles is generally associated with a waning 
of VZV cell-mediated immunity (CMI) over time. In parallel to the natural waning of VZV-CMI 
immunity, one theory posits that exogenous boosting of VZV-CMI decreases an individual’s 
likelihood of shingles reactivation [9–11]. Exogenous boosting occurs when a VZV-immune 
individual is exposed to a case of chickenpox or shingles, leading previous models to predict a 
sharp increase in shingles rates following chickenpox vaccination. There remain several 
unknowns surrounding the epidemiology and economics of chickenpox disease and vaccination, 
and its impact on shingles infection.   
1.1.3. Agent-based modelling of chickenpox and shingles  
Previous models, along with epidemiological and immunological studies, have 
demonstrated that contact with the VZV (i.e. contact with a chickenpox or shingles case) may 
boosts one’s immunity to VZV, and therefore reduce their risk of getting shingles in the future 
[9–11]. These same studies frequently show that chickenpox vaccination can reduce this 
boosting in the population, and therefore lead to an overall increase in shingles incidence; 
however, the empirical data to-date is largely inconclusive [12–16]. Adding to the confusion is 
the fact the quantitative values for the duration of immunity following exogenous boosting and 
the waning of natural VZV immunity remain largely unknown [16–18]. These concerns have 
raised questions about the impact and effectiveness of chickenpox vaccination and have left 
many countries debating whether to include the chickenpox vaccine in their routine 
immunization schedules [19]. One method of expanding our understanding of the dynamics 
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between chickenpox and shingles is to use infectious disease modelling, specifically agent-based 
modelling.  
1.1.4. Optimal scheduling of the chickenpox vaccine in Canada 
In Canada, many policy-makers are grappling with optimal universal vaccination 
schedules (e.g. number and timing of vaccine doses) for a variety of vaccinations (e.g. 
chickenpox, pertussis, HPV) to ensure high coverage rates and effective prevention of disease in 
the populations most at risk. For instance, there is a continued debate in Canada about the most 
effective pertussis vaccination schedule, including how many doses to give and when to give 
them, along with questions about whether vaccination program should focus on pregnant 
mothers, or cocooning around young infants [20,21]. There is also a debate in Canada around the 
timing of the chickenpox vaccine. All provinces and territories have some form of universal 
chickenpox vaccine, but there were eight different ways of delivering the vaccine (i.e. number of 
doses, dose timing, vaccine combinations) across the country in 2017 [22]. Agent-based 
modelling could provide some insight into the effectiveness of different chickenpox vaccine 
schedule, allowing the testing of a variety of vaccine schedules without having to consider the 
confounding factors that could influence disease outcomes in real-world data analysis. 
1.1.5. Economic evaluation of chickenpox vaccine in Canada 
While studies have measured the cost-effectiveness of chickenpox vaccination overall, to 
our knowledge none have tested the cost-effectiveness of the different vaccine schedules, 
particularly as each vaccination strategy may lead to diverse costs and effects, such as different 
ages of infection, incidence of shingles and chickenpox, vaccine uptake and number of 
vaccination doses. Moreover, currently in Canada there are a lack of post-implementation 
economic evaluations, including analyses on the chickenpox vaccination. Post-implementation 
economic evaluations are vital, as cost and outcome data is often lacking prior to the introduction 
of the vaccine, and the ability to predict the vaccination impact, particularly herd effects, is 
limited [23]. For instance, prior to vaccine implementation, it is often difficult to predict the 
ultimate market price of a vaccine, which can vary dramatically in space and time. While 
sensitivity conducted in the original cost-effectiveness studies may explore these unknown 
values, this will create more uncertainty around the final cost estimates, as was evidenced in 
Brisson et al. [24] where the results were very sensitive to vaccine price. Therefore, there is a 
need to evaluate whether existing vaccination programs are good value for their cost [23]. These 
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post-implementation studies allow researchers to validate estimates of costs and outcomes from 
pre-implementation evaluations, and judge the ability of pre-implementation analyses to predict 
the cost-effectiveness of the vaccine, potentially improving future studies [23]. This type of 
economic evaluation may be particularly important for chickenpox, as the original cost-
effectiveness studies demonstrated that chickenpox vaccination was only cost-effective under 
certain circumstances, and the outcomes of the analysis were sensitive to a variety of unknown 
factors, such as the price of the vaccine, vaccine efficacy and vaccine strategy [24–26].  
1.2. Theoretical foundation for the research 
1.2.1. History and economic theories underlying economic evaluations  
The scarcity of resources in health care require the development of methods to frequently 
and systematically evaluate health care alternatives [27]. Health economists suggest that these 
decisions should be based on economic efficiency; where societal net benefits are maximized.  
Economic evaluation methods to measure the value of different health alternatives have 
developed over time to guide decisions and policymaking [27].   
Supply and demand theory developed by Adam Smith emphasized that choices reflect 
both values and preferences, along with scarcity, and suggested that individuals weigh the 
marginal benefits (i.e. utility) and costs of different options before making a decision [28]. 
Building on Adam Smith’s work, economists theorized that the concepts of supply and demand 
would result in the maximum benefit for the minimum price, or the efficient allocation of 
resources [28]. Neo-classical economists found a way to formalize Adam Smith’s insights, 
through the theory of general equilibrium, which argues that individuals choose a bundle of 
goods from the market to maximize their utility, where the bundled options are restrained by 
their budget [28]. In comparison, ‘firms’ choose their inputs and outputs to maximize profits, 
which is restrained by their capacity for productivity [28]. These two competing forces ensure 
that in the perfect market, prices will adjust until supply equals demand and equilibrium is 
reached [28]. In this case, the price of the good is consistent with the market’s valuation of it.  
However, the goals and aims of society may differ substantially from individual 
preferences, and studies based on individuals may not consider societal issues [28]. Therefore, to 
deal with the issue of how to allocate societal resources, welfare economic approaches were 
developed. “Welfare economics is concerned with social welfare”, and therefore the costs and 
benefits of goods and services for society as a whole [2, p.9]. One of the first approaches was to 
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use the competition model described above to determine optimal social welfare. This method 
assumes that individuals can judge their own welfare, they are rational, the intervention can 
benefit one person without disadvantaging another, and there are no externalities (i.e. 
individuals’ utility functions do not overlap). Therefore, the optimal position (Pareto efficiency) 
in this framework is when it is no longer possible to improve an individual’s welfare without 
impairing another individual’s welfare; specifically, societal welfare is increased if everyone 
gains from a policy.  Kaldor and Hicks built on the Pareto criterion to address the issue that 
policies often have both winners and losers [28,29]. They developed a variant of the Pareto 
criterion, called the Kaldor-Hicks criterion, which included assumptions about an individual’s 
willingness-to-pay for a benefit or willingness to accept money for a loss [28,29]. The Kaldor-
Hicks criterion, that suggests a “project is undertaken if the net social benefits (defined as social 
benefits minus social costs) are positive.” [2, p.20], therefore those who are better off from an 
intervention could, in theory, compensate those who are worse off or re-allocate resources. 
 The valuation of health care programs and/or goods is particularly difficult, mainly 
because health care goods and the market for these goods are very different from other kinds of 
goods/markets [27,28]. First, individuals are not always rational with regards to health care (i.e. 
do not always make decisions that are best for their health) and individuals may find it difficult 
to judge their own welfare. Second, it may be difficult for an individual to reveal their health 
preferences or know their health preference a priori. Third, there is significant uncertainty 
concerning one’s future health and the outcome of the health intervention, making valuing the 
health needs (i.e. services or goods) of individuals difficult. Finally, there is significant 
asymmetry of information in health care. For instance, doctors often have more knowledge of 
certain aspects of an individual’s health (e.g. treatment and pharmaceutical options) than they do 
[27,28].  
The imperfections in the health care market may lead to issues in the valuation of the 
benefits of health care interventions, and therefore make it difficult to determine the appropriate 
allocation of resources. Furthermore, because of the widespread use of health insurance, prices 
do not commonly appear at point of consumption in the health care market, and consequently 
economists developed other methods for valuing health care interventions and/or services, 
including: (1) the welfarist approach, which aggregates individual values across society (e.g. 
aggregating willingness-to-pay for certain benefits) or (2) social decision-maker approach, where 
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the decision maker for society determines the appropriate valuation for a benefit [28]. These 
different methods for evaluating health care interventions aim to measure efficiency, including: 
(1) technical efficiency, which is concerned with the maximum improvement in an outcome for a 
specific amount of resources (i.e. what is the best outcome we can achieve with these 
resources?); (2) productive efficiency, which is the minimization of costs for a given benefit or 
the maximization of health benefit for a specific costs (i.e. which different combination of 
resources will achieve the best outcome); and (3) allocative efficiency, that considers how 
benefits are allocated among persons in a society, in combination with how resources are used to 
produce health (i.e. what is the right group of health care programs for our budget?) [28]. 
Allocative efficiency is particularly important as many health intervention lead to both an 
increase in costs as well as an increase in effects, and therefore decisions need to be made about 
which patient groups get the extra resources and benefits.  
 To measure these different types of efficiency and allocate scarce resources, economists 
developed economic evaluation, which evaluates interventions for their costs and benefits 
simultaneously [28]. Economic evaluations are a part of the health technology assessment 
process, where a health intervention or technology is systematically evaluated based on its social, 
economic, and ethical impact. In economic evaluation costs at the margin are considered (i.e. the 
cost of producing one extra unit of benefit); including incremental direct and indirect costs (e.g. 
opportunity costs) associated with implementation of the intervention. Simultaneously the 
benefits of the health intervention are evaluated; with the specific aim to identify the value of the 
health outcome associated with the intervention [28]. The method for measuring benefits 
determines the type of economic evaluation produced, with three main types in existence today, 
cost-effectiveness analysis (CEA), cost-utility analysis (CUA) and cost-benefit analysis (CBA) 
[27,28].  
CEA generally uses natural units that measure one-dimensional effects of the health 
outcome (e.g. deaths, cases). Therefore, CEA generally evaluates productive efficiency. 
However, there are many situations where health outcomes cannot be described by one element 
of the disease, in these cases a more general measure of value is used [27,28]. These types of 
economic evaluations, CUAs, use utility measures, such as Quality Adjusted Life-Year or 
Disability Adjusted Life Years to measure benefits both in terms of quantity (e.g. life-years) and 
quality [27,28]. Although, CUA is a broader measure of benefit and value, it is still primarily 
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concerned with productive efficiency. The broadest measure of value, and the one economists 
argue best captures social welfare is CBA. This method employs a monetary measure of utility, 
which is typically measured by asking individuals their willingness-to-pay for certain 
interventions or improvements in their health status [27,28]. Therefore, CBA, in comparison to 
CEA and CUA, can also answer whether the goal of the intervention is worth pursuing at all, and 
as such, it is a measure of allocative efficiency. However, many economists have raised concerns 
with the measurement and methodological limitations associated with measuring individuals’ 
willingness-to-pay for health interventions [30–32]. For instance, willingness-to-pay estimates 
are often under-sensitive to the magnitude of the benefit, therefore individuals completing 
contingency valuation surveys often give similar answers for a wide range of reductions in death 
or injury, and as such, overestimate the value of small risk reductions [33]. Furthermore, 
willingness-to-pay surveys often over-estimates the impact of the intervention, as respondents 
will pay more for an intervention when asked about it in isolation, in comparison to when they 
are asked about it in conjunction with other interventions [33].    
While these three types of economic evaluation continue to be used to improve the 
technical, productive, and at times, the allocative efficiency of the health care system, debates 
continue in the literature about how best to measure benefits, what benefits to include when 
conducting an economic evaluation of health care, and which method best captures social 
welfare [27,28].  
1.2.2. Theoretical foundation and history for agent-based modelling in economic evaluations 
Economic evaluations are one form of health technology assessment (HTA), a type of 
analysis used to make decisions regarding health interventions and programs [34]. Economic 
evaluations are often done alongside clinical trials to evaluate the costs associated with a health 
intervention, as well as the effectiveness. Clinical trials offer a convenient method for measuring 
the cost-effectiveness of an intervention early in the decision-making process. However, there 
are many limitations to this approach, including the inability to account for costs and outcomes 
over extended periods of time, the incapacity for evaluating programs that did not undergo 
clinical trials, and the inability to capture realistic costs associated with a health program [34]. 
For example, economic evaluations based on clinical trials need to account for the higher level of 
health care patients often receive (e.g. greater number of tests, greater degree of health care 
contact) and cannot measure costs or effects over long time horizon. Therefore, economic 
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evaluations, alongside other forms of health technology assessment started using decision-
analytic models. These models “represent an explicit approach to synthesising currently available 
evidence regarding the effectiveness and cost of alternative (mutually exclusive) healthcare 
strategies” [7, p.356]. These types of analysis have exploded in recent years, especially as health 
interventions become increasing complex, with implications stretching into the future. One type 
of decision-analytic model that has become increasingly popular in recent years are ABMs.  
ABMs are dynamic models with a focus on individuals (i.e. agents), each of whom have 
their own characteristics and behaviour based on a set of rules prescribed in the model [35]. 
These agents interact with each other and their environment, and their behaviour, actions and 
characteristics can change over time [35]. Thus, the defining element of ABMs is their ‘bottom-
up’ approach to representing a dynamic process or system (e.g. infectious disease), allowing the 
collection and interaction of agents in an environment to determine the population level 
outcomes [35]. These elements allow for complexity and flexibility in model design, with the 
opportunity to alter a variety of different parameters at both the individual (e.g. age, sex, 
location, attitude, disease state) and the population (e.g. public health alerts) levels. These 
elements differentiate ABMs from other types of models, including system dynamic and discrete 
event simulation models. Chapter 3 and 4 discusses in more detail the benefits and limitations 
associated with agent-based modelling. 
1.3. Outline of thesis 
The organization of this thesis is as follows: 
Chapter 1 introduces the thesis and outlines and summarizes the goals of the research for 
the subsequent chapters.  
Chapter 2 (Article 1) systematically gathers, reviews and summarises Canadian 
economic evaluations on vaccines using a scoping review methodology, with the goal of 
describing general trends and gaps in the literature. This chapter also helped identify novel and 
interesting research questions for this thesis. 
Chapter 3 provides a general overview of the history and epidemiology of chickenpox 
and shingles diseases, and the chickenpox vaccine, worldwide and in Canada to provide context 
for Chapters 4, 5 and 6. In this chapter, five fundamental aspects of chickenpox and shingles 
diseases are discussed: (1) VZV and immunology, (2) chickenpox disease and epidemiology, (3) 
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shingles disease and epidemiology, (4) chickenpox and shingles vaccination, and (5) infectious 
disease modelling.  
Chapter 4 (Article 2) presents details on the building and calibration of an agent-based 
chickenpox and shingles model, in order to simulate the epidemiology, transmission and 
outcomes of these two diseases. Using this model, we test how chickenpox vaccination impacts 
the incidence and age-distribution of shingles over 75 years post-vaccination, taking into 
consideration a variety of plausible assumptions about the waning and boosting of VZV 
immunity. It also present details on the building of the ABM that was used to conduct the 
analyses in Chapters 4, 5 and 6.  
Chapter 5 (Article 3) determines the effectiveness of the chickenpox vaccine over time 
and the optimal vaccine schedule by comparing the disease outcomes under several universal 
vaccination strategies currently employed in Canada, using the ABM constructed in Chapter 4. 
Furthermore, this chapter summarizes updates to the ABM needed to test the effectiveness of 
two chickenpox vaccination schedules.  
Chapter 6 (Article 4) measures the overall cost-effectiveness of chickenpox vaccine 
post-implementation both considering and ignoring the impact on shingles incidence. In this 
chapter we also analyse the costs and benefits of two different chickenpox vaccination schedules, 
to measure whether the timing of vaccine delivery has an impact on its cost-effectiveness. 
Furthermore, this chapter outlines updates to the ABM that were necessary to measure the costs 
and benefits of chickenpox vaccination and disease outcomes. 
Chapter 7 concludes the thesis by summarizing the key findings, outlining limitations of 
the research and suggesting areas for future exploration.  
This thesis did not require ethics approval as it used no individual data, and only included 
estimates from the literature in the building of the ABM and the running of experiments. 
However, we received ethical approval for the building of a chickenpox and shingles ABM, in 
conjunction with other projects related to infectious disease modelling of childhood infections. A 
copy of the notification of approval is available in Appendix A.  
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CHAPTER 2- ECONOMIC EVALUATIONS OF VACCINES IN CANADA: A 
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the review, reviewing articles for inclusion/exclusion, conducting analysis and interpretation of 
the data, and preparing the manuscript. Heather Gagnon reviewed potential articles for 
inclusion/exclusion and helped critically revise and finalize the document. Dr. Marwa Farag and 
Dr. Cheryl Waldner aided in conception and design of the study, the interpretation of findings, 
and helped critically revise and finalize the document. 
 
 
As the number of economic evaluations of vaccines continue to grow it is important we assess 
the current state of this expanding and meaningful literature. Therefore, in this chapter we aim to 
summarise and describe the evolution of published economic evaluations of vaccines in Canada. 
Using Arksey and O’Malley’s scoping review framework we assembled relevant research from 
both academic and grey literature. In this chapter we study the economic evaluation of vaccines 
literature for trends, strengths/weaknesses, transparency in reporting and gaps in research 
questions. We use the findings from this chapter to inform the focus the rest of the thesis. 
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2.1. Introduction 
 Vaccination is lauded as one of public health’s most significant achievements, 
contributing to improvements in morbidity, mortality and quality of life worldwide [1,2]. 
Originally, one of the major advantages of vaccination as a public health intervention was their 
low cost, as many of the classic Expanded Program on Immunization vaccines only cost a few 
cents per dose and were cost-saving to the healthcare system [1,3]. However, in recent years 
more technologically complicated vaccines (e.g. subunit, gene-based vectors, particle-based) and 
more strict licensing regulations for vaccine safety and efficacy testing have led to more 
expensive vaccine development and manufacturing, which raise the question of vaccine cost-
effectiveness [3].  
With ongoing debates in many countries concerning the implementation and funding of 
these new vaccines, especially within the context of growing financial strain on healthcare 
systems, economic evaluations are becoming increasingly important to policy-makers [3]. 
Economic evaluations can improve the quality and consistency of decision making by providing 
a systematic way of comparing whether a specific vaccination program should be adopted 
compared with doing nothing or implementing an alternative intervention (e.g. treatment, other 
vaccines). Economic evaluations can also help evaluate scheduling and target population(s) [4,5]. 
The number of vaccine-related economic evaluations has substantially increased in the 
last few years. However, we have very little knowledge of the coverage and quality of this 
research, as well as the potential gaps and limitations of these studies. [6]. Systematic reviews on 
economic evaluations of immunizations generally focus on the results from a particular vaccine; 
recent examples include varicella [7] and influenza [8]. Meanwhile, many countries have yet to 
review and synthesize their own research in this area. One of the few examples is Spain, who 
recently released two comprehensive systematic reviews on Spanish economic evaluations of 
vaccinations completed between 1990-2012 [9,10].  
 In comparison, researchers in Canada have never fully synthesized the extent and 
characteristics of research on economic evaluations of vaccines in Canada. As the number of 
licensed vaccines in Canada and the number of economic evaluations on those vaccines continue 
to increase, it is essential that Canada begins to critically analyse and summarise this work 
[6,11]. This research is important to ensure improvement in the usefulness, quality and 
applicability of vaccine-related economic evaluations and the decisions they inform. 
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Furthermore, as countries produce similar evidence, comparisons of reporting, methods and 
results between countries could contribute to the international discussion on the major gaps in the 
literature and the quality, standardization and transparency of these studies.  
This study aims to systematically gather, review and summarise Canadian economic 
evaluations on vaccines using a scoping review methodology, with the goal of describing general 
trends and gaps in the literature. 
2.2. Methods  
2.2.1. Scoping review methodology 
We based our methodology on Arksey and O’Malley’s (2005) [12] five step framework 
for conducting a scoping review, including (1) forming the research question, (2) identifying 
relevant studies, (3) study selection, (4) charting the data and (5) summarising and reporting the 
results. Each section is described in more detail below. Scoping reviews are designed to 
summarise rich and complex areas of research that have not be synthesized in the past [12]. A 
scoping review also offers policy-makers easily accessible and comprehensive cost-effectiveness 
information and evidence regarding vaccines. Moreover, a review helps identify gaps in the 
vaccine economic evaluation literature and aids policy-makers spend their limited research funds 
more effectively and efficiently. We chose to conduct a scoping review rather than a systematic 
review because it allowed us to methodologically examine the breadth and depth of the work on 
economic evaluations of vaccines in a Canada, a highly multi-disciplinary area, while allowing 
for more flexibility than a systematic review [13]. The aims of our study were more consistent 
with the goals of a scoping review (e.g. to map the current state of the literature and summarize 
the breadth and depth of the research) in comparison to the goals of a systematic review (e.g. to 
summarize the evidence on the effectiveness of an intervention or treatment) [13]. The scoping 
review methodology allowed us to summarize a wide range of evidence including both grey (e.g. 
government reports) and peer-reviewed literature. Furthermore, rather than having a very 
specific and narrow research question, we asked a broad research question that encompassed all 
types of diseases, populations (target vs. universal) and interventions (i.e. types of vaccine) [13].  
2.2.2. Identifying the research question 
To further focus our research question − “What has been published regarding economic 
evaluations of vaccines in Canada?” − we decided to only consider active immunization, 
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vaccines that impact human health, and studies that focused on a Canadian population. To ensure 
comparability we chose to include only full economic evaluations, which we defined based on 
Drummond et al., 2005, and therefore, partial economic evaluations such as cost-outcome 
description studies and cost-minimization studies were not included [5,14]. Furthermore, to 
ensure the comprehensiveness of the review, we included both peer-reviewed and grey literature 
in our search. Only English-language articles were part of the final analysis.   
2.2.3. Identifying relevant studies  
To identify peer-reviewed articles we searched five databases relevant to both public 
health and economic evaluations: Embase, Medline, Global Health, Cochrane Library- 
specifically the Health Technology Assessment Database - and the NHS Economic Evaluation 
Database. No limitations were placed on the date and all databases were searched up until March 
17th, 2015. We used a report-based expansion strategy centred on three essential keywords 
(‘immunization’ AND ‘economic evaluation’ AND ‘Canada’). See Appendix B, Table B.1. for 
a full list of search terms used. After title, abstract and full-text review, the reference lists of all 
included articles were searched for relevant citations. We validated each database search for its 
efficiency and accuracy using ten articles that the reviewers identified as being highly relevant to 
the topic area. We compared the ten articles to the citations we identified during each database 
search.  
 To identify grey literature, we searched both the ProQuest Dissertation and Theses 
database along with key organizational websites related to health technology assessment, 
vaccination and economics in Canada, such as Canadian Agency for Drugs and Technologies in 
Health’s (CADTH), the Health Quality Council from multiple provinces and Institute of Health 
Economics. We chose these organizations based on advice from a health sciences librarian, the 
opinion of experts in the field and the CADTH grey literature checklist [15]. In total we searched 
25 potentially relevant websites and organizations.   
2.2.4. Study selection  
All eligible articles were imported into Microsoft Access 2010 for relevance screening 
and duplicates were removed. Independently, two reviewers evaluated the titles, abstracts and 
full-text of peer-reviewed articles by answering ‘yes,’ ‘no,’ or ‘unsure’ to each of the following 
questions (in no particular order): 
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1. Was the research conducted on a Canadian population? (i.e. presented Canadian-specific 
data or results?) 
2. Was a full economic evaluation conducted (measured both costs and benefits, compared 
at least two interventions)? 
3. Did the topic area relate to active vaccination or immunizations? (e.g. different types of 
vaccines, different schedules)?  
4. Is a full-text available?  
5. Is the article in English?  
6. Were the results relevant to human health?  
Furthermore, we excluded conference proceedings and any research that was presented in 
more detail elsewhere. During title, abstract and full-text screening of an article if the answer to 
any of the above questions was ‘no’ then the article was excluded; otherwise, the article was 
included in the next stage of analysis. We calculated Cohen’s Kappa Coefficient at both the title, 
abstract and full-text screening stages to measure agreement between the two reviewers [16]. The 
reviewers resolved any disagreements through discussion and consensus. One reviewer screened 
the grey literature for inclusion or exclusion using the same process outline above; however, if 
the first reviewer was uncertain about the inclusion of an article it was given to the second 
reviewer. All the grey literature articles included in the final analysis were read by both 
reviewers.  
2.2.5. Charting the data 
Following full-text screening, the two reviewers charted each study chosen for inclusion 
using a standardized form designed to gather common and comparable information on each 
study. Data extracted included year of publication, region, targeted disease, type of economic 
evaluation (based on how benefits were measured), modelling type, herd immunity, target 
population, study perspective, time horizon, type of sensitivity analysis, comparator, the 
consideration of equity issues, general cost-effectiveness findings and stated conflict of 
interest(s). These variables were chosen based on CADTH’s Guidelines for the Economic 
Evaluation of Health Technologies: Canada [17] and the World Health Organization’s (WHO) 
Guide for Standardization of Economic Evaluations of Immunization Programmes [3] that 
outline information to include in an economic evaluation. We chose these two guidance 
documents as they were specific to Canada and to vaccines. The focus of our scoping review was 
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to summarize the range evidence and identify any gaps in the literature, rather than compare the 
results of the economic evaluation; therefore, we did not compare the articles based on quality. 
We charted each study’s adherence to these guidelines and evaluated each study on whether they 
adequately (according to guideline protocols) presented six key principles that are considered 
essential for a well conducted economic evaluation. These six key principles included: time 
horizon, perspective, comparator, model-type and choice of economic evaluation (including 
justification for choice of model and economic evaluation), and if uncertainty in the results was 
fully accounted for through sensitivity analysis.  This analysis gives policy-makers not only an 
idea of how economic evaluations are generally being conducted and presented in Canada, but 
also the effectiveness of their guidelines to inform research and whether the guidelines could be 
applied consistently across articles.   
2.2.6. Summarising and reporting the results 
 Following data extraction, we used thematic analysis (i.e. determining and recording 
patterns or ‘themes’ within the articles) and descriptive statistics to analyze general trends and 
patterns in the data. We used chi-square tests to ascertain whether there was an association 
between stated conflicts of interests (i.e. at least one authors reported they were either currently 
working for the pharmaceutical industry or currently receiving funding) and their final cost-
effectiveness recommendations (i.e. whether the authors stated the vaccine of interest was cost-
effective or not, regardless of whether their determination was appropriate). Furthermore, we 
studied the association between the publication year (i.e. <2010 or ≥2010) and the studies 
adherence to the six key principles of an economic evaluation discussed in the WHO and 
CADTH guidelines (i.e. adhered to guidelines or not). We also examined the association between 
publication year (i.e. <2010 or ≥2010) and choice of modelling type (i.e. static vs. dynamic). We 
chose 2010 as the cut off year as it provided adequate time after the publication of the WHO 
(2008) and CADTH (2006) guidelines for authors to incorporate the recommendations in their 
research. Finally, we calculated the number of studies that took place prior to licensure of the 
vaccine in Canada, between licensure and the implementation of the vaccination program being 
studied, and those that occurred after the implementation of the vaccine in the region considered 
in the study. We were particularly interested in economic evaluations that aimed to re-evaluate 
the cost-effectiveness of the vaccine post-implementation and therefore included retrospective 
data (ex-post).  
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2.3. Results 
Following the database search and the removal of duplicates, 908 peer-reviewed articles 
remained to be screened. Based on title and abstract screening we eliminated 792 articles, 
leaving 116 articles for full-text review, of which 55 were included in the final analysis (Figure 
2.1). All ten ‘original’ studies chosen as being highly relevant to the research and used to 
validate the search methods were identified in each of the database searches. There was 
substantial agreement between the two reviewers; Cohen’s Kappa Coefficient was 0.81 for the 
title and abstract screening and 0.85 for the full-text screening. The reviewers reached consensus 
in all cases of disagreement. 
Following the grey literature search and title screening we retrieved 38 potentially 
relevant studies and dissertations from 25 websites and the ProQuest Theses database, of which 
five were retained in the final analysis. Sixty peer-reviewed and grey-literature studies were 
included in the final scoping review analysis (Figure 2.1).  
2.3.1. Summary of studies included in the review 
The number of articles by year of publication, region, disease, type of economic 
evaluation, modelling type, consideration of herd immunity, perspective, time horizon and 
sensitivity analysis were summarized (Table 2.1). The number of economic evaluations of 
vaccines increased from 1988 to March 2015; 66.7% of economic evaluations were published 
within the last ten years (i.e. since 2005) (Figure 2.2). Most studies focused on Canada in 
general (58.3%), with Quebec (13.3%), Ontario (10.0%) and British Columbia (8.3%) producing 
the most province-specific vaccine economic evaluations. Economic evaluation of vaccines in 
Canada considered 20 different diseases including, from most common to least common -  
influenza (pandemic-2 and seasonal-8) [18–27], Human Papillomavirus (HPV) [28–36], 
pneumococcal [37–45], pertussis [46–50], meningitis A,C, Y and/or W135 [51–55], hepatitis B 
[56–60], varicella [61–63], measles, mumps and/or rubella [64–66], herpes zoster [67,68], 
rotavirus [69,70], rabies [71], hepatitis A [72], tetanus [73], hepatitis C [74], meningitis B [75], 
group B streptococcus [76], and Escherichia coli [77] (Figure 2.2). 
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Figure 2.1. Flowchart for the identification and selection of studies included in the scoping review  
 
Grey literature identified 
from 25 websites and 
organizations and ProQuest 
Theses (n=38) 
Grey literature full text 
review (n=38) 
Duplicates excluded  
(n=369) 
Grey literature included  
(n=5)  
Articles included (n=60) 
Full text review  
(n=116) 
Peer-reviewed articles 
included (n=55) 
Peer-reviewed articles 
identified from Medline, 
Embase, Global Health 
and Cochrane (n= 1,277) 
Articles excluded after 
full text review (n=94):  
- Not full economic 
evaluation (n=43) 
- Conference 
proceeding (n=25) 
- Already presented 
elsewhere (n=10) 
- Not Canadian (n=8) 
- Not focused on active 
vaccination (n=5) 
- Not related to 
humans or no full-
text (n=3) 
Peer-reviewed articles 
excluded after title/abstract 
review (n=792) 
Title/abstract review  
(n=908) 
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Table 2.1. Summary descriptive statistics and variable frequency for 60 vaccine economic 
evaluations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Includes the provinces of New 
Brunswick, Nova Scotia, Prince 
Edward Island, and Newfoundland 
and Labrador. 
**Includes the territories of Yukon, Northwest Territories, and Nunavut. 
 
Variable  Number of 
studies 
included 
Percentage 
of total 
(n=60) 
Source 
Peer-reviewed  
Grey-literature 
 
55 
5 
 
91.7% 
8.3% 
Year of publication 
Before 1995 
1995-2004 
After 2005 
 
3 
17 
40 
 
5.0% 
28.3% 
66.7% 
Region 
Canada 
Atlantic*  
Quebec 
Ontario 
Manitoba 
Saskatchewan 
Alberta 
British Columbia 
Territories**  
 
35 
2 
8 
6 
1 
0 
3 
5 
0 
 
58.3% 
3.3% 
13.3% 
10.0% 
1.7% 
0.0% 
5.0% 
8.3% 
0.0% 
Disease  
Influenza 
HPV 
Pneumococcal 
Pertussis 
Meningoccocal 
A,C,Y or W135 
Hepatitis B 
Varicella 
Measles, Mumps 
or Rubella 
Herpes Zoster 
Rotavirus 
Rabies 
Hepatitis A 
Tetanus  
Hepatitis C 
Meningoccocal B 
Group B 
Streptococcus 
Escherichia coli 
 
10 
9 
9 
5 
 
5 
5 
3 
 
3 
2 
2 
1 
1 
1 
1 
1 
 
1 
1 
 
16.7% 
15.0% 
15.0% 
8.3% 
 
8.3% 
8.3% 
5.0% 
 
5.0% 
3.3% 
3.3% 
1.7% 
1.7% 
1.7% 
1.7% 
1.7% 
 
1.7% 
1.7% 
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Table 2.1. Continued  
 
 
Variable  Number 
of studies 
included 
Percentage 
of total 
(n=60) 
Type of Economic 
Evaluation 
Cost-utility 
Cost-effectiveness 
Cost-benefit 
 
 
37 
30 
7 
 
 
50.0% 
40.5% 
9.5% 
Modelling Type 
Simple Tree 
Static cohort 
Dynamic cohort 
Individual-based 
No modelling (e.g. 
RCT, simple calc.) 
 
16 
25 
7 
5 
 
7 
 
21.6% 
41.7% 
11.7% 
8.3% 
 
11.7% 
Consideration Herd 
Immunity 
Yes 
No 
 
 
25 
35 
 
 
41.7% 
58.3% 
Time Horizon 
≤1 year 
>1-29years 
30-79 
80+ 
Not stated 
 
7 
14 
8 
25 
6 
 
11.7% 
23.3% 
13.3% 
41.6% 
10.0% 
Perspective 
Individual/Familial 
Healthcare pay 
Public Pay 
Societal 
Not stated 
 
4 
35 
10 
28 
8 
 
  6.7% 
58.3% 
16.7% 
46.7% 
13.3% 
Sensitivity Analysis 
Yes-deterministic 
Yes-probabilistic 
No 
 
53 
23 
5 
 
88.3% 
38.3% 
8.3% 
Alternative/comparator 
No vaccine 
Different schedules 
of vaccines 
Different types of 
vaccines 
 
40 
 
16 
 
16 
 
66.7% 
 
26.7% 
 
26.7% 
Conflict of Interest 
Yes 
No 
 
28 
32 
 
46.7% 
53.5% 
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The most popular type of economic evaluation used in Canadian studies was cost-utility 
analysis (50.0%); although, it was often combined with cost-effectiveness analysis. The majority 
of the cost-utility analyses used QALY as the outcome measure. More than half of the studies 
used static modelling (e.g. simple tree or static cohort) (63.3%). Most studies used a life-time 
horizon (i.e. 80+ years) (41.6%), with a healthcare payer (58.3%) or societal perspective 
(46.7%), often combining the two perspectives. Researchers employed a wide range of 
comparators (Table 2.2). The vaccine of interest was compared to no vaccine in 66.7% of 
studies. The evaluation compared different ways of administering the vaccine (e.g. different 
schedules or target populations) in 25.0% of studies. Different types of vaccines (brands or 
antigen formulations) for the same disease were compared in 26.7% of studies, with some studies 
employing more than one type of comparator. Most studies (86.7%) evaluated publicly-funded 
vaccines that were included on at least one provincial immunization schedule (Table 2.2). 
Finally, only six studies in our analysis had a discussion of equity, which mainly focused on the 
fact that they were unable to address issues of equity within their analysis. 
2.3.2. Factors associated with reporting practices and study findings 
 In reports where there was a stated conflict of interest, the authors were more 
likely to assert the vaccine of interest was cost-effective relative to the comparator (OR= 7.36; 
CI= 1.04, 17.8; p-value=0.04) than in reports with no reported conflict. Furthermore, studies 
published from 2010-2015 were more likely to follow the six key principles in the WHO and 
CADTH reporting guidelines compared to those studies published before 2010 (OR= 4.58, CI= 
1.33, 18.7, p-value = 0.01) (Figure 2.3). However, there was no difference in the type of model 
employed before 2010 compared to 2010-2015 (OR= 3.05; CI= 0.66, 16.8; p-value=0.16). All of 
the five individual-based models were published in the last five years [22,29,31,32,71].  
Most studies (66.7%) were completed before the vaccine program of interest was 
implemented in Canada with 8.3% before the vaccine was licensed. One in four studies (25.0%) 
were completed after the vaccine program was implemented. Only five post-implementation 
studies (8.3%) were ex-post and therefore evaluated vaccination strategies using retrospective 
data on costs and effectiveness [22,23,44,49,53]. 
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Figure 2.2. Timeline of Canadian economic evaluations of vaccines 
*Each flag colour in the above figure represents a different disease.  
   
 
27 
Table 2.2. The vaccine comparators and schedules used in each economic evaluation 
Vaccine Number of 
studies- No 
vaccine  
Number of 
studies- Type 
of vaccine 
Number of studies- 
Vaccine program**  
Funding and 
Target 
Population*** 
Escherichia coli 1 (0/1)* - - Private 
Group B 
streptococcus 
1 (1/1) - - Not yet available 
Hepatitis A -  1 - Private 
Hepatitis B 5 (3/5) - 1 Public-Universal 
Hepatitis C 1 (1/1) - - Not yet available 
Herpes Zoster  
2 (2/2) 
- - Private 
HPV 7 (7/7) 4 2 Public-Universal 
Influenza- 
(Seasonal & 
H1N1) 
6 (5/6) 1 4 Public- 
Universal/Targeted 
Measles or 
Mumps or 
MMR 
2 (2/2) - 3 Public-Universal 
Meningococcal 
A, C, Y, W135 
2 (1/2) 2 1 Public-Universal 
Meningitis B 1 (0/1) - - Public-
Targeted/Private 
Pertussis 1 (1/1) 2 2 Public- Universal 
Pneumococcal 4 (4/4) 4 1 Public-Universal 
Rabies 1 (1/1) - - Private 
Rotavirus 2 (2/2) 2 - Public-Universal 
Tetanus 1 (1/1) - - Public-Universal 
Varicella 3 (2/3) - 1 Public-Universal 
*Ratio represents the number of studies that found the vaccine was cost-effective compared to no 
vaccine.  
** For example: schedule, booster dose, universal vs. targeted.  
***Funding and target population for vaccines as of March 2015.  
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Figure 2.3. Comparison of number of economic evaluations by criteria of interest 
2.4. Discussion 
In recent years, the number of economic evaluations on health interventions have 
increased in Canada and worldwide [17,78]. The results of our scoping review are consistent 
with these trends, with 50.0% of the economic evaluations of vaccines in Canada being produced 
in the last five years [17,78]. There are many explanations for this increase in economic 
evaluations, including increasing pressures on the budgets of healthcare systems, as well as the 
advent of new, complex and more expensive vaccinations [78,79]. Therefore, it is perhaps 
unsurprising that the influenza, pneumococcal and HPV vaccines represented almost 50.0% of 
the economic evaluations, as the immunization programs for these diseases, including the 
schedules, vaccine-type, administration techniques and target populations have all changed over 
the last few years. For instance, recently decision-makers have raised questions surrounding the 
cost-effectiveness of male HPV vaccination, using the modified live intranasal influenza vaccine 
in children between two and 17, and which pneumococcal vaccine (i.e. PCV13, PCV10 and 
PCV7) would give the best value for the money, particularly considering the impact of serotype 
replacement and otitis media [27,29,31,32,37,39,40,45].  
Most economic evaluations focussed on publicly-funded vaccines that were part of at 
least one provincial immunization schedule. A very small proportion of the research was done on 
privately-available vaccines, such as travel (e.g. yellow fever, Japanese encephalitis) and 
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workplace vaccines (e.g. rabies) [71,77]. Furthermore, there is only a small amount of research 
on vaccines not yet available or licensed in Canada (e.g. chlamydia, herpes simplex), with some 
notable exceptions (i.e. hepatitis C and Meningococcal B) [74,75]. Anticipatory economic 
evaluations can provide essential information on the needs for additional research and 
investment.  
 In Canada, most of economic evaluations occur after the vaccine has been licensed but 
before the implementation of the vaccine program in the population (ex-ante). These ex-ante 
studies are important as they provide decision-makers with an estimate of the value of instituting 
a new vaccine and the costs and benefits of different vaccination programs (e.g., privately, 
targeted, universal). However, ex-ante evaluations are difficult to perform as country-specific 
effectiveness and cost data is often lacking before implementation, and the ability to predict the 
vaccination impact, particularly herd effects, is limited [80]. For instance, prior to vaccine 
implementation it is difficult to predict the real market price of a vaccine, which can vary 
dramatically in space and time. Therefore, there is a need to evaluate whether existing 
vaccination programs are good value for their cost, especially because effectiveness and cost data 
can change drastically over time [80]. These ex-post studies allow researchers to validate 
estimates of costs and outcomes from pre-implementation evaluations, and potentially improve 
future studies [80].  
 However, we saw little evidence of ex-post economic evaluations. For instance, the costs 
and outcomes of the varicella vaccine ex-post have not been compared with the two inconclusive 
studies conducted ex-ante (69,70). In fact, only five studies were identified where the goal was to 
determine the efficiency of a mass immunization after its implementation in the population 
[22,23,44,49,53]. This gap in the literature may be partially due to the politics of de-
implementation, especially as scaling back an intervention is a complicated process in health care 
and often met with resistance. However, the lack of retrospective research has left many 
unanswered questions, such as ‘How good are Canadian economic evaluations at predicting the 
cost-effectiveness of vaccines and should these studies inform our policy-making?’  This gap in 
the literature may be partially due to a lack of industry willingness to fund ex-post studies or 
because of noted methodological limitations, including issues with estimating the ‘no program’ 
scenario, attributing decrease in disease to vaccination and predicting future benefits [80]. 
However, Newall et al. (2014) [80] has identified a variety of approaches that help address these 
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issues, noting that as retrospective studies become more important and frequent, it would be 
beneficial to increase the guidance available to researchers undertaking such analyses. In the 
future, a clearer understanding of the accuracy of economic evaluation predictions could help 
researchers improve research techniques and potentially increase the efficiency of current 
vaccination programs. 
 Most of the studies in this review compared the vaccine of interest to no vaccination. 
While this is an essential initial comparison, once a vaccine is well-established, there are other 
questions that economic evaluations can help answer, including questions about vaccine 
programming and scheduling. In Canada, healthcare is primarily under provincial/territorial (not 
federal) jurisdiction and as a result there is a diversity of vaccine programs, technologies and 
schedules throughout the country. To date there have been no reported studies of which 
vaccination programs are most efficient or cost-effective, or whether these differences are 
justifiable due to the epidemiology and costs in different Canadian regions.   
The use of modelling in economic evaluation of vaccines has increased in the last few 
years. Most studies continue to employ static models (e.g. decision tree, Markov processes) as 
compared to dynamic models (e.g. system dynamics, individual-based models). In dynamic 
models, the risk of infection can change over time. There has been no apparent increase in the 
application of dynamic modelling and no relationship between modelling type and year of 
publication [81]. Although dynamic models are not always necessary to represent vaccine 
preventable diseases (e.g. tetanus, Herpes Zoster), they allow for the intrinsic consideration of 
vaccine externalities (herd immunity, shifts in age of infection and serotype replacement). 
Consideration of externalities is limited in the Canadian literature, with fewer than half of studies 
in our review considering herd immunity. Failure to include the impact of herd immunity can 
significantly underestimate the effectiveness of a vaccine [81]. An increase in dynamic 
modelling, where relevant, could improve the accuracy of economic evaluations of vaccines and 
should be an area of future research.   
Individual-based models are, however, becoming increasingly popular in economic 
evaluations [22,29,31,32,71].  These models have the advantage of being able to replicate 
individual-level behaviour and interactions (e.g. transmission, risk behaviours, disease history), 
which may have substantial impacts on the economic evaluation. Individual-based models not 
only intrinsically account for the impact of herd immunity but also help researchers study the 
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influence of key subsets of the population. Three separate economic evaluations on HPV used a 
common individual-based model called HPV-ADVISE to estimate the costs and benefits of 
different vaccination strategies and scenarios in Canada [29,31,32]. The HPV-ADVISE model 
informed HPV vaccine policy-making regarding the cost-effectiveness of various vaccine types 
(bivalent versus quadrivalent versus nine-valent), catch-up programs, type replacement, 
schedules (ages, number of doses), as well as male-vaccination. HPV-ADVISE is an example of 
the power and flexibility of individual-based modelling and how information sharing can 
improve economic evaluation research and therefore the policy-informing power of these types 
of studies. However, there are also trade-offs to consider with dynamic models, specifically 
individual-based models, as they are often more complex, time consuming and can require more 
fine-grained data, potentially impacting the reliability and timeliness of the results. 
Authors’ choice of the time horizon and discount rate can significantly impact the 
outcomes of an economic evaluation. As is noted in many guidelines for economic evaluations, 
for accurate analysis the chosen time horizons must encompass all costs and benefits of a policy 
decision [17]. However, as we saw in this analysis many economic evaluations adopt a shorter 
than necessary time horizon (e.g. economic evaluations adopting the same time horizon as a 
clinical trials), creating the possibility of a time horizon bias, wherein the cost-effectiveness of an 
intervention is often underestimated. Another important element of economic evaluations that 
can significantly impact the outcomes of a cost-effectiveness analysis is the perspective and 
therefore, which costs are considered in the analysis. It is essential that economic evaluations 
clearly justify their choice of perspective and discuss the costs not considered, however a 
complete discussion of choice of perspective was often missing in the studies of our analysis. 
However, as recommended in the CADTH guidelines [82], studies are starting to adopt a two -
perspective approach, where they not only consider the economic benefits and cost from a 
narrower view point (e.g. healthcare payer) but also using the most comprehensive approach (i.e. 
societal perspective). Reporting of time horizon and study perspectives in economic evaluation 
of vaccines must improve to ensure the transparency of complex analyses and to provide the 
details necessary for informed decision-making.  
In our review only six articles included some assessment or discussion of equity in their 
analysis. Lack of equity considerations and inability to account for equality in resource allocation 
analyses are common criticisms of economic evaluations [83]. Debate continues around whether 
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economic evaluations have the responsibility to consider equity; however, the lack of 
information on the differential impact of interventions often means policy-makers are hesitant to 
use the results of economic evaluations [83]. In recent years there have been a number of 
methodological advancements to help economists account for equity as part, or as an extension, 
to their cost-effectiveness analysis (e.g. extended or distributional cost-effectiveness); however, 
the use of these tools is still limited [84]. As the field of economic evaluations of vaccines 
continues to grow it is important that these studies consider and discuss how their findings may 
have an impact on the equity of health care delivery and health outcomes.  
 Research shows that guidelines for economic evaluation from non-governmental 
organizations, governments and journals can help increase transparency and reliability of these 
studies [78]. In fact, one of the main reasons the WHO created guidelines for economic 
evaluation of vaccines in 2008 [3] was to address the limitations they observed in evaluations 
reported prior to 2005, and to enhance standardization and comparability between studies [2]. 
Both Baladi et al. (1998) and Neumann et al. (2005) discovered a growing adherence to 
recommended practices in cost-effectiveness and cost-utility analyses worldwide and in Canada, 
which they attributed to stricter journal protocols and guidelines in publishing these studies 
[78,85]. Our results further support these findings indicating that since the publication of WHO 
and CADTH guidelines there has been an increase in the standardization of the methods used in 
economic evaluation and in the transparency and reporting of the research in Canada [3,17]. 
Although, we noted a change in the consistency of reporting following the introduction of the 
guidelines, there remained certain study elements commonly omitted, such as the study 
perspective, modelling technique description and time-horizon. The large number of assumptions 
and parameters used in economic evaluations make reporting guidelines essential, as simple 
changes to the perspective adopted, discount rate or time horizon chosen can have a major 
impact on the results [6]. Therefore, the transparency and reliability of these studies should 
continue to improve, and the guidelines must be continually updated to ensure that the results are 
both useable and translatable. 
 The use of national guidelines and publishing protocols is particularly relevant and 
important to our sample of articles, as just under half the studies had reported conflicts of interest 
and these studies were significantly more likely to find the vaccine of interest cost-effective. 
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Therefore, transparency and consistency in economic evaluations are essential to ensure policy-
makers can use the results to make accurate and unbiased decisions  
This study had a number of limitations. First, we were unable to search for or include 
articles in French, and therefore may have missed contributions to the economic evaluation 
literature, especially as Quebec was the most prolific areas in the production of economic 
evaluations of vaccines. Second, only one reviewer was able to screen the grey literature articles 
for inclusion. Nevertheless, all final decisions were discussed between the two reviewers to 
ensure agreement about all studies included in the analysis. Finally, we did not compare the 
results of the economic evaluations because we had included articles for a variety of diseases and 
with a wide range of quality.   
2.5. Conclusions 
To date economic evaluations of vaccines in Canada have not been summarised or reviewed, 
potentially limiting the influence these studies have on policy-making. This scoping review acts 
as a guiding document for policy-makers and researchers, to provide easy access to essential 
information about vaccines. Our scoping review outlined many gaps in the literature, including 
the lack of studies on various privately-available vaccines, different vaccination schedules and 
programs, and the shortage of ex-post implementation economic evaluations. Furthermore, we 
identified important trends in the literature, including an increasing number of economic 
evaluations on vaccines and a focus on newly-available vaccines.  
We found some weaknesses in the literature, including the limited use of dynamic 
modelling and consideration of herd immunity, the significant association between declared 
conflicts of interest and an increased frequency of a positive cost-effectiveness result, as well as 
the under-reporting of time-horizon, perspective and modelling type. However, the scoping 
review outlined some key strengths of the Canadian literature, including an increase in the 
application of individual-based modelling techniques. Furthermore, the implementation of 
national guidelines appears to have had an impact on the standardization and transparency of 
economic evaluation in Canada and remains an important consideration for countries without 
similar guidelines.  As more countries start to map this literature and analyse the trends and 
limitations, then comparisons between countries, their economic evaluation literature and their 
vaccination programs; could provide valuable input for improving the quality and usefulness of 
economic evaluations of vaccines.  
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CHAPTER 3- BACKGROUND ON CHICKENPOX AND SHINGLES 
The scoping review in the previous chapter identified several gaps and limitations in the 
Canadian economic evaluations of vaccines literature, including in studies that focus on 
chickenpox and shingles. All the economic evaluations of universal chickenpox vaccination in 
Canada were conducted prior to the vaccine’s implementation into any provincial vaccination 
schedule. Furthermore, while many chickenpox economic evaluations used dynamic models, 
they did not employ an agent-based infectious disease model, which is a tool that could further 
our understanding of chickenpox disease and vaccination, including the costs and outcomes 
associated with both. This chapter provides context for the last three articles (Chapters 4, 5, and 
6) of this thesis, including background on the varicella zoster virus (VZV), the immune response 
to VZV infection, transmission and epidemiology of chickenpox and shingles, as well as the 
pathogenesis, diagnosis and treatment of these diseases. This chapter summarizes the history of 
the chickenpox vaccination both worldwide and in Canada, along with current research on how 
universal vaccination affects population-level chickenpox and shingles outcomes.  Furthermore, 
this chapter discusses several types of infectious disease models, including agent-based 
modelling, which is employed in the following chapters to estimate the epidemiology and cost-
effectiveness associated with chickenpox vaccination. 
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3.1. Varicella zoster virus and immunology 
Varicella zoster virus (VZV) is an enveloped double stranded DNA virus that can cause 
two distinct diseases, varicella (chickenpox) and herpes zoster (shingles). Chickenpox is the 
primary infection with VZV and generally occurs in childhood. However, as a member of the 
Herpesviridae family, during primary infection VZV has the capacity to travel to the sensory 
ganglia and remain latent in neurons for years. Reactivation of latent VZV can cause a secondary 
infection in the form of shingles.  
VZV spreads almost entirely from cell-to-cell making cell-mediated immunity (CMI) 
particularly important in the development of long term immunity to VZV [1]. While humoral 
immunity may also play a role, it is not sufficient to ensure protection. Patients with 
compromised CMI (e.g. HIV/AIDS) are at an increased risk of developing VZV infections and 
more severe chickenpox [1,2]. An increased risk of shingles in CMI-impaired individuals 
supports the hypothesis that immunological control is important in the suppression of VZV 
reactivation. In fact, the decline of CMI with age is one of the theories why age remains the main 
risk factor for shingles infection. While there is only one serotype for chickenpox, there are 
various genotypes, which have a distinct geographical distribution [1]. 
3.2. Chickenpox disease and epidemiology 
Chickenpox is characterized by an itchy, sometimes painful generalized vesicular rash, 
often coinciding with malaise and fever, with symptoms continuing for 5-7 days. Other 
symptoms include, anorexia, headache, and mild abdominal pain.  Although, in healthy children 
chickenpox is generally a self-limiting disease, there are a wide variety of possible 
complications. Secondary bacterial infection (e.g. group A streptococcal infection) is the most 
common complication in childhood but other complications include acute cerebellar ataxia, 
encephalitis, and congenital varicella syndrome [3]. Severe illness and/or complications are more 
common in certain risk groups, including, pregnant woman, neonates, infants, and 
immunodeficient patients, particularly those with cellular immune deficiencies [3,4]. 
Furthermore, chickenpox can be more severe in adolescence and adulthood. Generally, once an 
individual has had chickenpox they remain immune for life [4]. However, some evidence shows 
that subclinical reinfection, also known as endogenous boosting can occur, and one theory posits 
that this increase an individual’s immunity to future virus reactivation.  
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3.2.1. Chickenpox diagnosis and treatment  
Diagnosis of chickenpox is usually done using both clinical and epidemiological 
evidence, including the identification of the characteristic vesicular rash, along the individual’s 
history of chickenpox and their recent contact with a chickenpox or shingles case [1].  Lab 
testing of vesicles or body fluids using PCR to identify viral DNA is becoming the favoured 
diagnostic test, as it is generally considered the most sensitive, although it is not routinely done 
on patients [1]. Serological testing for VZV antibodies is often used to assess health care 
workers’ immunity to chickenpox; however, they have yet to find a true measure of protection as 
the absence of antibodies in a vaccinated individual does not reliably mean they are at risk of 
disease [1].  
While most cases of chickenpox are treated with supportive care, antiviral therapies do 
exist for chickenpox infections. Antivirals may decrease the severity and reduce recovery time 
for chickenpox infection; however, they do not appear to have an impact on virus transmission 
[1]. Therefore, these medications are generally not prescribed for a typical chickenpox case but 
are used for immunocompromised individuals who contract chickenpox and for more severe 
cases of shingles [1]. Other medical options to help prevent or attenuate chickenpox infection 
include post-exposure prophylaxis. Chickenpox vaccination given within 5 days of exposure is 
commonly used for post-exposure prophylaxis. While it shows inconsistent results for the 
prevention of disease, it is highly effective in limiting disease severity. Another option for post-
exposure prophylaxis is passive immunization with immune globulin, which, is the 
recommended method to limit the severity of the infection in immunocompromised individuals, 
neonates, premature infants and pregnant woman [5] 
3.2.2. Epidemiology chickenpox pre-vaccine era worldwide 
Prior to vaccination, chickenpox was endemic worldwide, with the majority of 
individuals being infected by mid-adulthood [1]; however, the rate of chickenpox infection and 
the age-distribution differed by temperate and tropical climates [2]. In temperate climates pre-
school children had the highest burden of chickenpox infection, with 90% of individuals having 
been infected by adolescence [4]. In comparison, in tropical climates there was a higher mean 
age of infection along with a higher percent of adults who are susceptible [1,6]. Theories as to 
why we observed these differences in VZV epidemiology between temperate and tropical 
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climates include the fact more children attend school and day in temperate climates and for 
longer [6].  
In Canada, prior to chickenpox vaccination, there were approximately 350,000 
chickenpox cases per year, or 11.9 cases per 1,000 persons [7]. Periodic outbreaks tended to 
occur at a cycle of 2-5 years, with 90% of children infected by age 12 [7]. In the United Sates 
there were approx. 4.1-5 hospitalization per 100,000 persons and 0.4-0.6 deaths per million 
persons per year [1]. At the same time, chickenpox contributed to a considerable number of 
school and work days missed [8]. All these factors, including hospitalization costs, general 
practitioner costs and productivity loss contributed to chickenpox’s substantial economic impact 
[8,9]. 
 3.3. Shingles disease and epidemiology 
3.3.1. Reactivation and boosting 
Shingles is a disease caused by the reactivation of the VZV in individuals previously 
infected with chickenpox. Following primary infection of VZV, the virus can move to the 
sensory ganglia and remain latent there for future reactivation as shingles [2]. Reactivation of 
VZV causing shingles is generally associated with a decrease of VZV cell-mediated immunity 
(VZV-CMI) associated with ageing and senescence. Research shows that CMI is the key 
response to controlling VZV in the host, as viral spread occurs from infected cell to uninfected 
cell [1]. For instance, those with impaired CMI have higher rates of shingles and chickenpox, 
and the infection is often more serious in these cases [1]. The current assumption in the literature 
is that immunity to VZV wanes over time and once it reaches a certain undefined critical 
threshold, VZV has the possibility to reactivate in the form of shingles. Other factors have been 
shown to effect immunity to VZV, including changes in mental health such as depression and 
stress, concurrent infection, trauma to the dermatome, gender and possibly race [2].  
In parallel to the natural waning of VZV-CMI immunity, one theory posits that 
exogenous boosting of VZV-CMI is a determinant of shingles reactivation [10]. According to 
Hope-Simpson [10] exogenous boosting occurs when a chickenpox immune individual is 
exposed to a case of chickenpox or shingles. Multiple studies show that populations commonly 
exposed to children and chickenpox (e.g. pediatricians, mothers) have lower shingles incidence 
rates than the general population; however, these findings are inconsistent [1,11,12]. 
Furthermore, shingles vaccine administered to chickenpox immune individuals induces a 
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substantial boost in VZV-CMI; however, the length of the boost (i.e. time protected from 
shingles) remains unknown [13]. At the same time, some studies suggest an individual’s immune 
system may react to an attempted reactivation of VZV, in effect boosting the immune system and 
preventing future reactivation, this event is known as endogenous boosting [14].   
3.3.2. Shingles diagnosis and treatment 
Shingles is generally a more serious disease than chickenpox, causing significant 
radicular pain that lasts for a prolonged period, even years in some cases. Shingles is 
characterized by a vesicular rash, similar to that seen in chickenpox; however, it is usually only 
seen along a single dermatome. Shingles can occur in the absence of a rash, although it is rare. 
Other symptoms include, itching and prodromal pain that varies by consistency, character 
(boring, aching, shooting) and severity by case [2]. Shingles is also associated with multiple 
complications. One of the most frequent and severe complication is post-herpetic neuralgia 
(PHN), which is prolonged neurogenic pain (ranging from >30-90 days) that is often debilitating 
[15]. Other complications include, sight-threatening eye infections, neuromuscular disease (e.g. 
Guillain-Barre Syndrome), secondary bacterial infection, and nerve palsies [15].  
Like chickenpox, diagnosis of shingles is usually done clinically with the appearance of 
the rash accompanied by prodromal pain. Treatment for shingles includes antiviral therapy, for 
both healthy and immunocompromised patients, and should be started as soon as possible. Pain 
management, including the use of strong analgesics, is also a key factor in the medical 
management of shingles [4]. The number and costs of antivirals and analgesics prescriptions for 
shingles have increased in the past few years [16].  
3.3.3. Epidemiology of shingles worldwide and in Canada 
Studies from across the world, including Canada, Japan, US, Taiwan and Israel estimated 
an overall age-adjusted incidence rate of shingles between 3.4 and 5.0 cases per 1,000 persons 
prior to chickenpox vaccination. Shingles rates can differ significantly by country, for instance in 
Europe the rate of shingles varied from 2 to 4.6 cases per 1,000 person-years with no particular 
geographical trend [17]. Estimates in Canada average around 4.6 shingles cases per 1,000 
healthy persons per year, with a lifetime risk of 15-20% [4,18,19]. A few studies have shown that 
the incidence rate of shingles had been steadily increasing in the years leading up to chickenpox 
vaccination [20]. For example, a study from Alberta found that the rate of shingles increased 
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from 2.7 to 4.3 cases per 1,000 persons per year between 1986 and 2002 [21]. While this study 
did not adjust for age, Edgar et al. (2007) [18] and Marra et al (2006) [22] found similar 
increases in the age-standardized incidence rate of shingles in Canada. Adjusting for age is 
important as the incidence and severity of shingles does increase with age, for instance the rate 
of infection for persons over 65 (8-11 cases per 1,000 persons) is two to three times higher than 
the overall age-adjusted incidence rate [4]. Therefore, approximately half of adults who reach 85 
years old suffered at least one episode of shingles [4]. Although shingles does not spread through 
contact, shingles can represent a mode of VZV exposure to individuals susceptible to 
chickenpox, and therefore can introduce VZV into small communities unable to sustain endemic 
chickenpox transmission.  
3.4. Chickenpox and shingles vaccination 
All chickenpox vaccines are developed using the Oka strain of the VZV and were 
originally tested during clinical trials completed in the 1970s [1]. Currently licensed vaccines 
include monovalent vaccines, Varivax (Merck) and Varilrix (GSK) and combination vaccine 
measles, mumps, rubella, varicella (MMRV), such as Proquad (Merck) and Priorix-Tetra (GSK) 
[1]. All vaccines currently licensed are live-attenuated and administered subcutaneously. 
Chickenpox vaccines are considered very safe; however, adverse side effects do occur. The most 
common adverse events are minor, and include tenderness and redness, fever and mild rash [1]. 
The risk of febrile seizures in 12-months-old infants who receive the MMRV combination 
vaccine was slightly but significantly higher than those who receive MMR+V (MMR and 
varicella separately) [23]. All the chickenpox vaccines are generally considered safe and 
effective in immunocompromised individuals. However, there is the potential for severe 
reactions, including skin rash and fever, and the vaccine is sometimes contraindicated for this 
group.  
3.4.1. Chickenpox vaccination efficacy and effectiveness 
Following chickenpox vaccination, most healthy children demonstrate an IgG antibody 
response, with one study showing approximately 84% of children seroconverted following first 
dose vaccination [24]. This is comparable to a larger study of primary vaccine failure in the US 
which found 24% of individuals who received one-dose chickenpox vaccination had no 
detectable antibody to the virus [25]. These two studies, together with other estimates of 
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seroconversion and primary vaccine failure, suggests approximately 9% to 24% of healthy 
children are not fully protected following initial chickenpox vaccination [1,26,27]. Two-dose 
chickenpox primary vaccination failure is likely very low, with one randomized control study 
demonstrating a 94.9% efficacy against any disease and 99.5% effective against severe/moderate 
disease following vaccination with MMRV [28].  
In comparison, the importance of secondary-vaccine failure or waning of immunity 
continues to be debated in the literature [29]. Chaves et al. [30] examined the rate of 
breakthrough chickenpox in the 10 years since implementation of the vaccine program in the US 
and found the rate of breakthrough significantly increased with the time since vaccination, 
suggesting an element of waning of vaccine immunity. However, while studies have confirmed 
these findings others have found that vaccine-derived antibodies persist in the individual long-
term. Furthermore, it is difficult to determine whether the persistence of immunity is due to re-
exposure to wild-type disease as many of these studies were conducted while chickenpox was 
still circulating in the population [4]. If secondary vaccine failure does occur, further study is 
needed to determine the rate at which it occurs, the significance of re-exposure events and the 
importance of a second dose. A systematic review of the real-world chickenpox vaccine 
effectiveness suggested that single dose vaccination had a median effectiveness of approximately 
83% against disease of any severity, although it ranges dramatically from 20% to 100% when 
comparing among individual studies [4]. However, this review also estimated the effectiveness in 
preventing moderate disease was very high at 95% and found complete protection against severe 
disease [4].  
3.4.2. Chickenpox vaccine globally and in Canada 
 In the United States one-dose chickenpox vaccination was licensed in 1995 and shortly 
after was first recommended for routine use in children. In 2007 the Advisory Committee on 
Immunization Practices shifted their recommendations to a 2-dose schedule (12-15months and 4-
6 years) [5,31]. Canada licensed the Oka strain chickenpox vaccination in 1998, and Prince 
Edward Island became the first province to implement universal vaccination in 2000 [32,33]. By 
2007 all provinces had a routine one-dose chickenpox vaccination program. However, in 2011 
the Canadian Pediatric Society recommended a switch to a two-dose schedule, citing 
breakthrough cases, continued outbreaks and concern the disease was shifting to older 
populations where it is often more severe [34]. At the same time, many countries, including most 
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European countries, have decided to delay the implementation of universal chickenpox vaccine 
in their routine schedules, often citing cost-effectiveness, the generally low severity of 
chickenpox infections and the potential impact on shingles rates [35].  
 Currently, while most provinces and territories have a two-dose vaccine program, the 
schedules implemented by province/territory varies widely across Canada, with eight different 
schedules amongst the 13 provinces/territories [36]. These schedules differ in the timing of the 
first dose (12 to 15 months), the timing of the second dose (e.g. 18 months vs. 4-6 years), the 
type of vaccine given at the first and second dose (varicella vs. MMRV) and the availability of 
catch-up doses [36]. In 2001, Alberta became one of the first provinces to implement a routine 
chickenpox vaccine program with Varivax® for children aged 12 months [37]. In 2010, they 
switched to the combined vaccine MMRV (Priorix-Tetra®) for vaccination at 12 months and 
proceeded to add a second dose of MMRV at 4-6 years in 2012 [37].  
3.4.3. Burden of illness post-chickenpox vaccination 
Following chickenpox vaccine implementation in the US chickenpox incidence decreased 
by over 90%, while simultaneously precipitating an 88% reduction in hospitalizations, and 74% 
to 92% fewer deaths associated with chickenpox [38–40]. Similar declines were seen in 
Canadian provinces following the initiation of chickenpox vaccination. For instance, eight years 
following the introduction of chickenpox vaccination in many provinces Waye et al. [41] found 
that chickenpox hospitalization decreased by up to 86% nationally (86% in children aged 1-4 and 
46% in adults 40-59). Simultaneously, Wormsbecker et al. [42] found annual declines in office 
visits ranging from 7.7-9.1% in Ontario between 2004 and 2011. These findings demonstrate the 
effectiveness of chickenpox vaccination to reduce the medical outcomes associated with 
chickenpox, as well as illustrate the ability of herd immunity to diminish the impact of 
chickenpox in non-vaccinated populations. However, outbreaks and breakthrough cases continue 
to occur in Canada [34,43,44].  
Like many other vaccine-preventable diseases, diagnosis of breakthrough infection for 
chickenpox is difficult, as symptoms are often less severe, and individuals may not have the 
characteristic rash. Lab-diagnosis of chickenpox infection can also be hampered by vaccination 
as the evidence shows that established lab tests used to identify wild-type chickenpox are not 
accurate tests for identifying vaccine-VZV [15]. Estimating the number of individuals with 
breakthrough illness is also difficult as the cases are quite mild and therefore individuals may not 
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seek medical attention. However, estimates suggest that around 3-9% of total chickenpox cases 
are breakthrough cases and this number is likely to grow as a greater percentage of the 
chickenpox incidence [41,45].  
As mentioned above adverse events are relatively uncommon with chickenpox 
vaccination; however, the increased risk of febrile seizures with MMRV has policy-makers re-
considering when they give the first dose of varicella vaccination and whether they continue to 
provide MMRV to children 12 months old. Furthermore, due to the close relationship between 
chickenpox and shingles, researchers and policy-makers have also raised concerns about the 
indirect negative consequences of universal chickenpox vaccination. Multiple modelling studies 
of the biological and epidemiological relationship between chickenpox and shingles predict that 
if exogenous boosting exists then the implementation of the chickenpox vaccine, and therefore 
the reduction in natural boosting opportunities, could lead to an increase in shingles cases [12].  
However, the impact of chickenpox vaccination on shingles is unconfirmed, with studies of the 
burden of shingles post chickenpox vaccination remaining inconsistent [12].  
3.5. Infectious disease modelling 
3.5.1. General background on infectious disease models 
Models are simplified representations of reality, providing a formal framework for 
analysis by synthesizing information from multiple sources. Models are becoming increasingly 
useful in health and have been applied to a variety of health conditions, programs and processes. 
One area of growing interest is using models to represent the spread, prevention and treatment of 
infectious diseases. Infectious diseases are typified by the fact that the disease survives and is 
transmitted by travelling from one host to another. This means an individual’s risk of getting the 
disease is dependent on population factors, particularly the number of protected, infected and 
susceptible people in a population. The fact risk can vary over time depending on disease 
transmission makes modelling infectious diseases complex. However, disease models can be the 
only way to predict and measure the consequences and outcomes associated with the prevention 
and treatment of infectious disease.  
Models can be used in the understanding, testing and evaluation of infectious diseases 
and their prevention and treatment programs. Examples of where infectious disease models have 
been used include, the calculation of unknown infectious disease parameters (e.g. basic 
reproductive number), measuring the effectiveness of an intervention, determining population 
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level effects (e.g. herd immunity threshold), and conducting economic evaluations [46]. One of 
the big questions that models can help to answer is whether different prevention programs, for 
example vaccination, are effective at preventing negative disease outcomes. Typically, the only 
way to measure the effect of a vaccine on incident cases, prior to its implementation, or prior to 
changing vaccination program (e.g. type of vaccine, schedule, target population), is to use 
dynamic infectious disease models.  
3.5.2. Types of infectious disease models 
In recent years there has been an explosion in the types of models used for infectious 
disease and the choice of model is highly dependent on the research question. A common 
distinguishing feature of models is whether they are static versus dynamic. Static models have a 
constant risk and therefore cannot account for the fact that the force of infection may change 
over time. While static models can capture the direct impacts of vaccination programs (e.g. the 
number of people who are directly protected through vaccination), they cannot capture the 
indirect effects (e.g. the number of people protected through vaccination due to a reduction in 
disease transmission). To capture these indirect consequences, researchers need to use dynamic 
models. While not always necessary in the estimation of vaccine cost-effectiveness, dynamic 
models allow the force of infection to change over time. Therefore, the model can explicitly 
illustrate the spread of infection through populations and with that the indirect effects associated 
with prevention methods (e.g. vaccination) and treatments (e.g. anti-retroviral for HIV). 
Examples of indirect effects of vaccination that can be captured by dynamic models include, 
type- or strain-replacement, immunity boosting effects, herd immunity and shifting of age 
patterns.  
Another key distinguishing factor between models is whether the unit of analysis is the 
population or the individuals. In an aggregate model, the population is structured into groups 
(e.g. susceptible, recovered, infected), and transitions between groups occurs based on certain 
probabilities (e.g. risk of infection). In comparison, in individual-based models there is a system 
of interacting individuals (e.g. agents). Each agent is defined based on several characteristics 
(e.g. age, sex, disease status) and population outcomes are emergent from the interaction 
between individuals. Other model benefits include the memory associated with the model (i.e. 
can the model consider what has happened to an individual and/or population before), whether it 
includes a network (i.e. do diseases and messages spread through the contact between 
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individuals, where connections are based on certain rules, for instance, based on distance or age), 
and its stochastics (i.e. random events and chance are built into the model, so every model run 
will be different). Therefore, ABMs may be used when an individual’s history of disease and 
treatment should determine their risk of a certain outcome, for example the very complex 
medical history of a diabetes patient may provide evidence of their risk of coronary artery 
disease. Individual-based models are also particularly useful when contact networks can have a 
profound impact on disease outcomes. For instance, individual-based model may be better suited 
to represent the spread of sexually transmitted infections, where an individual’s connection 
determines their risk of infection, or measles, where vaccine refusers may congregate in one 
geographical location.  
One of the newest types of models are agent-based models (ABMs), which include one or 
more populations composed of individual agents. In ABM, each agent is associated with, one or 
more states (e.g. age state, health or vaccination state), a variety of parameters (e.g. gender,) and 
have rules for interacting with other agents. These elements of ABM are found in the Person-
class of the modelling software Anylogic®. Each agent is embedded in an environment, called 
Main-class, where they may be part of a contact network connecting individual agents and where 
messages and disease can pass through the network. ABMs are generally individual-and 
network-based, dynamic, non-memoryless, and stochastic models. These factors mean ABMs are 
generally very flexible and can represent complex disease processes, as described above; 
however, they can be difficult and time-consuming to build and run, and require specific and 
difficult to acquire data and longer run times.   
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CHAPTER 4- EVALUATION OF THE EFFECT OF CHICKENPOX 
VACCINATION ON SHINGLES EPIDEMIOLOGY USING AGENT-BASED 
MODELLING  
Article reproduced with permission and with minor edits. Originally submitted as:  
Rafferty E, McDonald W, Qian W, Osgood  ND, Doroshenko A. (2018). Evaluation of the effect 
of chickenpox vaccination on shingles epidemiology using agent-based modelling. PeerJ. 
Accepted May 30th, 2018. My contributions to this manuscript included conceptualizing the 
model, conceiving and designing the study, running the experiments, analysing and interpreting 
the findings and manuscript preparation. Wade McDonald, with the help and guidance of 
Weichang Qian, updated my original chickenpox agent-based model to run on a larger 
population, included a more complex distance-based network, represented contacts based on age, 
calibrated the model to data from the literature, outputted results from each model run, created a 
system to run the model on multiple computers at one time and oversaw the running of our 
model experiments.  Dr. Nathaniel Osgood, aided in the conception and the design the study, and 
oversaw all model adaptations and model runs. Dr. Alexander Doroshenko aided in the 
conception and design of the study and also contributed to the analysis of our findings. All 
authors helped in the interpretation of findings and in reviewing and editing the manuscript.  
 
In this chapter, we describe the agent-based model we built to represent VZV disease, 
transmission, vaccination states and coverage, waning and boosting of immunity. We use this 
model to investigate how chickenpox vaccination in Alberta impacts the incidence and age-
distribution of shingles over 75 years post-vaccination taking into consideration a variety of 
plausible theories of waning and boosting of VZV immunity. We undertook this analysis based 
on the gaps in the literature identified in Chapters 2 and 3, specifically the lack of evidence of 
the impact of chickenpox vaccination on shingles disease outcomes. Previous models and 
epidemiological studies on the boosting of VZV-immunity for shingles found that while there is 
evidence that boosting of VZV exists, there is little evidence for the strength or duration of that 
boosting effect. Unknowns surrounding the unintended outcomes of chickenpox vaccination has 
prompted many countries to delay vaccine implementation, even though there is a safe and 
effective vaccine available. The model described in detail in this chapter also provides the 
foundation for testing the effectiveness and cost-effectiveness of chickenpox vaccination overall, 
and for two specific chickenpox vaccine schedules, as described in Chapters 5 and 6.  
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4.1. Introduction 
Varicella (chickenpox) and herpes zoster (shingles) are two diseases caused by the 
varicella zoster virus (VZV). Individuals are generally infected with chickenpox in childhood. In 
Canada prior to vaccination, approximately 11.7 per 1,000 persons were infected with 
chickenpox each year, which was estimated to cost about 122 million CAD$ annually [1]. 
Following primary chickenpox infection, the VZV migrates to the sensory nerve ganglia, where 
it remains latent and can subsequently reactivate as shingles, which causes a dermatomal rash 
often accompanied by itching and pain [2]. Shingles was estimated to occur at a rate of 1.2-3.4 
per 1000 per year (3.9-11.8 cases per 1,000 per year in those >65 years) in Canada before 
chickenpox and shingles vaccination [3]. Some studies suggest that the incidence of shingles was 
increasing in the decades before the introduction of chickenpox vaccination [4–6]. 
Although much remains unknown about shingles and the reactivation process, research 
has demonstrated that the maintenance of latency is largely governed by VZV cell-mediated 
immunity (VZV-CMI). Successful reactivation of shingles occurs when VZV-CMI weakens to a 
yet unknown level, which is often a result of the normal ageing process [7]. However, the 
literature shows there are likely other risk factors that can result in inadequate immune response 
to VZV reactivation at any age, including mental health, stress, comorbid infections (e.g., 
cytomegalovirus [CMV] infection) and immunosuppressive therapy, and disease-related 
immunosuppression (e.g. HIV-AIDS) [7]. In parallel to the natural waning of VZV-CMI 
immunity, one theory posits that exogenous boosting of VZV-CMI can reduce one’s risk of 
shingles reactivation [8–10]. Exogenous boosting occurs when a VZV immune individual is 
exposed to a case of chickenpox or shingles. 
The theory of exogenous VZV-CMI boosting has sparked a debate about whether the 
chickenpox vaccine will limit the boosting of immunity to shingles and therefore increase the 
incidence of the disease; however, the empirical data to-date is largely inconclusive [4,11]. This 
debate has prompted many countries, including the United Kingdom and France, to delay the 
implementation of a universal chickenpox vaccine, even though there is a safe and effective 
chickenpox vaccine available [12]. In comparison, other countries, including Canada and the 
USA, currently recommend a two-dose chickenpox vaccination schedule [13]. Alberta 
introduced a universal one-dose chickenpox vaccination program for 12-month-olds in 2001 and 
in 2012 added a second dose for children aged 4-6 years. Russell et al. found that shingles 
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incidence was increasing in Alberta in the period 1994-2010, both before and after the 
introduction of the chickenpox vaccination [4].  
The unique connection between chickenpox and shingles makes independently exploring 
their disease dynamics difficult. Using mathematical modelling to study the interacting factors 
related to these diseases – in particular, how chickenpox vaccination may impact shingles disease 
and epidemiology – complements conventional epidemiological studies and offers a unique 
approach to evaluating effects of vaccination in a controlled study using simulated data.  
Most previous modelling studies of shingles and chickenpox have been conducted using 
aggregate population-level models [6].  Both agent-based and aggregate models can simulate the 
indirect effects of varicella vaccination, including the changing risk of disease over time, herd 
immunity, age-category specific mixing and rates, and increasing age of infection. However, 
agent-based models (ABMs) provide a number of advantages in the study of many infectious 
diseases, including allowing the exploration and measurement of disease dynamics at multiple 
levels and the adjustment of both individual and population parameters [14–18]. In the study of 
the VZV, ABMs can provide for realistic and comprehensive simulation of the transmission of 
infection and boosting of immunity by explicit modelling of network-mediated contacts, and 
flexibility in specifying interpersonal contact. ABMs allow the simulation of between-host 
dynamics (e.g., transmission) at an individual level, while also capturing spatial limits on such 
transmission and allowing the simulation of continuous within-host dynamics, including for both 
aging and individual waning of VZV-CMI; the characterization of such factors as continuous 
processes offers flexibility in terms of reporting and characterization individual-level dynamics 
[15–17,19].  
ABMs can further represent detailed elements of vaccination, including vaccine attitudes, 
uncertainties in vaccine coverage and – critically for this study – continuous waning of vaccine 
immunity. Importantly for supporting options for later expansions and refinements of this model, 
the individual-level representation can readily represent reporting and vaccination attitudes 
dynamics based on family context. As ABMs support reporting an individual’s disease or 
vaccination status in light of their history, catch-up immunization and breakthrough illness can 
also be represented in a modular manner that scales well to more complex vaccination regimes.  
Finally, ABMs take into account stochastics and readily accommodate large number of 
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dimensions of heterogeneity, including sex, age, spatial location, comorbid conditions, and 
detailed information on condition-specific individual history [16–19].  
A systematic review of empirical and modelling studies on the boosting of VZV-CMI for 
shingles found that while there is evidence that boosting of VZV-CMI exists, there is little 
evidence of the strength or duration of that boosting effect [6]. The majority of chickenpox 
vaccination models that incorporated boosting have predicted there will be an increase in 
shingles incidence post chickenpox vaccination; however, most of them have assumed a high 
force of boosting [20–22]. While modelling studies have explored the plausibility of various 
types of boosting (e.g., progressive immunity, partial immunity, temporary immunity) [22,23], 
there is little exploration of the duration of shingles immunity following boosting and the rate at 
which an individual’s immunity to VZV wanes over time, and how changing assumptions 
regarding these factors may impact the rate of shingles following chickenpox vaccination. 
Within this work, we sought to develop an ABM of chickenpox and shingles disease and 
vaccination based on current immunological, medical and epidemiological data, and replicate the 
epidemiology of chickenpox and shingles in Alberta, Canada before chickenpox vaccination 
using diverse quantitative theories of waning and boosting of VZV immunity. In Alberta, 
universal chickenpox vaccination has been in place since 2002, and detailed population 
demographics and chickenpox and shingles epidemiological data is available for both before and 
after vaccine implementation. The primary objective of this study was to determine how 
chickenpox vaccination in Alberta impacts the incidence and age-distribution of shingles over 
the 75-year post-vaccination period, by determining plausible values for waning of natural 
immunity and the duration of exogenous boosting (i.e. the length of protection following a 
boosting event). 
4.2. Methods 
We developed an ABM using the multi-method simulation software AnyLogic® 
Professional (version 7.3.7), that represents chickenpox transmission, chickenpox and shingles 
disease and vaccination states, as well as the waning and boosting of VZV immunity (Data 
reference 1). The model is initialized after a 75-year burn-in period, with any calibration or 
experimentation taking place after that period. We included such a burn-in period representing 
the average lifespan, to ensure that individuals were at different stages of waning of VZV 
immunity and therefore at different risk of getting shingles. A long burn-in period meant when 
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we started running the experiments there were some agents in the recoveredCP state who had 
had their natural immunity to VZV waned almost to zero (i.e. about to transition to 
infectedShingles) and other agents who were at the start of the waning process. This study was 
approved by the Health Ethics Research Board at the University of Alberta, study ID 
Pro00068334. 
4.2.1. Model structure and agent-characteristics 
Statecharts related to within-host dynamics of the model are shown in Figure 4.1A. A 
disease statechart where agents are in protected, susceptible or disease states determined an 
agents’ probability of contracting chickenpox or shingles. The chickenpox and shingles 
vaccination schedules’ statecharts represented which vaccination each agent received. The 
chickenpox vaccination schedule was modelled based on the Alberta VZV vaccination policy 
[24].  Agents become due for chickenpox vaccines at the ages of 12 months for the first dose and 
at 4-6 years - for the second dose (Figure 4.1B.). A representation of one-dose shingles 
vaccination given to individuals 50 years or older is depicted in the statechart shown in Figure 
4.1C. However, currently shingles is not part of the publicly funded schedule in Alberta and 
therefore was not included as part of this analysis. As our model was calibrated to data from 
before the shingles vaccine was available in Canada, excluding the shingles vaccine did not 
impact our ability to accurately calibrate our model. An agent receives a vaccine dose with a 
probability based on its vaccine attitude as described below. If an agent receives the second dose 
but has not yet received the first, it may also receive a catch-up of the first dose with a certain 
probability. These probabilities are specified by parameters, as shown in Table 4.1. A full list of 
the parameters and their values are available in Appendix C. A demographic statechart 
represented Alberta births, ageing and mortality characteristics (Figure 4.1D). 
An agent’s chance of being infected with chickenpox was dependent on whether they 
came into contact with someone with infection and the risk of transmission on such a contact. In 
comparison, an agent’s likelihood of getting shingles was determined by their individual waning 
immunity timer. After chickenpox infection (i.e. when an agent enters the recoveredCP state), a 
countdown on “Immunity Waning Time” initiates; when it completes, the agents become 
susceptible to shingles (i.e. transition to infectedShingles at a specified rate). The “Immunity 
Waning Time” was represented by a formula derived from Ogunjimi et al. [25] and further by 
calibration (Figure 4.2 & Table 4.2). This equation inherits assumptions whereby force of 
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reactivation is represented by a gamma distribution, initial CMI is represented by a normal 
distribution and the waning of immunity rate for shingles is a fixed rate that can be altered using 
a coefficient, specifically the waning of immunity coefficient (WoI) [25]. The WoI is a 
parameter, whereby we can easily modify the waning of immunity rate by age. Furthermore, to 
account for the small but sharp increase in childhood shingles cases as observed in Russell et al. 
[4], we included a small proportion of the population between the ages of 0 and 19 (5%) who had 
a short waning of immunity timer, allowing the model to account for individuals who may have a 
weaker force of boosting, lower initial CMI (e.g., immunocompromised) or a very quick waning 
of the immunity rate.  
An agent’s “Immunity Waning Time” could also be increased by an exogenous boosting 
event, which occurred when an agent who is recovered from chickenpox is re-exposed to a case 
of chickenpox or shingles. Therefore, an agent’s chance of getting shingles was also determined 
by the number of years they were protected through boosting, what we call the duration of 
immunity through boosting (DoB). The model assumed progressive boosting, as postulated by 
Guzzeta et al. [22] and therefore the number of years of boosting protection was calculated by 
multiplying the number of times an agent comes into significant contact with the VZV by the 
duration in years of each boosting event. The number of boosting events was determined through 
the distance-based contact network and the duration of each boost was equal to the number of 
years of added protection from shingles derived through each boost. Altering the quantitative 
values of DoB and WoI of shingles resulted in significant changes in the incidence of shingles in 
the population. 
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Figure 4.1. Statechart structure for ABM (A) Disease and protection (B) Chickenpox vaccination schedule (C) Shingles 
vaccination schedule (D) Demographics (E) Hospitalization 
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Table 4.1. Data sources, key parameter values and values of calibration 
Parameter 
category 
Parameter Name Description Value Data Source 
Demographics Population size  Population size at the model’s initialization. 500,000  
Mortality rates Life tables for Alberta age group used to 
estimate mortality rates in our population 
Table- available from 
Statistics Canada 
Statistics Canada 
[26] 
Fertility rates  Pregnancy outcomes (live birth) for Canada 
by age group  
Table- available from 
Statistics Canada 
Statistics Canada 
[27] 
Age distribution Age distribution of the population at the 
model’s initialization 
Table- available from 
Statistics Canada 
Statistics Canada 
[28] 
Disease 
Mechanisms 
Waning of immunity time 
(shingles) 
This variable is calculated for each individual 
when they reach the recoveredCP state and 
can change with natural exogenous boosting 
of shingles immunity (i.e. contact with a case 
of chickenpox and shingles). A full 
description of how it is calculated is 
presented in Figure. 4.2.  
‘Years protected through 
infection’ (includes 
parameters ‘initial cell-
mediate immunity VZV’, 
‘force of reactivation’, 
waning of immunity rate 
and coefficient) + ‘Years 
protected through 
boosting’ (‘duration of 
boosting’ and number of 
boosting events) 
Ogunjimi et al. 
[25] 
Initial cell-mediated 
immunity VZV 
The distribution across the population of cell-
mediated immunity for shingles derived from 
initial infection with VZV. (See Figure 4.2) 
Max (0.001, normal 
(0.05,1)) 
Ogunjimi et al. 
[25] 
Force of reactivation Represents the distribution of force of 
reactivation for shingles. It is a unitless value 
used to calculate the ‘waning of immunity 
time’. (See Figure 4.2) 
Gamma distribution 
(2,0.1,0) 
Ogunjimi et al. 
[25] 
Waning of immunity rate 
shingles 
Annual loss of protection based on VZV-
CMI. 
0.4 Ogunjimi et al. 
[25] 
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Waning of immunity 
coefficient shingles (WoI) 
Coefficient to determine the annual loss of 
protection based on VZV-CMI. A coefficient 
allowed us to easily modify the waning of 
immunity rate with a parameter, specifically 
by age. 
Values tested in 
calibration: 0.45-0.93 
Values included in the 
analysis: 0.50-0.74 
See Table 4.2 
Calibration 
Duration of exogenous 
boosting (DoB) 
Number of years before your protection 
returns to previous levels (i.e. extra years 
protected) following an exogenous boost 
from a shingles or chickenpox case. 
Values tested in 
calibration: 0.42-10  
 
Values included in the 
analysis: 2-7 
See Table 4.2 
Calibration 
Disease 
Propagation 
Exogenous infection rate 
(1/Year) 
Represents rate per year of chickenpox 
infection imported from outside the pop.  
17.83 Calibration 
Probability of chickenpox 
infection on contact 
Determines the likelihood that chickenpox 
will be transmitted when an agent (with 
normal or breakthrough chickenpox, or 
shingles) contacts a susceptible.  
Normal: 0.781  
Breakthrough: 0.234 
Shingles: 0.234 
Ceyhan et al. [29] 
Gershon et al. [30] 
Calibration 
Network 
characteristics 
Connection Range 
(Length) 
Distance of an individual’s connection range. 
The range depended on whether you were 
included in the preferential mixing age or the 
normal mixing age.  
Preferential Range= 
21.245 
Normal Range= 8.958 
Control mixing 
patterns were 
calibrated based on 
cumulative 
incidence and age-
distribution of 
chickenpox and 
shingles over time. 
 
Statistics Canada 
[26–28] 
Mossong et al. [31] 
Shingles connection range 
modifier 
A ratio to lower the connection range of 
individuals with HZ to make it less infectious 
than chickenpox. 
0.124 
Base contact rate (1/Day) Number of contacts per agent per day, which 
dependent on if you were part of the 
preferential or normal age range. 
Preferential contact rate= 
20; Normal contact rate= 
3 
Preferential mixing age 
(Year) 
Age group where we have increase the 
connection range and base contact rate to 
better reflect the dynamics in the population. 
1-9 years 
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Population density 
(Agents per length)  
Represents the number of agents per arbitrary 
distance for urban and rural population. This 
parameter in combination with connection 
range determines the number of connections 
an agent has in our model.  
 
Urban: 0.3 
Rural: 0.2 
Chickenpox 
vaccine 
parameters 
 
 
 
Vaccination attitude in the 
population (%) 
Distribution of vaccine rejector, hesitant and 
acceptors in the population. 
Acceptor = 65, Hesitant = 
30, Rejector = 5 
Vaccine coverage 
generated by the 
model through 
calibration 
 
Alberta Health 
[32] 
 
 
Probability Catch-Up (%) Probability that an individual will get a catch-
up vaccine when due for second dose 
vaccination. 
55 
Probability first dose 
vaccination (%) 
Probability an individual will get first dose 
vaccination given their vaccine attitude. 
Acceptor= 97, Hesitator= 
75, Rejector= 3 
Probability second dose 
vaccination (%) 
Probability an individual will get second dose 
vaccination given their vaccine attitude. 
Acceptor= 98, Hesitator= 
82, Rejector= 33 
Primary vaccine failure 
chickenpox (%) 
The percent of individual that do not have an 
immune response to chickenpox vaccination.  
 
1st dose= 16-24 
2nd dose= 5-16 
Gershon et al. [30] 
Bonanni et al. [33] 
Duncan et al. [34] 
Waning of chickenpox 
vaccine immunity (1/Year) 
The rate that chickenpox vaccine immunity 
wanes each year.  
1st dose protected= 0.02 
2nd dose protected= 0.00 
Gershon et al. [30] 
 69 
Figure 4.2. Equations to calculate the shingles immunity waning timer 
 
 
 
 
 
 
 
Shingles Immunity Waning Timer = (1) Years Protected Through Infection + (2) Years 
Protected Through Boosting   
 
(1) Years Protected Through Infection = 
min (0,log(forceOfReactivation/InitialCMI)
min(0,log(1−waningOfImmunityRateShingles)
 
(2) Years Protected Through Boosting= Number of times an agent comes into significant 
contact with VZV (in the form of chickenpox or shingles) X The duration in years of 
each boosting event 
 
Where: 
ForceOfReactivation= The strength of shingles reactivation, i.e. the amount of VZV-CMI 
need to stop reactivation in the form of shingles, the value for each individual in our 
population is drawn from a gamma distribution. 
InitialCMI= The initial level of VZV-CMI protection conferred following chickenpox, the 
value for each individual in our population is drawn from a normal distribution.  
WaningOfImmunityRateShingles= the rate of annual loss of VZV protection (1/years). 
The WaningOfImmunityRateShingles is a fixed rate that can be altered in our model using 
the waning of immunity coefficient.  
Duration of each boosting event= The number of years of protection gained through each 
significant boosting event, this value is based on calibration results.  
 
This equation was derived from the model presented in Ogunjimi et al. [25] 
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Table 4.2. Calibration results to determine duration of immunity following boosting and 
waning of immunity coefficient 
 Duration of immunity 
following boosting- 
DoB (years) 
Waning of immunity 
coefficient- WoI 
(1/year) 
P-values1 
Combination 12 0.42 0.45 <0.001 
Combination 2 2 0.50 0.051 
Combination 3 3 0.55 0.313 
Combination 4 4 0.60 0.052 
Combination 5 
(Baseline 
Scenario)3  
5 0.63 Reference 
Combination 6 6 0.68 0.963 
Combination 7 7 0.74 0.121 
Combination 8 8 0.79 0.001 
Combination 9 9 0.85 <0.001 
Combination 10  10 0.93 <0.001 
1P-values for Mann-Whitney U test comparing age-specific shingles incidence sum of residuals squared for 
Combination 5 (Baseline Scenario, DoB=5 years WoI= 0.63) to all other Combinations (1-4 and 6-10). Calibrations 
scenarios deemed statistically not different (i.e., p-value >0.05) were included in the main experiment. Calibration 
scenarios which were statistically different from the best-fit calibration experiment were excluded. 
2Represents combinations of DoB and WoI, all other parameters in the model stayed the same.  
3Baseline scenario was the combination of DoB and WoI with the smallest absolute median difference between 
model incidence rates of shingles and empirical data for each age group as determined by lowest sum of residuals 
squared 
 
4.2.2. Contacts, network and spatial context 
The VZV model represented agents in a stylized geographic area, where agents are 
connected to other agents based on their proximity to one another (a distance-based network). 
When agents are randomly placed in the model environment they are connected to all other 
agents within their connection range (connectionRange_Norm). The contact rate 
(baseContactRate_Norm) determines the number of contacts (e.g. messages) an agent makes to a 
connected agent per day. It is through these messages, sent through connections and contacts, 
that individuals can transmit chickenpox infection and provide boosting of VZV. These contact 
and mixing patterns were calibrated to cumulative incidence and age-distribution of chickenpox 
over time using a pattern-oriented modelling approach [4,35,36]. Moreover, to capture the 
transmissibility of VZV, we included a parameter for the risk of chickenpox infection on contact. 
We included different infection rates for when a susceptible agent came into contact with a 
normal chickenpox case (probCPDiseaseOnContact), a breakthrough case of chickenpox 
(probCPDiseaseOnContactWithBreakthrough) and a shingles infection 
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(probCPDiseaseOnContactWithShingles) [29]. These probabilities also determined the 
likelihood of someone receiving a boost of VZV immunity from each infection type. 
Furthermore, to represent the increased contact time and range of connectivity among 
day-care and early school-aged children, we incorporated differing connection ranges and 
contact rates based on age [31]. Those aged one to nine years were considered ‘preferential 
contacts’ in our model, and therefore have a higher contact rate (baseContactRate_Pref) and 
connection range (connectionRange_Pref) when interacting with individuals within the same age 
range. We chose this group to represent ‘Preferential Contacts’ as these are the age groups with 
the highest rates of chickenpox infection as described by Kwong et al. [35]. These network 
adjustments ensured more realistic contact network assumptions than random-mixing and 
compartmental models do, such that not only age-group preferences of contacts were captured, 
but also increased global connectivity due to bridging effects of younger age groups was 
considered (Data reference 2). We also included a low-density periphery and a higher density 
central region to better represent how disease spreads in a typical public health district in Albert 
(or comparable jurisdiction) spanning an urban center and rural regions. Approximately 20% of 
our population were part of low density regions and the remainder, 80%, reside in a high-density 
region.  
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Figure 4.3. Model-generated (blue line) and published (red line) age-specific incidence rates 
for chickenpox and shingles used in model calibration – baseline scenario (A) Model data is 
based on 30 paired simulations for the baseline scenario (DoB= 5 years; WoI= 0.63); empirical 
data as described by Kwong et al. [35]; best fit is achieved at 2.5 multiple of empirical data; (B) 
Model data is based on 30 paired simulations for the baseline scenario; empirical data as 
described by Russell et al. [4] (In all images the blue polygon represents pointwise minimum and 
maximum values) 
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4.2.3. Parameterization 
To parameterize the model, we conducted a comprehensive literature review of 
chickenpox and shingles disease, including modelling, epidemiological, and immunology studies 
and drew evidence from Alberta’s Interactive Health Data Application (IHDA) [37]. The main 
parameters are listed in Table 4.1. We drew demographic data, including Alberta life tables, and 
population and age distributions, and Canadian fertility rates from Statistics Canada [26–28]. 
Chickenpox vaccination parameters, such as those associated with primary vaccine failure and 
waning of vaccination immunity were derived from literature [30,33,34]. We built the 
mechanism whereby vaccine coverage was generated by our model based on distribution of 
vaccination probabilities and population vaccination attitudes as described by Doroshenko et al. 
[38]. We classified all individuals into three groups: those who accept, reject and are hesitant to 
receive vaccination, and we assigned vaccination probabilities for each of these groups. We used 
calibration to ensure that model-generated vaccine coverage rates were comparable to those 
reported in Alberta [37]. For the baseline scenario in the main experiment, chickenpox 
vaccination maintained an average coverage for the first dose of 85.58% (95% CI 85.54-85.62) 
and second dose coverage of 80.28% (95% CI 80.24-80.32) across all years and all model runs. 
4.2.4. Calibration and validation of the model 
We calibrated our model using a step-wise approach. First, we ran an initial AnyLogic® 
calibration experiment to determine the values for four unknown parameters in our model, 
duration of immunity following exogenous boosting (DoB), waning of immunity coefficient 
(WoI) (the parameter that modified the waning of immunity rate), exogenous infection rate (i.e. 
the number of chickenpox cases brought in from outside the simulated population) and shingles 
connection range (i.e. modification factor for the connectionRange for people with shingles, to 
account for the closer contact required to spread VZV through shingles in comparison to 
chickenpox). The calibration experiment automatically varied these parameters and validated 
model output against age-specific incidence of shingles prior to vaccination as described by 
Russell et al. [4] (Figure 4.3B) and chickenpox prior to vaccination, as described in Kwong et al. 
[35] (Figure 4.3A). As we only had empirical data for medically-attended chickenpox [35], we 
tested different underreporting factors and found that reported chickenpox cases constituted 
approximately 40% of all cases in our model (an underreporting factor of 2.5, consistent with 
previous studies that suggest the degree of underreporting can range between 2.5 and 7.7 in a 
country where chickenpox is notifiable) [39]. Furthermore, the overall chickenpox incidence 
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when the vaccination function was disabled in the model was consistent with findings in Canada 
prior to vaccination [40].  
This initial calibration experiment predicted an exogenous infection rate of 17.8 per year 
and a shingle connection range modifier of 0.12 (suggesting shingles is 8 times less likely to 
spread VZV infection than chickenpox). Furthermore, based on the automated experiment values 
for DoB of 0.42 years and a waning of immunity coefficient of 0.45/year we produced age-
specific incidence rates for shingles and chickenpox consistent with empirical data.  
Using the initial calibration values described above as a starting point, we then further 
investigated whether different combinations of DoB and WoI could reproduce empirical data. 
We used a pattern-oriented modelling approach [36] to compare the incident rates resulting from 
a range of plausible values for DoB and WoI to the empirical incidence rates for chickenpox and 
shingles [4,35,36,41,42]. At this stage we considered paired values of DoB and WoI to have 
satisfied calibration if the resulting overall rate of chickenpox and shingles, over a model run of 
100 years on 50,000 population, was within 10% of the empirical values [36,41,42]. Based on 
these guidelines we found nine other values for a combination of DoB and WoI that met the 
second step of calibration. 
Finally, we then ran the ten combinations that met the initial calibration criteria noted 
above for a period of 100 years on 500,000 population sample. Output from each run was then 
compared to empirical data on age-specific incidence rates for chickenpox and shingles. We 
calculated the absolute median difference between model incidence rates of shingles and 
empirical data for each age group to determine which combination had the smallest difference as 
determined by lowest sum of residuals squared. The combination with the lowest sum of 
residuals squared (27.95) for shingles was then considered our baseline scenario in our main 
experiment, which represented best fit (Baseline scenario= DoB 5 years and WoI 0.63) (Data 
reference 3). The sum of residuals squared from each combination was then compared to the 
baseline scenario and tested for statistically significant difference using the Mann-Whitney U test 
at the 5% level of significance. Based on the findings of the statistical tests and as a form of 
scenario analysis, we included both the baseline scenario along with any other DoB and WoI 
combinations that were not statistically different (p value >0.05) from baseline. These model 
runs became the scenarios in our main experiment.  
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4.2.5. Main experiment 
For each of the six scenarios chosen for the main experiment, we conducted at least 30 
paired runs, with and without chickenpox vaccination. Running paired runs for each scenario 
allowed the measurement of differences in shingles rates with and without vaccination for each 
DoB and WoI combination. Paired model runs were given the same random seed to ensure 
consistency between parameter and variables in each of the pairs. To determine the number of 
model runs required to achieve saturation of the results we compared the distributions of the 
chickenpox and shingles incidence from two sets of 15 model runs. We found no significant 
difference in distribution for chickenpox and shingles incidence using the Kolmogorov-Smirnov 
Two Sample Test (see Appendix E, Tables E-1 and E-2). Based on these findings we ensured 
each scenario was run at least 30 times, to support the ability of our results to predict a range of 
results with accuracy. Chickenpox vaccination was represented as part of a two-dose schedule, as 
described above. In our model, we implemented chickenpox vaccination starting at 25 years after 
the initialization of the model and continued for 75 years. We calculated 95% predictive intervals 
(2.5th and 97.5th percentiles) for change in cumulative shingles incidence between vaccination 
and no-vaccination scenarios for each time points and scenario. The cumulative incidence rate of 
shingles cases between the runs with and without chickenpox vaccination were compared at the 
5% level of significance using the Kolmogorov-Smirnov statistical test at four different time 
periods, specifically at 10, 25, 50 and 75 years, following introduction of vaccination.  
4.2.6. Sensitivity analysis 
We ran several scenario analyses that tested how varying vaccination parameters may 
impact the count of shingles cases following chickenpox vaccination. Specifically, we compared 
a one-dose to a two-dose chickenpox vaccine schedule.  In a separate set of analyses, we 
compared coverage rates by moving 10% of hesitant individuals to vaccine acceptors (higher 
vaccine coverage) in one sensitivity analysis and 10% of hesitant individuals to vaccine rejectors 
(lower vaccine coverage) in the second sensitivity analysis. Furthermore, we tested the impact of 
removing the boosting of shingles immunity (i.e., positing no added years of protection on 
contact with a chickenpox/shingles case) to see the overall impact of removing this biological 
effect on the shingles incidence estimates both before and after chickenpox vaccination. We 
calculated 95% predictive intervals for change in cumulative shingles incidence between 
vaccination/no-vaccination scenarios for each time point and sensitivity analysis combination.  
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4.3. Results 
4.3.1. Input calibration  
Based on the last step of our calibration we found that the age-specific shingles residuals 
for the baseline scenario (DoB= 5 years; WoI= 0.63) were not significantly different to five of 
the other combinations (Table 4.2). These combinations were then included as six scenarios in 
our main experiment (Scenario 2-7, sum of residuals squared for shingles ranges from 27.95 to 
41.51, p-value >0.05) (Date Reference 2). All sum of residuals squared for chickenpox by age 
group were not statistically different from baseline for each combination of DoB and WoI (sum 
of residuals squared for chickenpox ranges from range 249.20 to 251.00, p-value >0.05). As one 
of the calibration validity tests, we tried to fit model to empirical data with no boosting, however 
when we disabled boosting we could not replicate the age-specific incidence rate observed in 
Alberta prior to vaccination [4].  
4.3.2. Main experiment 
Chickenpox vaccination lead to a large drop in chickenpox cases across all six scenarios. 
In the baseline scenario, the cumulative incidence of chickenpox dropped from 1,254 cases per 
100,000 person-years pre-chickenpox-vaccination to 193 cases per 100,000 person-years 10 
years after the vaccine implementation. The cumulative incidence of chickenpox was further 
reduced to 49 cases per 100,000 person-years 75 years following vaccination. In comparison, all 
scenarios from 10-years and 25-years post-vaccination showed significantly greater shingles 
incidence with vaccination compared to the no- vaccination (Table 4.3). However, the degree of 
this increase and its subsequent decline was markedly different between experiments (Figure 4.4 
and Table 4.3). For instance, in Scenario 2 there was an increase of approximately 22.73 cases 
per 100,000 person-years after 10 years; by comparison, in Scenario 7 the magnitude of the 
increase was greater at 99.29 cases per 100,000 person-years over that decade (p < 0.001). At 75 
years post-vaccination, cumulative incidence ranged from a decline of 69.55 to an increase of 
71.21 per 100,000 person-years for 2 and 7 years of boosting respectively (p < 0.001). By the 75-
year interval, the shingles incidence in all experiments was below the rate with no-vaccination 
(Figure 4.4); however, the cumulative incidence in Scenarios 5-7 was still higher with 
vaccination than without. In all our scenarios, vaccination did eventually lower the overall rate of 
shingles; however, the amount of time was dependent on the DoB and the WoI.
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Table 4.3. Change in all-ages cumulative incidence of shingles over 75 years after implementation of chickenpox vaccination, 
by scenario and time period. 
 
Time periods 
T0-T10  T0-T25  T0-T50  T0-T75  
Scenario 
number 
Cumulative 
incidence- 
chickenpox 
vaccination 
scenario1 
Change in 
cumulative 
incidence2,3 
(95% CI)4 
[% change] 
Cumulative 
incidence- 
chickenpox 
vaccination 
scenario 
Change in 
cumulative 
incidence (95% 
CI) 
[% change] 
Cumulative 
incidence- 
chickenpox 
vaccination 
scenario 
Change in 
cumulative 
incidence  
(95% CI) 
[% change] 
Cumulative 
incidence- 
chickenpox 
vaccination 
scenario 
Change in 
cumulative 
incidence 
 (95% CI) 
[% change] 
Scenario 2  
(DoB=2yr; 
WoI= 0.50) 
405.61 
22.73 
(18.78, 25.18) 
[5.4%] 
402.86 
18.55  
(15.77, 20.23) 
[4.8%] 
375.10 
-8.66  
(-11.10, -5.94) 
[-2.3%] 
313.35 
-69.55  
(-72.13, -66.90) 
[-18.2%] 
Scenario 3  
(DoB=3 yr; 
WoI= 0.55) 
453.01 
41.08  
(35,78, 45,18) 
[10.0%] 
461.13 
47.97  
(45.68, 50.70) 
[11.6%] 
436.68 
23.90 
(21.59, 26.25) 
[5.8%] 
365.29 
-48.317 
(-51.84, -46.05) 
[-11.7%] 
Scenario 4  
(DoB=4 yr; 
WoI= 0.60) 
492.83 
59.0993  
(56.14, 64.78) 
[13.7%] 
515.82 
82.20  
(79.16, 85.14) 
[18.9%] 
497.10 
61.59  
(58.03, 64.78) 
[14.1%] 
413.98 
-22.36  
(-26.94, -18.47) 
[-5.1%] 
Baseline 
Scenario  
(DoB=5 yr; 
WoI= 0.63) 
491.18 
71.74  
(64.84, 76.68) 
[17.1%] 
530.23 
109.54  
(105.29, 112.95) 
[26.0%] 
520.23 
97.40 
(93.73, 100.75) 
[23.0%] 
434.60 
10.31  
(4.6, 13.73) 
[2.4%] 
Scenario 6  
(DoB=6 yr; 
WoI= 0.68) 
512.58 
84.05  
(75.58, 101.22) 
[19.7%] 
573.94 
144.39  
(139.34, 153.38) 
[33.6%] 
572.35 
138.55 
(133.31, 146.45) 
[31.9%] 
475.83 
39.79  
(34.35, 46.30) 
[9.1%] 
Scenario 7 
(DoB=7 yr; 
WoI= 0.74)  
537.47 
99.29  
(90.42, 108.96) 
[22.7%] 
627.23 
185.68 
(177.69, 190.64) 
[41.9%] 
632.65 
185.49 
(181.76, 190.64) 
[41.5%] 
522.70 
71.21  
(67.05, 76.41) 
[15.8%] 
1Median shingles cumulative incidence with chickenpox vaccination per 100,000 person-years (averaged over 30 or more model runs). 
2Change in shingles cumulative incidence per 100,000 person-years calculated as the median shingles incidence with chickenpox vaccination minus the median 
shingles incidence without chickenpox vaccination. Positive number represents an increase in cumulative incidence and negative number – a decrease. 
3Using the Kolmogorov-Smirnov test all changes in cumulative incidence for every time and scenario combination were statistically significant (p<0.05). 
495% predictive interval (2.5th and 97.5th percentile) 
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Figure 4.4. All-ages shingles annual incidence over time after implementing chickenpox 
vaccination by duration of immunity following boosting, 30 paired simulations (A) Scenario 
2 (DoB= 2) (B) Scenario 3 (DoB=3) (C) Scenario 4 (DoB=4) (D) Scenario 5 (DoB=5) (E) 
Scenario 6 (DoB=6) (F) Scenario 7 (DoB=7) (In all images the blue polygon represents 
pointwise minimum and maximum values) 
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At the 10-year interval post-vaccination, all age groups greater than 10 years old showed 
small but equal increases in the number of shingles cases. However, at each subsequent time 
point (as a greater number of persons of younger age are protected with chickenpox vaccination 
from initial infection with the virus), cases of shingles were progressively more concentrated in 
the older age-groups. In contrast, in the younger age group we observed a decrease in shingles 
almost immediately following chickenpox vaccination (Figure 4.5). 
We also noted an interesting phenomenon in the no-vaccination model runs. There was 
an overall increase in shingles cases even without vaccination; in the baseline scenario, 97% of 
model runs found the incidence of shingles was lower at time 10 years (median- 418 per 100,000 
person-years), in comparison to time 75 years (median- 425 per 100,000 person-year). The age-
structure of the population was also changing over this time period (i.e. skewed to an older 
population), which may account for this increase in shingles incidence over time. Moreover, the 
average number of boosts per individual calculated in our model over their life-time (with no 
chickenpox vaccination) was 1.83 with the majority of people receiving 0 or 1 boosts.  
4.3.3. Sensitivity analysis 
The only sensitivity analysis where shingles incidence was significantly different from 
baseline was when we removed exogenous boosting from the model (Table 4.4). In fact, 
removing the biological effect of boosting had a substantial impact on the number of shingles 
cases both before and after vaccination, with cases rising to levels much higher than what was 
seen in Alberta prior to vaccination [4]. Without chickenpox vaccination, the shingles rate was 
very high at 724 cases per 100,000 person-years. Simultaneously, this is the one analysis where 
the rates begin to decline immediately following vaccination with a decline in cumulative 
incidence of 215 per 100,000 person-years 75 years after the implementation of the chickenpox 
vaccine (Table 4.4). The 95% predictive intervals for the change in shingles incidence for all 
other sensitivity analyses at all other timepoints overlapped dramatically with the change in 
shingles incidence for the baseline scenario.
  
8
0
 
Table 4.4 Scenario analysis - change in all-ages cumulative incidence of shingles over 75 years after implementation of 
chickenpox vaccination, by scenario and time period 
 
Time periods 
T0-T10  T0-T25  T0-T50  T0-T75  
Sensitivity 
analysis 
number 
Cumulative 
incidence- 
chickenpox 
vaccination 
scenario1 
Change in 
cumulative 
incidence2 
(95% CI)3 
 
[% change]4 
Cumulative 
incidence- 
chickenpox 
vaccination 
scenario1 
Change in 
cumulative 
incidence 
(95% CI) 
 
[% change] 
Cumulative 
incidence- 
chickenpox 
vaccination 
scenario 
Change in 
cumulative 
incidence 
(95% CI) 
 
[% change] 
Cumulative 
incidence- 
chickenpox 
vaccination 
scenario 
Change in 
cumulative 
incidence 
(95% CI) 
 
[% change] 
Baseline 
scenario  
(DoB=5 yr; 
WoI= 0.63) 
491.18 
71.74  
(64.84, 76.68) 
 
[17.1%] 
530.23 
109.54  
(105.29, 112.95) 
 
[26.0%] 
520.23 
97.40 
(93.73, 100.75) 
 
[23.0%] 
434.60 
10.31  
(4.6, 3.73) 
 
[2.4%] 
One dose 
vaccination 
schedule 
 
489.67 
70.94  
(64.74, 75.89) 
 
[17.0%] 
527.84 
107.12 
(102.41, 110.93) 
 
[25.4%] 
514.33 
91.39  
(86.71, 94.54) 
 
[21.6%] 
435.07 
10.20  
(5.07, 13.92) 
 
[2.4%] 
Lower 
coverage 
rates 
 
489.09 
70.026 
(62.66, 76.22) 
 
[17.0%] 
528,87 
108.37 
(104.45, 112.21) 
 
[25.7%] 
519.25 
96.15 
(92.74, 99.07) 
 
[22.7%] 
434.84 
10.00 
(5.09, 12.64) 
 
[2.3%] 
Higher 
coverage 
rates  
 
490.31 
72.15 
(62.91, 78.94) 
 
[17.2%] 
530.73 
109.62 
(104.88, 114.77) 
 
[26.0%] 
520.88 
97.38  
(94.41, 102.03) 
 
[23.0%] 
434. 
9.65 
(4.84,  
14.17) 
 
[2.3%] 
Removing 
exogenous 
boosting  
 
725.12 
-8.76 
(-11.88, -6.50) 
 
[-1.2%] 
702.40 
-30.64  
(-33.46, -28.38) 
 
[-4.2%] 
632.66 
-97.97 
(-102.63, -94.51) 
 
[-13.4%] 
512.40 
-215.64  
(-220.93, -210.84) 
 
[-29.6%] 
1Median shingles cumulative incidence with chickenpox vaccination per 100,000 person-years (averaged over 30 or more model runs). 
2Change in shingles cumulative incidence per 100,000 person-years calculated as the median shingles incidence with chickenpox vaccination minus the median 
shingles incidence without chickenpox vaccination. Positive number represents an increase in cumulative incidence and negative number – a decrease. 
395% predictive interval (2.5th percentile and 97.5th percentile) 
4Percent change was calculated as the number with vaccination minus the number without vaccination divided by the number with vaccination 
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Figure 4.5. Mean cumulative count of shingles cases averted/added following vaccination 
by the age group and time point, baseline scenario (DoB= 5 year; WoI= 0.63) Positive 
number on the y-axis indicates the number of shingles cases added and negative number – the 
number of shingles cases averted. 
4.4. Discussion 
Our ABM successfully simulated chickenpox and shingles dynamics over time by 
creating a 500,000-person, distance based-contact network, with detailed representation of 
boosting and waning of immunity. We calibrated the model to six different scenarios for DoB 
and WoI for shingles, suggesting that many different quantitative values for these two unknown 
parameters are consistent with the empirical data. Based on this calibration, we determine that 
shingles incidence-post vaccination is highly sensitive to the values for both DoB and WoI, 
although all scenarios eventually led to a reduction in shingles incidence rates relative to baseline 
rates.  
Infectious disease models can provide valuable insight into the complex relationship 
between chickenpox and shingles, allowing epidemiologists and biologists to test theories, study 
the impact of different parameters, and judge the outcomes of various interventions. To date the 
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majority of chickenpox and shingles models, including the only model representing a Canadian 
population [43] are aggregate compartmental models, which limit their flexibility and 
heterogeneity [20,44–48]. To our knowledge, one of the only individual-based model was 
created by Ogunjimi et al. [25] to combine within- and between host dynamics, and VZV 
immunological data to estimate boosting characteristics. Our model utilized their representation 
of the biological conditions for chickenpox and shingles infection and VZV-cell mediated 
immunity; however, it differs from the Ogunjimi model in several key ways [25]. Ogunjimi’s 
model represented contacts using a probabilistic method whereas ours implemented a distance-
based network and included an increased contact range for school-aged children [25,49]. The 
Ogunjimi model used a population that remained fixed in size and was based on Belgian 
demographics, while our model implemented an open and non-fixed population based on Alberta 
data, with realistic demographic changes over time. Furthermore, the Ogunjimi model assumed 
100% vaccine effectiveness and incorporated only a one-dose chickenpox vaccination schedule, 
while ours included representations of vaccine attitudes as a dynamic predictor of vaccine 
coverage and probability of primary vaccine failure.  
Our model concurs with previous models and biological studies that suggest exogenous 
boosting of VZV immunity is a likely factor in the limiting reactivation of VZV, as we were not 
able to recreate the empirical data observed in Alberta without incorporating some element of 
boosting [6]. Longitudinal immunological studies show individuals re-exposed to chickenpox, 
either on a one-time or continuous basis, have a corresponding increase in VZV-specific 
immunity [50–52]. However, these studies generally only look at the short-term immunological 
effects of boosting (up to one-year post-exposure) and not everyone is boosted following re-
exposure, raising questions about the duration of immunity following boosting and the degree, 
number and quality of exposures needed to produce a boost of VZV-CMI [6]. A recent study 
showed that only 17-25% of grandparents who were exposed to chickenpox received a 
significant boost in VZV-specific immunity and that this boost typically lasted less than a year 
[53].  
Using our agent-based model, we varied these unknown boosting parameters (e.g., DoB, 
WoI, degree and probability of boosting on contact) to see how those variations impacted the 
outcomes of chickenpox vaccination. By varying DoB and WoI simultaneously, we identified 
several boosting of immunity scenarios that could fit current Alberta data. In comparison, many 
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previous chickenpox and shingles models have made some strict assumptions about boosting of 
immunity, with the parameter values for the force or duration of immunity following boosting set 
high. For instance, Ouwens et al. [20] assumed that the force of boosting would be equal to the 
force of infection, while Brisson et al. [21] postulated each boost would result in 24 years of 
protection. It is perhaps not surprising that under these assumptions, many of the compartmental 
models predicted an increase in shingles following chickenpox vaccination. 
Our results illustrated that the short-term increase in shingles cases following chickenpox 
vaccination is largely dependent on the DoB and WoI -- quantities whose values are still widely 
debated in the literature. Varying these values had a major impact on outcomes of chickenpox 
vaccination, with the percentage increase in incidence rate ranging between 4.8%-41.9% (25 
years post-vaccination) between the most and least conservative DoB estimates. The only other 
study to vary the natural DoB, to our knowledge, was by Jan Van Hoek et al. [54], who found a 
short natural boosting and a longer shingles vaccine protection leading to variable increase in 
shingles following chickenpox vaccination. However, in this study, the DoB assumed one of 
only three values (7.5, 20, 42 years), only varied DoB in conjunction with shingle vaccine 
boosting, used a compartmental model and did not describe how they calibrated the model to 
empirical data [54]. Our experiments with lower durations of boosting predicted increases in 
shingles cases post-chickenpox vaccination smaller than previous models [21,46,55]. This is 
likely because, these DoB were significantly lower than previous models but are consistent with 
immunological assays used to measure the duration of immunity following boosting in 
grandparents as described in the study above [53]. Furthermore, the rate of boosting in our model 
was driven within an age- and distance- based transmission network rather than a random-mixing 
network, potentially limiting contacts that could produce a boost, which is supported by the fact 
that our average number of boosts per person was low at 1.83.  
Our model results were congruent with other models that demonstrated, over a longer 
time horizon, shingles cases would decrease significantly following chickenpox vaccination. 
This decrease is because chickenpox vaccination decreases the burden of illness of chickenpox 
and the incidence of infection by VZV, thus reducing the population with dormant VZV, and 
producing a cohort effect as a greater and greater percentage of the population is vaccinated. 
Empiric studies post-chickenpox vaccination have started to show evidence of this cohort effect, 
with younger age groups who have received chickenpox vaccination having lower rates of 
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shingles than the corresponding age group prior to vaccination [56,57]. The ultimate drop in 
shingles cases will depend largely on what percentage of chickenpox vaccinated cohorts are 
susceptible to shingles, and therefore future studies should measure the likelihood of the vaccine 
strain of VZV remaining latent in the body, as well as its ability to reactivate.   
To date, empirical findings drawn from the era following introduction of chickenpox 
vaccination are largely inconsistent, making it difficult for policy-makers to know the continued 
impact of the chickenpox vaccine. While some studies show an increase in rates of shingles 
following the implementation of chickenpox vaccination, similar studies have shown that this 
increase started prior to vaccination, and other studies have found rates have stayed the same 
following vaccination [4,56]. Different contact and boosting patterns (e.g. number of boosting 
events, age at which boosts occur, age of chickenpox infection) in different countries may also 
shape some of the observed differences in the age-specific incidence rates of shingles by country 
and potentially the impact of chickenpox vaccination by country [47]. Two Canadian studies 
argued that the incidence rate of shingles was increasing prior to chickenpox vaccination 
implementation and has stayed consistent following the implementation; however, such studies 
took place only seven and eight years following vaccination, and one study did not adjust for age 
[4,56]. Our model demonstrated that at a lower DoB and higher WoI, the perceivable impact on 
shingles rates would be quite small, increasing from 383 cases per 100,000 person-years to 406 
per 100,000 person-years 10 years after chickenpox vaccination. This small increase may be 
difficult to measure or observe in empirical data where other factors influence the shingles rates 
(e.g., shingles vaccination, co-morbid infections, ageing of the population). We did not include 
some of the key determinants of shingles epidemiology in our model, including shingles 
vaccination and the impact of co-morbidities, making the comparison of empirical data and our 
model findings difficult.  
Our model produced some interesting secondary findings and observations. First, as with 
previous models, we found it challenging to account for the rate of shingles infection seen in the 
youngest age group [25]. Russell et al. [4] shows a small but sudden increase in the rate of 
shingles infection in one- to four-year-olds. We theorized that a substantial proportion of these 
cases could be due to immunocompromising conditions in young children that may place them at 
a greater risk of developing shingles. However, it would be interesting to further explore if these 
individuals alone could account for this increase and if this is a trend that is found across 
 85 
countries. Furthermore, we found that varying chickenpox vaccine coverage (by changing 
vaccine attitudes within 10%) had only a minor impact on shingles incidence. However, greater 
changes to vaccine coverage levels would eventually realize larger impacts on shingles 
incidence. One next step may be to test the impact of changing coverage rates over time, as 
experience illustrates that coverage rates may decrease as individuals become increasingly 
accustomed to the vaccine.  
Although our model is one of the most detailed extant representations of the interaction 
between chickenpox and shingles, it is subject to limitations. First, we ran our model on a 
population of 500,000, raising the question of applicability to larger populations. However, we 
observed very little deviation in our findings when we ran the model on 50,000 vs. 500,000, 
suggesting a robustness of results to broad ranges in population size. Second, following a review 
of the literature, we decided not to include endogenous boosting (i.e. self-boosting of VZV when 
the virus attempts to reactivate within an individual), as the relevance of endogenous boosting is 
debated in the literature and Ogunjimi et al. [25] found it insignificant.  Third, we had difficulty 
accounting for shingles in younger age groups, and therefore had to adapt our model to fit 
Canadian data. Fourth, we were only able to vary a couple of the parameters relevant to the 
boosting of immunity; future research should further explore the impact of changing multiple 
boosting parameters (e.g., probability of boosting on contact by age). Fifth, we did not include 
the shingles vaccine in the analysis because we wanted to focus on the effect of chickenpox 
vaccine on natural shingles infection. However, in future analysis, the ability of the shingles 
vaccine to mitigate any increases in shingles cases following chickenpox vaccination will be 
important to explore. It is for this reason our model includes the shingles vaccine functionality.  
Finally, we used a stylised distance-based network to represent transmission of infection and did 
not implement a truly age-dependant contact matrix.  
Future research and agent-based modelling should focus on studying some of the 
remaining unknowns surrounding the mechanisms of VZV reactivation, waning and boosting of 
immunity. ABMs could explore how changing the contact patterns alters the number and type of 
boosting events, and how this variation may explain the differences in shingles incidence both 
before and after chickenpox vaccination in different countries. Moreover, there should be 
ongoing comparison of model results and empirical findings post-chickenpox vaccination, so we 
can update model parameters to fit with changing data. Our findings highlight the importance of 
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not only studying when and if boosting occurs, but also the level of protection it confers on the 
individuals. While Ogunjimi et al. [53] provides a good start to measuring the quantifiable 
impacts of boosting, studies should measure the longer-term immunological impacts of re-
exposure and how those measurements translate to risk of reactivation. Furthermore, future 
research and models may want to look at the impact of other disease and population factors on 
the changing epidemiology of shingles, including immunocompromising conditions, 
immunocompromising drug therapies, co-morbid infections (e.g., CMV), and stress.  
4.5. Conclusion 
Our model highlights the importance of not simply knowing when and if the VZV 
boosting events occur but the specific duration of immunity following boosting, as these values 
can impact the effect of chickenpox vaccination on shingles incidence over time. Our study 
suggests that over the longer time period, there will be a reduction in shingles incidence driven 
mostly by the depletion of the source of shingles reactivation, assuming only a low percentage of 
chickenpox vaccinated individuals are at risk of VZV reactivation. These findings suggest that in 
the long-term a universal chickenpox vaccine would be a good policy to reduce both chickenpox 
and shingles cases. However, in the short to medium term some age cohorts may experience an 
increase in shingles incidence. Studies exploring Canadian’s willingness to pay to avoid 
chickenpox and shingles may provide insight into which trade-offs are worthwhile. Our model 
offers a platform to further explore the relationship between chickenpox and shingles, including 
analyzing the impact of different chickenpox vaccination schedules and cost-effectiveness 
studies. 
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CHAPTER 5- THE OPTIMAL SCHEDULE FOR CHICKENPOX 
VACCINATION IN CANADA: EXPLORING THE IMPACT OF TIMING, 
COVERAGE AND WANING OF VACCINE IMMUNITY ON DISEASES 
OUTCOMES USING AN AGENT-BASED MODEL 
My contributions to this manuscript included conceptualizing the model updates, conceiving and 
designing the study, running the experiments, analysing and interpreting the findings and 
manuscript preparation. Wade McDonald, updated the previous model to test two different 
vaccination schedules, added results outputted from the model, and oversaw the running of the 
model experiments. Dr. Nathaniel Osgood, aided in the conception and the design of the study, 
and oversaw all model adaptations and model runs. Dr. Alexander Doroshenko aided in the 
conception and design of the study.  
 
This chapter builds on the previous chapter by shifting the focus from the impact of chickenpox 
vaccine on shingles to its effect on chickenpox. We used the agent-based model described and 
calibrated in Chapter 4 to test the effectiveness of the chickenpox vaccine in preventing 
chickenpox disease, as well as its impact on breakthrough rates, physician visits and age of 
infection. Furthermore, policy-makers both in Canada and worldwide are interested not only in 
the effects of implementing the vaccine but also in understanding whether there is optimal timing 
for delivery of the chickenpox vaccine. The question of the most appropriate chickenpox vaccine 
schedule is especially relevant in Canada where the vaccine has been implemented for many 
years, with many provinces having different eligibility ages for first and second dose chickenpox 
vaccination. Therefore, in this chapter we compare the effectiveness of two chickenpox vaccine 
schedules common in Canada, Schedule long dosing interval at 12 months and 4-6 years, and 
Schedule short dosing interval at 12 months and 18 months.  
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5.1. Introduction 
 The scheduling of a vaccine is often a complex choice for health program administrators. 
Many factors should be taken into consideration when determining the most appropriate 
approach to implementing a vaccine in a population, including (1) the simplicity of 
implementation (e.g. are there other vaccines already provided at that age?; when will parents 
already be going to see a health care professional?); (2) the types of vaccines licensed (e.g. do 
program administrators need to consider the timing of other antigens included in a combination 
vaccine); (3) the effectiveness of various schedules (e.g. whether one schedule prevents more 
disease and hospitalizations overall, or prevents disease in a high risk group?); (4) the costs 
associated with different schedules; (5) public opinion and preference; (6) adverse events 
associated with the type of vaccine and the age it is administered (e.g. febrile seizure) [1].  
Chickenpox is a childhood disease caused by the varicella zoster virus (VZV). Prior to 
vaccination chickenpox caused an estimated 350,000 cases per year in Canada, a rate of 11.9 
cases per 1,000 persons per year [2]. While some countries, including the US and Canada, have 
implemented universal varicella vaccination programs, many countries are still debating the 
utility of including chickenpox in their routine immunizations [3]. Even in countries where the 
chickenpox vaccine is part of the universal vaccine schedule, questions remain about the most 
efficient and effective way to deliver the vaccine.  
The debate over chickenpox vaccine schedules is evident in Canada, where all provinces 
and territories have some form of universal chickenpox vaccine, but there were eight different 
schedules across the country in 2017 [4]. Provinces and territories recognize that variations in 
how chickenpox vaccine is administered in the population can impact a range of disease and 
vaccination outcomes, such as the risk of febrile seizures [5], the number of outbreaks of 
chickenpox and the number and severity of breakthrough cases [6]. In Alberta, along with 
Manitoba, there is a combined MMRV (measles, mumps, rubella, varicella) two-dose schedule, 
with the first dose offered at 12 months and the second dose at 4-6 years. In comparison, 
Saskatchewan, Prince Edward Island, Newfoundland and New Brunswick, offer MMRV at 12 
months and 18 months. Ontario (V- 15 months, MMRV- 4-6 years), British Columbia (V-12 
months; MMRV- 4-6 years) and Quebec (MMRV-18 months; V- 4-6 years) each have their own 
individual schedules. As is evident in the above examples, each of these schedules implement a 
different number of doses, various types of vaccines (i.e. combination vaccine MMRV or single 
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antigen vaccine varicella), and can alter the timing for both the first dose (12 months or 15 
months) and second dose (18 months or 4-6 years) [4]. However, very little is known about 
which schedule is the most effective at preventing chickenpox disease now and into the future 
[7].  
Appropriate vaccine scheduling is only one of a variety of other unknowns surrounding 
the chickenpox vaccine. For instance, the coverage varies by region and therefore it would be 
valuable to understand how different coverage rates may impact herd immunity and population-
level disease outcomes [8]. Moreover, there is a wide range of plausible estimates for primary 
chickenpox vaccine failure, and the rate at which vaccine immunity wanes remains largely 
unknown. Currently, researchers are unsure of the relative impact of these two variables on 
chickenpox disease outcomes in the long term [9–12]. Therefore, it is important researchers 
explore how these variables and other unknown factors may impact the effectiveness of the 
chickenpox vaccine overall and the effectiveness of various vaccine schedules 
Infectious disease models are one of the best methods to test the effectiveness of different 
interventions over a long time-frame. These models also allow researchers to ask ‘what-if’ 
questions about the disease and the interventions. Using infectious disease models, researchers 
can explore the sensitivity of model results to changes in certain parameters (e.g. how varying 
waning of chickenpox vaccine immunity rates may impact the vaccine’s ability to prevent 
disease over time). Agent-based models (ABMs) are particularly useful as they characterise each 
individual in the population (agent), and therefore present the individual-level factors that change 
an individual’s risk of infection and vaccination over time, such as their vaccine attitudes, their 
history of disease and their age.  
The primary objective of this study was to determine the impact of two different 
chickenpox vaccine schedules on chickenpox disease outcomes and epidemiology in Alberta. 
Using an ABM of chickenpox disease and vaccination calibrated to Alberta demographics, 
vaccination coverage and disease incidence rates prior to vaccination (chickenpox and shingles), 
we tested the impact of these two schedules across four different time periods (10, 25, 50 and 75 
years). Furthermore, we measured how different assumptions for primary and secondary vaccine 
failure, as well as vaccination attitudes and coverage rates, may alter the effectiveness of 
chickenpox vaccination overall and the effectiveness of two vaccine schedules. 
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5.2. Methods 
 We developed an ABM of chickenpox and shingles infection and transmission, along 
with chickenpox vaccination, using AnyLogic® Professional software (version 8.1) (Data 
reference 1). In-depth descriptions of the model structure, agent characteristics, distance-based 
contact network, and initial parametrization and calibration are available in Chapter 4. We 
implemented a 75-year burn-in period, to allow the chickenpox and shingles infection rates to 
reach equilibrium and to ensure we had a distribution of individuals at risk of shingles. At 100 
years we initiated chickenpox vaccination and gathered data for 75 years post-vaccination.  
5.2.1. Model structure and agent characteristics 
 We used the chickenpox and shingles ABM developed in Chapter 4 to represent the 
spread of chickenpox through a population over time. Agents were placed within a stylised 
environment of 500,000 persons. We used a distance-based contact network to create 
connections (i.e. number of other agents one agent is connected to; connectionRange_Norm) and 
contacts (number of times connected agent contact each other; baseContactRate_Norm) among 
agents. Younger persons, aged one to nine, were considered our preferential age group, and 
therefore connected with agents of the same age farther away (connectionRange_Pref) and a 
higher number of contacts (baseContactRate_Pref). Finally, we included an element of 
exogenous infection where an individual could be infected with chickenpox from outside our 
modelled population (ExogenousInfectionRate); this model element allowed for the 
representation of disease importation into the population. It was through these connections and 
assumptions that chickenpox disease spread.  
We chose to use an ABM because it can account for, and represent in detail, a variety of 
disease dynamics prominent in chickenpox and shingles, including herd immunity, waning of 
VZV immunity, shifting of age of infection, breakthrough illness and varying transmissibility 
depending on type of infection (e.g. breakthrough, shingles), among others. ABMs are stochastic 
and account for randomness in disease infection; therefore, they can accurately replicate the 
patterns of outbreaks and recovery associated with infectious diseases. ABMs can capture non-
random interactions within a network (e.g. interaction based on distance), where contacts may be 
recurrent and sustained over extended periods of time, much like real-life. ABM allow 
researchers to capture the vaccine, disease and health service histories of agents in detail, which 
can significantly alter their risk of infection and can help us capture a variety of disease and 
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vaccination outcomes. For instance, in our ABM it is possible to calculate the number of 
breakthrough cases of chickenpox, determine if they are due to primary or secondary vaccine 
failure, and select a certain percentage of the breakthrough cases to get a weaker form of 
chickenpox, with a shorter duration of infection and transmission, and lower risk of 
hospitalization and death. 
Our ABM includes four different statecharts, which determines an agent’s current disease 
(Disease statechart) and vaccination state (Vaccination statechart), their age and risk of mortality 
(Demographic statechart), as well as their health service utilization (Hospitalization statechart). 
(See Figure 4.2, Chapter 4)   
5.2.2. Model parameterization 
 We parameterized the model through a review of the literature, including peer-reviewed 
articles on modelling, epidemiology, effectiveness and immunology, population-level health 
administration data (e.g. vaccine coverage) and demographic data. (e.g. mortality and fertility 
rates). See Table 4.1 in Chapter 4 for a list of the parameters included in the construction of the 
chickenpox model. A full list of the parameters’ values used in this analysis is available in 
Appendix F.  
5.2.3. Chickenpox and shingles disease and transmission 
 The disease statechart determines an agent’s disease-state and therefore risk of infection 
from either chickenpox or shingles, states include ‘maternalAntibody’, ‘susceptible’, vaccine 
protected 1 (‘Protected1’) and 2 (‘Protected2’), susceptible to breakthrough 
(‘susceptibleBreakthrough’), infected chickenpox (‘infectedCP’; ‘infectedWeaklyCP’), 
recovered chickenpox (‘recoveredCP’), ‘infectedShingle’, post-herpatic neuralgia (‘PHN’), and 
‘recoveredFromShingle’, amongst others (See Figure 4.2, Chapter 4). A more detailed 
description of how chickenpox and shingles disease are acquired and transmitted in our model, 
and the model representation of boosting and waning of VZV immunity and their impact on 
chickenpox and shingles incidence, both before and after chickenpox vaccination, is presented in 
Chapter 4.  
5.2.4. Chickenpox vaccination 
 The chickenpox vaccination statechart determines when an agent is due for their first and 
second doses of the chickenpox vaccine, and whether the agent ends up receiving each dose of 
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the vaccine. The ABM can model the two main vaccination schedules used in our analysis (i.e. a 
schedule with a long dosing interval [schedule LDI]- 12 months/4-6 years and a schedule with a 
short dosing interval [schedule SDI]- 12 months/18 months) by setting the CPVaccStrategy 
variable, although many other vaccine schedules could be tested by changing the dueFor1stDose 
and dueFor2ndDose parameters. Based on the pre-set vaccination schedule, agents receive a 
message to get vaccinated when they reach a certain age. The agents’ probability of getting 
vaccinated (e.g. transitioning into received1stDose instead of no1stDose), is then determined by 
their vaccine attitude (i.e. vacc_rejector, vacc_hesistant and vacc_acceptor). All these factors 
ultimately govern the coverage rate of chickenpox vaccine at first and second dose, which is an 
output of the model.  
Whether an individual is effectively protected against chickenpox following vaccination 
is determined in the disease statechart, where agents have a certain risk of primary vaccine 
failure upon receipt of the first and second dose vaccine (probabilityOf1stDoseEffective; 
probabilityOf2ndDoseEffective). If the first dose is effective the agent transitions to ‘Protected1’, 
and if it is not effective they transition to ‘susceptibleBreakthrough’; if the second dose is 
effective they can transition from Protected1’ state to ‘Protected2’, or from 
‘susceptibleBreakthrough’ to ‘Protected1’. We also included the possibility for secondary 
vaccine failure, and therefore agents in ‘Protected1’ had a certain probability per year 
(waningOfImmunityRateCPvacc) of transitioning to ‘susceptibleBreakthrough’, and agents in 
‘Protected2’ had a certain risk per year (waningOfImunityRateCPVacc2) of transition into the 
‘Protected1’ state.  
Thus, agents who are vaccinated but not protected from chickenpox, either due to 
primary or secondary vaccine failure gather in the ‘susceptibleBreakthrough’, state where they 
have the same risk of being infected on contact as those in the ‘susceptible’ state. However, if 
they are infected they have a certain probability of being ‘infectedWeaklyCP’ instead of 
acquiring the full infection (‘infectedCP’). Adding an ‘infectedWeaklyCP’ state allowed us to 
capture the lower risk of serious infection in breakthrough cases; therefore, in this state there was 
no risk of dying or being hospitalized with chickenpox [9]. 
 By using the disease and vaccination elements described above our ABM could capture a 
wide range of outcomes, including the rate and percent of breakthrough illness in the population, 
the effectiveness of the vaccine in preventing disease and the number of agents in the population 
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that have full chickenpox infection versus an attenuated infection. Representing both primary 
and secondary vaccine failure independently also gave our model the flexibility to separately test 
the effect of each of these variables on chickenpox disease outcomes.  
5.2.5. Healthcare utilization 
 The disease and hospitalization statecharts in our ABM capture a variety of disease 
outcomes, including chickenpox and shingles incidence and age of infection, as well as deaths 
(probabilityOfComplicationDeathCP). Furthermore, we can evaluate various health care 
utilization outcomes; for instance, when an agent is infected with chickenpox, they have a certain 
probability of visiting a physician (probGPVisitCP), going to the emergency room 
(probEDVisitCP) or being hospitalized (tfFracHospitalizedCPbyAge). An agent’s probability of 
being hospitalized for chickenpox is based on their age, with a higher risk of hospitalization in 
older age groups. Each agent who received an effective first dose of chickenpox vaccination also 
had a certain risk of having an adverse event, specifically a febrile seizure (probFebrileSeizure). 
5.2.6. Shingles disease 
 Based on our findings in Chapter 4, we decided to make the following assumptions 
about shingles: a duration of immunity following boosting of five years and a waning of VZV 
immunity coefficient of 0.63. The waning of immunity coefficient, in combination with the 
waning of immunity rate, determine how quickly an agent’s immunity to VZV wanes 
immediately following chickenpox infection. The duration of immunity following boosting 
values represents the number of years (5 years) an agent’s VZV immunity would be boosted if 
they came into effective contact with VZV (i.e. a chickenpox or shingles case) and if they are 
recovered from chickenpox. In combination these values determined the likelihood of an agent 
getting shingles following chickenpox infection, as well as the timing of the infection. We 
selected these values for duration of immunity following boosting and waning of immunity 
because they produced the best model to empirical data fit in the pre-vaccine model calibration 
completed in Chapter 4.  
5.2.7. Model validation 
 Our model calibration prior to vaccination was completed in Chapter 4. In that chapter 
we confirmed that the overall age-specific incidence for chickenpox and shingles in our model 
was consistent with what was observed in Canada (Alberta and Ontario) prior to vaccination 
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[13,14]. To check the consistency of our model outcomes to post-vaccination outcomes in this 
chapter, we compared the model results to what was observed in the Canadian literature 
following chickenpox vaccination.  
 We compared the model data (for both schedule LDI and schedule SDI chickenpox 
vaccination) to empirical data for five different outcome variables: percent decrease in 
chickenpox hospitalization, percent decrease per year in physician visits, first and second dose 
chickenpox vaccine effectiveness (i.e. percentage reduction in risk of disease among vaccinated 
persons relative to unvaccinated persons) and vaccine coverage, and finally the percent of total 
cases that are breakthrough cases. The aim of these tests was not to precisely reproduce the 
empirical data following chickenpox vaccine but to show our results were consistent with the 
Canadian literature.   
5.2.8. Main experiment 
The main objective of this study was to test the impact of two different chickenpox 
vaccine schedules on chickenpox disease outcomes and therefore to determine whether 
vaccination timing significantly influenced disease outcomes. A secondary objective of the 
analysis was to test the impact of chickenpox vaccine into the future, to measure how current 
assumptions about vaccine effectiveness and coverage would influence disease outcomes 75 
years following the implementation of the chickenpox vaccine. Therefore, for the main 
experiment we tested three different scenarios, (1) no vaccination- we ran the model for 75 years 
(100 year to 175 year) following the 75 year burn in period without introducing vaccination; (2) 
schedule LDI- we introduced vaccination at year 100 and ran the model for 75 years, with 
children receiving first dose chickenpox vaccination at 12 months and second dose vaccination 
between 4-6 years; (3) schedule SDI- we introduced vaccination at year 100 and ran the model 
for 75 years, with children receiving first dose chickenpox vaccination at 12 months and second 
dose vaccination at 18 months. All other variables remained constant across all three scenarios.  
 We tested the impact of these three different scenarios on four disease outcomes, 
chickenpox incidence, breakthrough rate, shingles incidence and age of chickenpox infection. 
For each scenario in the main experiment we conducted a minimum 30 runs. Based on the 
previous sample calculation describe in Chapter 4, and practical considerations (i.e. model run 
time) we decided to maintain our sample size at 30 paired runs minimum. By pairing runs across 
the three scenarios we could ensure consistency in the random seeds used to populate the model 
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(i.e. all models started with the same values for the parameters and variables). We calculated a 
95% predictive interval (2.5th and 97.5th percentile) across all model runs, for each disease 
outcome of interest. Furthermore, we tested for statistically significant difference between 
schedule LDI and schedule SDI for all model outcomes using the non-parametric Kolmogorov-
Smirnov test.  
5.2.9. Sensitivity analysis 
 Sensitivity analyses allowed us to test our model assumptions and study their impact on 
overall disease outcomes 75 years post-vaccination. For the first sensitivity analysis we moved 
15% of vaccine hesitant individuals to vaccine acceptors which resulted in higher vaccination 
coverage (vaccine attitude high), and subsequently moved 15% of hesitant individuals to vaccine 
rejectors, resulting in lower vaccination coverage (vaccine attitude low). Second, we varied 
primary vaccine failure from 9% to 24% for first dose vaccination and 5% to 16% for second 
dose vaccine, the lowest and highest values for vaccine failure reported in reviews of the 
literature. [11,12,15–17] Third, we compared disease outcomes between schedules when we 
lowered the waning of chickenpox vaccine immunity for both first and second dose to zero and 
subsequently raised it to 5% per year. We ran a minimum of 30 paired model runs of schedule 
LDI and schedule SDI for each sensitivity analysis and measured the 95% predictive interval to 
see if changing these parameters had an impact on the model outcomes for each schedule.   
5.3. Results 
5.3.1. Model validation 
 Our model findings at 10 years post-vaccination were consistent with empirical data. All 
model results for the five different outcome variables for schedule LDI and schedule SDI as 
compared to empirical data are presented in Table 5.1. The 95% predictive interval (2.5 and 97.5 
percentile) for schedule LDI/schedule SDI and the confidence intervals for empirical data 
overlapped for percent decrease in chickenpox hospitalization, physician visits per year and 
coverage rates. Coverage rates ranged from 85.2% to 85.3% for the first dose, and 73.8% to 
74.4% for the second dose. The predictive intervals and confidence intervals for vaccine 
effectiveness for model data and empirical data largely overlapped; however, we observed a 
slightly lower effectiveness in our first dose vaccination and a slightly higher effectiveness in our 
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second dose vaccination. Our breakthrough cases for schedule SDI were slightly lower than 
those reported in the literature.  
 
Table 5.1. Vaccine and disease outcome variables 10 years post-chickenpox vaccination in 
comparison to empirical data from the literature 
Parameter Model Data- 
Schedule LDI1,2 
(95% predictive 
interval) 
Model Data- 
Schedule SDI1,2 
(95% predictive 
interval) 
Empirical data 
(95% CI)3 
Ref 
Chickenpox 
hospitalization  
(% decrease) 
80% (77%, 86%) 81% (79%, 84%) 79% (74%, 82%) [18] 
Chickenpox 
physician visits 
(% decrease per 
year) 
8.0% per year  
(7.7%, 8.6%) 
8.2% per year  
(8.0%, 8.4%) 
<1 year: 7.7% 
1-4 years: 9.1% 
5-11 years: 8.4% 
>12 years: 8.4% 
[19] 
Vaccine 
effectiveness 
- 1st dose 
- 2nd dose  
 
 
76% (72%,80%) 
94% (92%, 
97%) 
 
 
79% (74%, 84%) 
96% (95%, 98%) 
 
 
81% (78%, 84%) 
92% (88%, 95%) 
[9] 
Breakthrough  
(% of total cases)  
2.0% (1.1%, 3.2%) 0.7% (0.5%-1.5%) 2%-3.1% [18,20] 
Vaccine Coverage 1st dose: 85.1% 
(84.7%, 85.6%)  
2nd dose: 73.9% 
(73.0%, 74.7%) 
1st dose: 85.4% 
(84.8%, 85.9%) 
2nd dose: 74.6% 
(73.8%, 75.6%) 
1 dose: 86.7% 
2nd dose: 75.3% 
[21] 
1Model data is presented as medians 10 years post-vaccination to compare to a time-period similar to that reported in 
the empirical data. 
2Schedule LDI is 1st dose MMRV at 12 months and 2nd dose at 4-6 years, and Schedule SDI is first dose of MMRV 
at 12 months and second dose at 18 months.  
3If available the 95% CI from the empirical study is reported 
5.3.2. Main experiment 
Generally, we found that chickenpox vaccination led to a significant decrease in 
chickenpox incidence at 10, 25, 50 and 75 years post-vaccination implementation (See Table 
5.2, Figure 5.1). While the lowest chickenpox incidence occurred at 75 years post-vaccination, 
the first 10 years had the most dramatic decrease.  Following the initial dramatic decrease in 
chickenpox cases our model predicted the average chickenpox incidence rate staying in relative 
equilibrium, with period but small outbreaks of the disease (See Figure 5.1). Moreover, we saw 
a dramatic increase in the average age of chickenpox infection following vaccination. In this case 
the average age continued to increase consistently over time, with the oldest age of infection 
being 75 years post-vaccination. 
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We observed relatively minor differences when we compared chickenpox and shingles 
disease outcomes between the two vaccination schedules (See Table 5.2, Figure 5.1). Schedule 
SDI led to a slightly larger decrease in chickenpox cases in comparison to schedule SDI; 
however, the 95% predictive intervals overlapped. When comparing the paired sets directly, 
100% of paired runs found that schedule LDI resulted in a higher chickenpox incidence rate than 
schedule SDI. The absolute difference in incidence rate was 0.1 cases per 1,000 person-years 
(after 75 years). Therefore, in the Alberta based on these numbers schedule LDI would prevent 
approximately four hundred more chickenpox cases per year than schedule SDI. At the same 
time, we observed overlapping 95% predictive intervals for the shingles incidence between the 
two schedules, suggesting no significant difference. However, 75% of paired model runs found 
schedule SDI had a slightly higher shingles incidence than schedule LDI. Both the number of 
breakthrough cases and the age of chickenpox infection were strikingly different when 
examining the two vaccine schedules (Table 5.2). For instance, at each time point post-
vaccination, age of chickenpox infection was consistently and significantly higher in schedule 
SDI (100% of paired model runs), while there were significantly more breakthrough cases with 
schedule LDI (100% of paired model runs). In fact, over the 75 years post-vaccination schedule 
LDI had a breakthrough rate 62% higher than schedule SDI.  
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Table 5.2. Health outcomes by time since vaccination and scenario over 37 paired model 
runs, median (95% predictive interval)  
 Time since vaccination  
10 years1 25 years 50 years 75 years P-value2 
Chickenpox 
incidence per 1,000 
person-years 
- No vaccine 
- Schedule LDI3 
- Schedule SDI3 
 
 
 
12.6 (11.5, 13.8)4 
2.5 (1.6, 3.2) 
2.3 (1.3, 2.8) 
 
 
 
12.2 (11.6, 12.8) 
1.2 (0.8, 1.5) 
1.1 (0.7, 1.3) 
 
 
 
12.2 (12.0, 12.5) 
0.79 (0.58, 0.93) 
0.66 (0.45, 0.79) 
 
 
 
12.1 (12.0, 12.3) 
0.60 (0.46, 0.70) 
0.50 (0.36, 0.59) 
 
 
 
- 
Ref 
<0.001 
Breakthrough rate 
per 100,000 
person-years 
- Schedule LDI 
- Schedule SDI 
 
 
 
5.3 (3.2, 6.9) 
1.6 (1.3, 2.1) 
 
 
 
4.8 (4.1, 5.2) 
2.0 (1.8, 2.2) 
 
 
 
6.7 (6.2, 7.3) 
3.7 (3.5, 4.0) 
 
 
 
7.8 (7.0, 8.6) 
4.8 (4.6, 5.1) 
 
 
 
Ref 
<0.001 
Shingles incidence 
per 1,000 person-
years 
- No vaccine 
- Schedule LDI 
- Schedule SDI 
 
 
 
4.0 (3.9, 4.0) 
4.4 (4.3, 4.5) 
4.4 (4.4, 4.5) 
 
 
 
4.0 (4.0, 4.0) 
4.9 (4.9, 5.0) 
4.9 (4.9, 5.0) 
 
 
 
4.0 (4.0,4.1) 
4.9 (4.9, 5.0) 
4.9 (4.9, 5.0) 
 
 
 
4.0 (4.0, 4.1) 
4.2 (4.2, 4.2) 
4.2 (4.1, 4.2) 
 
 
 
- 
Ref 
0.018 
Median Age of 
chickenpox 
infection 
- No vaccine 
- Schedule LDI 
- Schedule SDI 
 
 
 
9.7 (9.5, 9.9) 
12.5 (12.0,13.3) 
13.6 (13.0, 14.1) 
 
 
 
9.8 (9.7 9.9) 
17.4 (16.9, 18.1) 
18.9 (18.5, 19.6) 
 
 
 
10.0 (9.8, 10.1) 
23.6 (23.0, 24.2) 
26.0 (25.2, 26.5) 
 
 
 
10.1 (10.0, 10.2) 
28.4 (27.9, 29.0) 
31.2 (30.4, 32.0) 
 
 
 
- 
Ref 
<0.001 
1All time-periods represented the cumulative number started at year 0 (first year of vaccination).  
2P-values compare schedule LDI and schedule SDI for statistical significance using Kolmogorov-Smirnov test at 
time 75 years.  
3Schedule LDI is 1st dose MMRV at 12 months and 2nd dose at 4-6 years, and Schedule SDI is first dose of MMRV 
at 12 months and second dose at 18 months.  
4All point estimates are medians and ranges are presented as 95% predictive intervals (2.5th percentile and 97.5th 
percentile) 
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Figure 5.1. Chickenpox incidence (per 100,000 person-years) over time by scenario 
5.3.3. Sensitivity analysis 
Generally, we found that changing the primary vaccine failure rate or altering the vaccine 
attitudes (i.e. changing vaccine coverage) in our population did not impact our overall findings. 
While decreasing and increasing primary vaccine failure lead, respectively, to a significant jump 
and reduction in breakthrough cases, the overall incidence of chickenpox stayed relatively 
consistent.  Increasing the percentage of ‘rejectors’ in our population did decrease the coverage 
rates for first (75% for both schedules) and second dose (66% for both schedules) chickenpox 
vaccine substantially (approximately 10% reduction in coverage) and increased the incidence of 
chickenpox by 30-40% relative to baseline. However, this only translates to an increase of 0.3-
0.4 cases per person-year. Increasing the percentage of ‘acceptors’ in our population had a 
smaller, non-significant effect, with coverage for both schedules increasing to 89% and 80% for 
first and second dose, respectively. Chickenpox incidence rates for this scenario stayed very 
similar to baseline values. Increasing the waning of immunity rate to 5% per year had the biggest 
impact on chickenpox incidence, with over two times as many cases with the higher waning 
immunity rate in comparison to baseline. Furthermore, the number of breakthrough cases 
increased to a very high rate, with 47-81 breakthrough cases per 100,000 person-years.  
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Table 5.3. Health outcomes for different sensitivity analyses over 30 model runs, median (95% predictive interval)  
 Waning rate 
low1 
Waning rate 
high 
Primary 
vaccine failure 
low2 
Primary 
vaccine failure 
high2 
Vaccine 
attitude low3 
Vaccine 
attitude high 
Baseline 
Chickenpox 
incidence  
per 1,000 person-
years 
- Schedule LDI4 
- Schedule SDI4 
 
 
 
 
0.5 (0.4, 0.7) 
0.4 (0.3, 0.6) 
 
 
 
 
1.6 (1.5, 1.8) 
1.0 (0.9,1.2) 
 
 
 
 
0.5 (0.4, 0.6) 
0.4 (0.3, 0.6) 
 
 
 
 
0.7 (0.5 0.8) 
0.5 (0.4, 0.7) 
 
 
 
 
1.1 (1.0, 1.2) 
0.8 (0.6, 0.9) 
 
 
 
 
0.6 (0.4, 0.7) 
0.5 (0.3, 0.6) 
 
 
 
 
0.6 (0.5, 0.7) 
0.5 (0.4, 0.6) 
Chickenpox 
breakthrough rate 
per 100,000 person-
years 
- Schedule LDI 
- Schedule SDI 
 
 
 
 
5.2 (4.9, 5.6) 
3.1 (2.8, 3.3) 
 
 
 
 
82 (76, 88) 
47 (44, 50) 
 
 
 
 
3.4 (3.2, 3.6) 
2.3 (2.2, 2.5) 
 
 
 
 
11 (11, 12) 
6.9 (6.7, 7.2) 
 
 
 
 
20 (19, 22) 
12 (11, 13) 
 
 
 
 
9.0 (8.6, 9.7) 
6.2 (5.7, 6.4) 
 
 
 
 
7.8 (7.3, 8.3) 
4.8 (4.6, 5.1) 
Age of chickenpox 
infection (years) 
- Schedule LDI 
- Schedule SDI 
 
 
28 (27, 28) 
31 (30,31) 
 
 
27 (27, 28) 
29 (29, 29) 
 
 
30 (30, 31) 
33 (32, 33) 
 
 
28 (27, 28) 
30 (30, 31) 
 
 
26 (25, 26) 
28 (27, 28) 
 
 
29 (28, 29) 
31 (31, 32) 
 
 
28 (28, 29) 
31 (31, 32) 
1For ‘Waning rate low’ the first and second dose vaccine waning of immunity rate was set to zero; for ‘Waning rate high’ the first and second dose waning of 
immunity rate was set to 5%.   
2‘Primary vaccine failure low’ was set to 9% for first dose and 5 % for second dose; ‘Primary vaccine failure high’ was set to 24% for first dose and 16% for 
second dose.  
3For ’Vaccine attitude high’ we changed the vaccine attitude weights to acceptor= 80%, hesitator= 15%, rejector= 5%; For ‘Vaccine attitude low’ we changed the 
vaccine attitude weights to acceptor= 65%, hesitator= 15%, rejector= 20%.  
4Schedule LDI is 1st dose MMRV at 12 months and 2nd dose at 4-6 years, and Schedule SDI is first dose of MMRV at 12 months and second dose at 18 months. 
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5.4. Discussion 
Using our ABM we were able to replicate the epidemiology of chickenpox and shingles 
both prior to vaccination and following its implementation. Our model results were validated by 
findings in the literature, including chickenpox vaccine effectiveness in preventing infection, as 
well as the percent decrease in chickenpox hospitalizations and physician visits following 
vaccination implementation [9,13,18–20]. While our model results found a slightly lower 
effectiveness in first dose vaccination and a slightly higher effectiveness in second dose 
vaccination in comparison to the literature, we postulate this finding may be explained by the 
fact that there is a large amount of variability in vaccine effectiveness estimates in real-world 
studies [9]. Furthermore, we observed a low breakthrough rate for schedule SDI; however, as 
most jurisdictions, including the United States, offer the second dose of chickenpox at 4-6 years 
of age, it is perhaps not surprising that the rates are more consistent with schedule LDI. 
Furthermore, the number and rate of breakthrough cases can change dramatically as a result of 
time since vaccination, as well as the case definition used to identify breakthrough cases, and the 
surveillance and case-identification process utilized to monitor cases (e.g. active surveillance 
during an outbreak or passive surveillance through physician visits). Our model produced 
coverage rates similar to what is observed in Alberta for chickenpox vaccination using a 
distribution of vaccine acceptors, hesitants and rejectors in our population [21]. Using the ABM 
we tested the effectiveness of chickenpox 75 years into the future, along with the effectiveness of 
two diverse vaccine schedules.  
Previous models have explored the effectiveness of the chickenpox vaccination in 
preventing disease [22–25], with two providing a Canadian-focus [26,27]. In the most recent 
Canadian chickenpox modelling study, Brisson et al. [27] used an age-structured transmission 
model to predict the impact of both a one-dose and two-dose chickenpox vaccination schedule. 
His model predicted an initial rapid decrease in chickenpox cases following implementation of a 
two-dose vaccination, reducing cases of chickenpox by 72-97% over 80 years [27]. These 
findings are similar to our model predictions, which also had a substantial fall in chickenpox 
incidence, specifically a reduction of approximately 95% of chickenpox cases, 75 years 
following vaccination introduction. 
However, we noted some difference between our model findings and the Brisson model 
[27]. For instance, the Brisson model predicted a slow rise in chickenpox cases 40 years into the 
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vaccine program, whereas our model at around the same time point showed a steady number of 
chickenpox cases, with the incidence staying in equilibrium [27]. Furthermore, the Brisson 
model consistently predicted a substantial outbreak of chickenpox 10 years after vaccine 
introduction [27].  Our model also predicted outbreaks of chickenpox; however, we did not 
observe one large chickenpox outbreak but small and periodic outbreaks of cases, demonstrating 
low but sustained transmission of chickenpox in the ABM population. We postulate the 
perpetuation of chickenpox in our model is likely due to three factors; (1) the ability of shingles 
and breakthrough infection to transmit chickenpox, although at a lower rate, (2) the inclusion of 
exogenous infection in our model and (3) the fact that vaccine immunity may wane over time.  
Pivotal differences in modelling techniques and assumptions between this study and 
Brisson et al. [27] may further explain some of the conflicting findings. First, we fit our ABM to 
real-world data from Canada 10 years following the implementation of the chickenpox 
vaccination, including decrease in hospitalizations and physician visits, along with number of 
breakthrough cases and coverage rates. In comparison, Brisson et al. [27] generally used data 
from clinical trials to calibrate his model. We built on the Brisson model by updating parameters 
estimates based on current literature, including primary and secondary vaccine failure, coverage 
rates, as well as boosting and waning of VZV immunity. For instance, the Brisson model 
included a waning of immunity rate of 0.01 for second dose vaccination in the base case while 
our ABM assumed a waning of zero for this group [9]. Second, our model utilized a distance-
based contact network which allowed for realistic spread of infection through a population. 
Mediating contacts through a network may have limited the size of the chickenpox outbreaks, 
and consequently provides a fundamental explanation for why our model did not predict a large 
outbreak of chickenpox soon after vaccine implementation, but instead predicted small and 
episodic outbreaks. Third, because our work took place after the implementation of the second 
dose of the chickenpox vaccine in Canada we were able to build on Brisson’s analysis to 
compare chickenpox vaccine schedules currently being used in various provinces [27]. Fourth, 
using an ABM, the disease and vaccination patterns in the population were emergent based on 
the individual characteristics of the agents. For instance, each agent had risk of transmission 
based on their type of infection (i.e. normal, breakthrough and shingles cases), a risk of infection 
based on their disease state and their contacts, and a likelihood of vaccination dependent on their 
vaccination attitude. 
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Our model consistently predicted a smaller decrease in chickenpox incidence for 
schedule SDI vaccination (12 months and 18 months), in comparison to schedule LDI (12 
months and 4-6 years) (100% of paired model runs). Recent research in both Canada [13] and 
Europe [28] show that chickenpox incidence is highest in the under 5 age group. Since the 
second dose of schedule SDI happens much earlier than schedule LDI it mitigates the negative 
effects of primary vaccine failure and ensures more children are protected during this high-risk 
age. Therefore, we postulate the overall benefit of schedule SDI is based on its ability to prevent 
more chickenpox cases, both breakthrough and normal, before age five, which is consistent with 
our findings that schedule SDI has an older average age of infection than schedule LDI. 
Interestingly, we found even with a significantly higher waning of vaccine immunity rate and 
when more individuals identify as vaccine ‘rejectors’ (lower vaccine coverage) schedule SDI 
prevented a higher number of chickenpox cases than schedule LDI. Our findings are consistent 
with a recent modelling study done in Italy which looked at how altering chickenpox vaccination 
factors affect overall disease burden [29]. Using a dynamic transmission model Holl et al. [29] 
showed that shorter dosing intervals (5 months) are preferable to longer dosing intervals (5 
years), because it limits the number of breakthrough cases of people experiencing primary 
vaccine failure. In comparison, when Brisson et al. [27] compared effects of providing a second 
dose of varicella at three different time points, an infant program (1st and 2nd doses- 1 year), pre-
school program (1st dose- 1 year, 2nd dose- 5 years) and grade 4 (1st dose- 1 year, 2nd dose- 9 
years), he found the longest time difference between doses (i.e. a grade 4 vaccine) would lead to 
the largest decrease in chickenpox cases. The main benefit of the grade 4 vaccination was that it 
significantly reduced the size of the large initial outbreak predicted by the Brisson model but not 
observed in our model or empirical data [13,19,27,30]. Furthermore, Brisson et al. [27] found 
that the effectiveness of different timings for the second dose of chickenpox vaccination was 
largely dependent on mixing and vaccine effectiveness assumptions, including the waning of 
chickenpox vaccine immunity in older age groups, two elements we have updated in our ABM.  
Most chickenpox vaccine literature suggests that while there is a relatively high rate of 
primary vaccine failure but there is limited evidence of waning of immunity [9,17]. One 
exception is Chaves et al. [10] who reported an increased incidence of varicella among 
vaccinated persons with time since vaccination with a single dose; however, Gershon et al. [17] 
and Chaves et al. [10] postulate that primary vaccine failure may partially contribute to an 
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increase in cases over time. Using literature estimates for primary and secondary vaccine failure, 
Bonanni et al. [16] concluded that a shorter time interval between the two doses may reduce 
breakthrough varicella. Again, these findings are consistent with our model which showed a 
breakthrough rate that was 62% lower in schedule SDI than in schedule LDI, even 75 years post-
implementation. This finding suggests with the current model assumptions, primary vaccine 
failure is having a greater impact on normal and breakthrough chickenpox disease rates than 
waning of immunity.  
It is important to note that, because of the short amount of time since chickenpox vaccine 
introduction, we may find that the waning of immunity has a bigger impact on chickenpox 
infections in the future. In the past, other vaccines initially demonstrated high efficacy, but that 
efficacy decreased dramatically over time. The best example of this is the acellular pertussis 
vaccine, where there was a significant initial decline in cases, but the incidence of pertussis 
slowly started to increase as an individuals’ immunity to the vaccine waned. Our sensitivity 
analysis showed that while a lower waning of immunity had a negligible impact on disease 
outcomes, when we assumed a higher waning of immunity rate we saw significantly more 
chickenpox and breakthrough cases 75 post-vaccine introduction. However, even at this high 
waning of immunity rate we still saw a significant decrease in chickenpox cases with chickenpox 
vaccination.  
While our model found evidence that schedule SDI could lead to a greater reduction in 
the incidence of chickenpox as compared to schedule LDI (100% of paired runs finding lower 
chickenpox incidence in schedule SDI), these results are not conclusive, particularly as the 95% 
predictive intervals overlapped. Therefore, it is important policy-makers consider other factors 
when determining the appropriate schedule for the chickenpox vaccination. For instance, if 
chickenpox is provided in a combination MMRV vaccine, then policymakers should also 
consider how the timing of the dose may impact the other antigens in the vaccine [31]. In fact, 
Perez et al. [31] found a decreasing pattern in the proportion of individuals who were 
seronegative to measles when the first dose of the measles-containing vaccine was given at 11, 
12, 13-4 and 15-22 months. Another element to consider is the safety profile of the vaccines, 
specifically if the risk of adverse events changes with vaccine schedule. For instance, 
MacDonald et al. [5] found an increased risk of febrile seizures in individuals who received first 
dose MMRV vaccine compared to those who received MMR and V separately. Moreover, 
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coverage rates may also change with different vaccination schedules, with combination vaccines 
in general, and MMRV in particular, associated with a significantly higher coverage rate than 
other vaccine alternatives (e.g. MMR) [32,33]. While our sensitivity analyses showed that higher 
coverage rates only have a minor impact on overall chickenpox incidence, lowering coverage 
rates by approximately 10% could lead to significantly more chickenpox cases in both schedules, 
and therefore it may be an important consideration when implementing a vaccine program. 
While this study was to our knowledge the first to explore the differential impact of 
chickenpox vaccine strategies using an ABM, it had some notable limitations. First, we were 
only able to run our model on a population of 500,000 people and over 30 paired runs. A larger 
number of runs could result in smaller predictive intervals and therefore a more accurate picture 
of the relative effectiveness of different chickenpox vaccination schedules. However, as stated in 
Chapter 4, we saw very little deviation in our model when we ran it on both smaller and larger 
populations suggesting a robustness of results to broad population ranges. Second, due to the 
complexity of the chickenpox vaccination schedules across Canada we were only able to test a 
few of the different schedules and their impact on certain outcomes in this analysis. In the future 
we hope to explore these questions in more detail using this ABM. Third, while we used a 
distance-based contact network to account for disease transmission in our model, we were not 
able to completely replicate a realistic age-dependant contact matrix. Researchers are currently 
building these realistic networks through empirical studies of individuals and their contacts in 
Canada [34]. When these networks become more available we hope to apply them to our model.  
As the two vaccination strategies outlined in this study may lead to diverse costs and 
effects, prior to making decisions about the relative benefits of the schedule, it is important 
future research test the cost-effectiveness of various chickenpox vaccination schedules. This 
study and our ABM provide the foundation for analysing a more complex set of potential 
schedules and their impact on a wider set of outcomes. 
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CHAPTER 6- THE COST-EFFECTIVENESS OF CHICKENPOX 
VACCINATION IN ALBERTA, INCLUDING AN ANALYSIS OF DIFFERENT 
SCHEDULES 
My contributions to this manuscript included conceptualizing the model updates, conceiving and 
designing the study, helping debug model issues, running the experiments, analysing and 
interpreting the findings and manuscript preparation. Wade McDonald, updated the previous 
model to measure the costs and effects (QALY) associated with chickenpox disease and 
vaccination, added to the results outputted from the model, helped debug issues related to model 
output (e.g. issues measuring QALY) and oversaw the running of the model experiments. Dr. 
Nathaniel Osgood aided in the conception and the design the study and oversaw all model 
adaptations and model runs. Dr. Marwa Farag, Dr. Wu Zeng, Dr. Alexander Doroshenko aided in 
the conception and design of the study, and the interpretation and analysis of the findings.  
 
Following our findings in Chapter 5 that chickenpox vaccine significantly reduces disease 
incidence over time; as well as our discovery of the differential effectiveness of two different 
vaccination schedules, the next step of our analysis was to determine the cost-effectiveness of 
chickenpox vaccination overall and for different vaccination schedules. Based on our findings in 
Chapter 4 we were also able to include the impact of chickenpox vaccination on shingles 
incidence in our cost-effectiveness analysis. In this chapter, we discuss how we updated the 
agent-based model developed in previous chapters to calculate the costs and QALYs associated 
with certain events (e.g. doctor visits, hospitalizations, vaccination). As the ABM was already 
calibrated to Alberta empirical data on chickenpox and shingles both before and after the 
implementation of the chickenpox vaccination, as well designed to test the impact of chickenpox 
vaccination on chickenpox and shingles disease outcomes, it was well placed to evaluate the 
cost-effectiveness of chickenpox vaccination. Therefore, we tested the overall cost-effectiveness 
of chickenpox vaccine in Alberta for both the schedule with a long dosing interval and a short 
dosing interval, as well as the cost-effectiveness between the two schedules.
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 6.1. Introduction 
Chickenpox is generally considered a mild, self-limiting childhood disease; however 
severe complications can occur which can lead to expensive hospitalization and death [1].  To 
reduce the impact of the disease and its complications a chickenpox vaccine was develop in the 
1970s [2], and since its development it has been included as part of the routine childhood 
vaccination studies in many countries, including Canada and the United States [3,4]. Although 
many factors contribute to a country’s decision to implement the chickenpox vaccine in their 
routine immunization schedule, the chickenpox and vaccine-associated costs, its impact on 
quality of life and the overall cost-effectiveness of the vaccine are often key considerations 
[3,5,6].   
Systematic reviews of economic evaluations of the chickenpox vaccination demonstrate 
that vaccination in high-risk groups and routine childhood vaccination are cost-saving from a 
societal perspective (i.e. both health care and indirect costs) [7,8]. However, the cost-
effectiveness of the vaccine from the healthcare perspective (i.e. costs of chickenpox to the 
health care system) is more uncertain, with studies from around the globe predicting cost-
effectiveness ratios in the range of $11,900 to $99,300 per life-year gained [8,9]. The infectious 
disease models that estimated the cost-effectiveness of a universal chickenpox vaccination in 
Canada, found similar results to these reviews, as vaccination was cost-saving when considering 
indirect costs but generally cost-ineffective from the healthcare perspective [10,11].  
The two Canadian universal chickenpox vaccine economic evaluations were conducted 
prior to the implementation of the vaccine in the population (ex-ante), and therefore provided 
useful information to policy-makers deciding whether to include the chickenpox vaccine in 
provincial vaccine schedules. However, as we noted in Chapter 2, economic evaluations 
conducted pre-vaccine implementation, need to make assumptions about unknown parameter 
values such as, attainable coverage levels, the cost of the chickenpox vaccine and its real-world 
effectiveness. A review of economic evaluations of chickenpox by Thiry et al. [9] suggested that 
future economic evaluations of chickenpox would benefit from more accurate data on the 
effectiveness of the chickenpox vaccine, including the possibility of waning of immunity and the 
impact on shingles incidence [7,9]. An update of these economic evaluation would not only 
provide policy-makers with a more pertinent estimate of the cost-effectiveness of chickenpox but 
also an idea of the accuracy of economic evaluations done prior to vaccine licensing and 
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implementation. Furthermore, ex-post (i.e. post-implementation) economic evaluation provide 
researchers the opportunity to answer policy-questions that become pertinent following the 
implementation of the vaccine. 
Thiry et al. [9] further noted that to date many economic evaluations of chickenpox use 
static models, and that future research should prioritize the use of dynamic models that can 
capture the indirect effects of vaccination. In fact, dynamic models are particularly important to 
measuring the cost-effectiveness of the chickenpox vaccine, as they can highlight important 
externalities and dynamic elements of vaccination, like boosting and waning of natural and 
vaccine immunity, as well as herd immunity. Furthermore, dynamic models are generally more 
sensitive to changes in vaccine parameters, such as vaccine coverage and effectiveness [7,9]. 
Guidelines for economic evaluation, including those released by WHO [12] and the Canadian 
Agency for Drugs and Technologies in Health [13] recommend cost-effectiveness studies have 
the capacity to measure the indirect effects and costs associated with vaccinations. Agent-based 
models (ABM) are uniquely placed to measure the cost-effectiveness of preventive infectious 
diseases interventions, especially one as complicated as the chickenpox vaccination, as they can 
recreate realistic disease dynamics (e.g. contact-based transmission, small and episodic 
chickenpox outbreaks). Furthermore, in agent-based modelling the population-level cost and 
quality adjusted life-years (QALYs) estimates naturally emerge from the costs and QALYs 
captured for each individual in the model, much like real-life. Furthermore, ABMs can capture 
the costs and QALY of a wide range of disease, vaccination and healthcare utilization outcomes. 
Although previous economic evaluations found that chickenpox vaccination may be cost-
effective under certain circumstances, there remains a lot of unknowns surrounding the costs and 
effects of this relatively new vaccine. One reason some countries have resisted implementing the 
chickenpox vaccine is the concern that vaccination could limit natural boosting of varicella 
zoster virus (VZV) immunity, which some studies suggest will increase shingles incidence [14–
16]. While most chickenpox economic evaluations show that chickenpox vaccine is likely cost-
effective or cost-saving from the societal perspective, this changes dramatically if the 
chickenpox vaccine leads to an increase in shingles cases [11,17]. In Chapter 4 we demonstrated 
that chickenpox vaccination may have a relatively small impact on shingles outcomes, under the 
reasonable assumption of a short duration of VZV boosting. [16,18,19]. Furthermore, we 
illustrated an ultimate decrease in shingles cases over time, due to the lower risk of developing 
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shingles with vaccine-strain VZV. These factors may influence the overall cost-effectiveness of 
the chickenpox vaccine.  
Policy-makers continue to debate the most cost-effective schedule for the chickenpox 
vaccines, including the number of doses, the use of combination vaccines, and the appropriate 
timing for vaccine delivery. The question of the cost-effectiveness of the different chickenpox 
vaccine schedules remains unanswered in the literature. The cost-effectiveness of different 
chickenpox vaccine schedules could be altered by several factors. Specifically, reduction in 
cases, as well as shifts in the type and age of chickenpox infection with different schedules may 
impact both costs and QALY. For example, breakthrough cases of chickenpox are generally not 
as severe, and therefore on average these cases are less costly and have a smaller impact on 
QALYs lost than normal cases of chickenpox. In comparison, a shift in chickenpox to older age 
groups will lead to more severe and costly cases of the disease [2,14,17].  
Based on these defined gaps in literature we aimed to test the cost-effectiveness of the 
chickenpox vaccine in Alberta, Canada, by inputting updated data on the costs, utilities, health 
utilization probabilities associated with chickenpox disease and vaccination into a complex ABM 
of chickenpox and shingles transmission, disease outcomes and vaccination. Furthermore, using 
our ABM we aimed to compare the cost-effectiveness of the chickenpox vaccine under two 
diverse schedules, as well as the cost-effectiveness between schedules, to measure if dose timing 
has an impact on cost-effectiveness.   
6.2. Methods 
6.2.1. Economic evaluation methods 
We conducted a cost-utility analysis using the Canadian Agency for Drugs and 
Technologies in Health (CADTH) guidelines for economic evaluations [13]. We undertook both 
a publicly-funded healthcare payer and a societal perspective to fully capture the costs and 
effects of chickenpox vaccination. The healthcare perspective provides policy-makers estimates 
of the direct costs associated with chickenpox vaccination and is particularly relevant to health 
care budgeting. However, as chickenpox and shingles are both diseases that are shown to reduce 
productivity and garner significant personal costs per case, it was also imperative to conduct the 
cost-effectiveness analysis from the societal perspective [20–22]. Furthermore, considering the 
cost-effectiveness from both perspectives will allow for greater comparability with previous and 
future Canadian cost-effectiveness of chickenpox vaccination studies [10,11]. However, there 
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may be decision-making challenges, including for resource allocation, if the societal and 
healthcare perspective have different findings. 
Our target population was children aged 12 months to 4-6 years who are eligible to 
receive the chickenpox vaccine in Alberta. Our model was previously fit to Alberta data before 
the implementation of chickenpox vaccination (Chapter 4) and checked for consistency with 
data post-vaccination (Chapter 5). We applied two different vaccine schedules used by a variety 
of Canadian provinces, to test how schedule can impact the cost-effectiveness of the chickenpox 
vaccine. We discounted both costs and QALYs at a rate of 1.5% [13]. Discounting is the process 
by which we adjust future costs and benefits to present value; in this case costs and QALYs 
accrued one year after the start of vaccination are valued 1.5% less than costs and QALYs 
accrued within the first year of vaccination. Furthermore, we used a long time-horizon of 75 
years to ensure we could capture all the costs and outcomes associated with chickenpox 
vaccination.  
6.2.2. Model description and parameterization  
Full descriptions of the ABM we used in this analysis are available in Chapter 4 and 
Chapter 5. In these two chapters we describe how the model represents chickenpox and shingles 
disease transmission and acquisition, and chickenpox vaccine implementation, as well as the 
parameters used to populate the original model. Furthermore, we explain how we calibrated the 
model to empirical data both before (Chapter 4) and after (Chapter 5) chickenpox vaccine. 
Below we describe the updates we made to the chickenpox and shingles ABM to conduct an 
economic evaluation analysis. The data-inputs required to conduct the cost-effectiveness analysis 
(i.e. health care utilization probabilities, costs and quality of life parameters) are presented in 
Table 6.1 and Table 6.2. A complete outline of the parameters we used in the model is available 
in Appendix G.  
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Table 6.1. Probabilities of health utilization in ABM 
ABM parameter 
name  
Parameter description Parameter estimates Reference 
probGPVisitCP Percent of total chickenpox cases that will 
visit a GP on infection 
40% 
 
Kwong et al. [23]; Lieu et 
al., [24]; Bilcke et al.  [25] 
tfFracHospitalized
CPbyAge 
Percent of chickenpox cases that go to the 
hospital by age group.  
 
 
0-1 years= 1.8%; 2-4 years= 0.4%; 5-11 years= 
0.2%; 12-18 years= 0.4%; 19-24 years= 0.5%; 25-
44 years= 1.4%; 45-65 years = 1.9%; 65+ years= 
7% 
 Brisson et al. [26] 
 
 
tfLOSHospitalized
byAge 
Length of stay in days that a chickenpox 
case stays in hospital by age.  
<1 years = 2.92 days; 1-4 = 3.23 days; 5-9 
years= 4.30 days; 10-14 years = 5.13 days; 15-
19 years = 8.86 days; 20+ years = 5.70 days 
Nowgesic et al. [27]; Law et 
al [28] 
 
probEDVisitCP Percent of chickenpox cases that go to the 
emergency room  
0.035 
 
Kwong et al. [23] 
probEDVisitShingl
e 
The percent of shingles cases that of 
shingles cases that visit a GP. The rates we 
calibrated shingles incidence to are for 
medically attended shingles and so we 
assumed everyone would go to the GP.  
1.0 Russell et al [29]; Brisson et 
al. [26]; Edgar et al. [30] 
tfFracHospitalizedS
hinglebyAge 
Probability of a shingles cases being 
hospitalized by aged group.  
0-4 years = 0.0055; 5-14 years= 0.0035; 15-44 
years = 0.0028; 45-64 years = 0.007; 65+ years= 
0.0265 
Brisson et al. [26] confirmed 
by Tanuseputro et al. [31] 
and updated to current day 
using Friesen et al. [21]  
tfLOSHospitalized
ShinglebyAge 
Average length of stay in the hospital for a 
shingles case by age group 
0-4 years= 5.1 days; 5-14 years= 4.6 days; 15-44 
years= 8 days; 45-64 years= 11.6 days; 65+ years= 
20 days 
Brisson et al. (2001)- [26]  
 
tableFunctionChan
ceOfPHNByAge 
 
Percent of shingles patients who develop 
PHN by age. PHN is defined here as 
clinically relevant pain for >90 days.  
0-48 years= 5%; 49-60 years= 14.6%; 61-70 years= 
20.5%; 70+ years= 33.8% 
Dolet et al. (2010) [32] with 
assumption for the 0-48 
group based on Friesen et al. 
2017[21] 
CustomDistribution
PHNDuration 
The average length in days of a case of 
PHN. number of days a case for a case of 
PHN.  
90-120 days= 25%; 120-244 days= 50%; 244-700 
days= 25% 
Drolet et al. (2010) [32]and 
Kawai et al. (2014) [33] 
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Table 6.2. Cost and utility parameter values 
Parameter (ABM name)  Description Estimate1 Reference 
Direct costs 
costGPVisitCP Average cost per chickenpox case that goes to a GP in 
Canada.   
$40.96 Alberta Health [34] 
costPerDayHospitalizedCP Cost per hospitalization for chickenpox per day.  $1,523 Law et al. [28]; Nowgesic et al. [27]  
costEDVisitCP  Cost per emergency room visit for a chickenpox case.  $139 Dawson et al. [35]; Alberta Health [34] 
costPerPrescriptionMedCP 
 
Cost per prescription medication (government paid) for 
chickenpox. Public spending as a percentage of total 
prescription med spending in Alberta= 42.5% 
Government 
costs= $0.75  
 
Law et al. [20]; Canadian Institute for 
Health Information [36]; Alberta 
Health [34] 
costPersonalExpenseCP 
 
Personal out of pocket expenses to care for a chickenpox case 
by age group. Costs include, over-the-counter and prescription 
medication, travel and gifts.  
costPersonalE
xpense 
CPUnder4= 
$105.60 
costPersonalE
xpense 
CPOver4= 
$43.84 
Law et al. [20] 
costGPVisitShingle GP costs for each shingles episode, and therefore can include 
multiple visits to the doctor.  
$84.95 per 
shingles episode  
Friesen et al. [21]  
 
costPerDayHospitalizedSh
ingle 
Cost per day hospitalized for shingles.  $929.81 per day Friesen et al. [21] 
costPerPrescriptionMedShi
ngle 
Cost for prescription medications (government paid) per 
shingles episode. Public spending as a percentage of total 
prescription med spending in Alberta= 42.5% 
$58.31 
 
Friesen et al. 2017 [21]; Canadian 
Institute for Health Information [36] 
costPersonalExpenseShing
le 
 
Personal expense costs per shingles case. Includes prescription 
and over-the-counter medication as well as travel costs.   
$84.86 Oster et al. [37], Rafferty et al. [38]; 
Friesen et al. [21]; Canadian Institute 
for Health Information [36] 
Indirect costs 
costProductivityLossCP2 Cost per case of chickenpox for lost productivity, all ages, 
includes time taken off work and leisure, and money spent 
paying for caregiving.  
$280.84 per 
case 
De Wals [39] 
costProductivityLossHospi
talized 
Productivity losses per day from being in hospital. These costs 
are the number of hours lost from being in hospital or taking 
care of your child in hospital multiplied by the average wage 
in Canada.   
$224.10 per day 
 
 
De Wals [39]; Statistics Canada [40] 
costProductivityLossShing
lesOver50 
Cost per case of shingles for lost productivity, for individuals 
50 years and over with no PHN.  
$345.41 per 
case 
Drolet et al. [22]; Statistics Canada 
[40] 
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costProductivityLossShing
lesUnder50 
Cost per case of shingles for lost productivity, for individual 
under 50 years of age with no PHN.  
$666.44 per 
case 
Drolet et al. [22]; Statistics Canada 
[40]; Trading Economics [41] 
costProductivityLossPHN
Over50 
Cost per PHN case of shingles for lost productivity in 
individuals over 50 years of age.  
891.98 per case 
 
Drolet et al. [22] 
costProductivityLossPHN
Under50 
Cost per PHN case of shingles for lost productivity in 
individuals under 50 years of age.  
$1,720.99 per 
case 
 
Drolet et al. [22]; Statistics Canada 
[40]; Trading Economics [41] 
costProductivityLossHospi
talizedShinglesOver50 
Cost per hospitalized case of shingles per day for lost 
productivity in individuals over 50.  
$76.19 per day Brisson et al. [26]; Statistics Canada 
[40]; Trading Economics [41] 
costProductivityLossHospi
talizedShinglesUnder50 
Cost per hospitalized case of shingles per day for lost 
productivity in individuals under 50.  
$147.01 per day Brisson et al. [26]; Statistics Canada 
[40]; Trading Economics [41] 
Vaccination and intervention costs 
CostCPVacc Cost to vaccinate a child with the varicella, using the MMRV 
vaccine within Alberta public health clinics. Including 
procurement costs, labour costs and supply costs.  
CostCPVaccDo
se1= $55.22 
CostCPVaccDo
se2= $55.22 
Institute Health Economics [42]; 
Mercer [43]; Personal Communication 
costFebrileSeizures The cost to treat a febrile seizure in the emergency room.  $139 Dawson et al. [35] 
Quality of life 
qualityOfLifeBase Utility weight for individuals with no pain, i.e. baseline.  0.855  
Van Hoek et al. [44] 
qualityOfLifeCPUnder15 Utility weight for individuals under 15 who get a regular case 
of chickenpox 
0.76 Brisson & Edmunds [45]; supported by 
Hoek et al. [46]; Bilcke et al. [25]; 
Merrett et al. [47] 
qualityOfLifeCPOver15 Utility weight for individuals over 15 who get a regular case 
of chickenpox, similar to a mild case of shingles.  
0.67 Van Hoek et al. [46] supported by 
Drolet et al. [22] 
qualityOfLifeWeakUnder5
0 
Utility weight for individuals under 50 who get a 
breakthrough case of chickenpox.  
0.83 
 
Van Hoek et al. [46] 
qualityOfLifeWeakOver50 Utility weight for individuals 50 and over who get a 
breakthrough case of chickenpox.  
0.76 Van Hoek et al. [46] 
qualityOfLifeHospitalized
CP 
Utility weight for individuals who are hospitalized for 
chickenpox.   
0.36 
 
Merrett et al. [47] 
qualityOfLifeShingles Utility weight for individuals who get a normal case of 
shingles.  
0.59 Drolet et al. [32] supported by Brisson 
et al. [48] and Wijck et al. [49] 
qualityOfLifePHN Utility weight for individuals who get PHN from shingles 0.67 Drolet et al. [32]; supported by Brisson 
et al. [48] 
qualityOfLifeHospitalized
Shingle 
Utility weight for individuals who are hospitalized from 
shingles.  
0.32 Van Hoek et al. [44] 
1All costs are presented in 2017 Can$ and were adjusted using the Canadian consumer price index [50]. 
2Productivity costs include both time off work and caregiver time.  
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The first update to the model was to add in health utilization probabilities. Based on 
certain disease and vaccination events we added in probabilities of going to a physician or 
emergency room, being hospitalized, having a vaccine adverse event and having a disease 
complication that lead to death. Therefore, individuals who entered the ‘infectedCP’ state had a 
certain probability of visiting a physician (probGPVisitCP) or the emergency room 
(probEDVisitCP), as well as being hospitalized (tfFracHospitalizedCPbyAge) and dying from a 
complication (probabilityOfComplicationDeathCP). For ‘infectedWeaklyCP’ we included a 
probability of a physician visit (probGPVisitCPWeak); however, there was no risk of an 
emergency room visit, hospitalization or death from this state.  
Similarly, individuals who were in the ‘infectedShingles’ state had a certain probability 
of death from shingles (probabilityOfComplicationDeathShingle), probability of post-herpetic 
neuralgia (PHN) based on age (tableFunctionChanceOfPHNByAge) and probability of 
hospitalization based on age (tfFracHospitalizedShinglesByAge). If an agent was hospitalized for 
shingles or chickenpox they transitioned from the ‘home’ state in the statechartTreatment to the 
‘inHospital’ state, where their length of stay was dependent on their age 
(tfLOSHospitalizedCPbyAge and tfLOSHospitalizedShinglebyAge). Finally, there was a 
probFebrileSeizure associated with entering the Protected1 state following the receipt of 1st dose 
vaccination to account for vaccine adverse events.  
To conduct the analysis from both the healthcare and societal perspectives, we included 
direct health care costs, personal costs and productivity loss, which were represented in the 
model either as episodic costs (i.e. single costs triggered by a certain event) or state-based cost 
(i.e. added up each day an agent remained in a state). All costs are presented in 2017 Can$, and 
were adjusted for inflation using the Canadian consumer price index [50].The direct medical 
costs to the health care system were mainly episodic costs that depended on the health care 
utilization probabilities described above, and included physician (costGPVisitCP; 
costGPVisitShingles), emergency room visit (costEDVisitCP; costEDVisitShingle), as well as the 
medication costs provided through the Government of Alberta for each chickenpox and shingles 
case (costPerPrescriptionMedCP; costPerPrescriptionMedShingle). Hospitalization costs were 
included as a state-based cost that was triggered every day an individual remained in the 
‘inHospital’ state (costPerDayHospitalizedCP; costPerDayHospitalizedShingle).  We also 
included the cost of chickenpox vaccination as an episodic cost when an individual receives 
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either 1st or 2nd dose vaccination (costCPVaccDose1; costCPVaccDose2). Costs included as part 
of vaccination costs were procurement costs, as well as labour, administration and supply costs. 
Finally, we included a cost for febrile seizures from 1st dose vaccination (costFebrileSeizure).  
Personal costs included over-the-counter medication, travel and personal prescription 
medication costs. These costs were largely episodic, partially based on age and occurred when 
someone entered either the ‘infectedCP’ state (costPersonalExpenseCPUnder4; 
costPersonalExpenseCPOver4) or the ‘infectedShingle’ state (costPersonalExpenseShingle). 
Finally, we considered productivity losses, which were calculated in the disease and treatment 
statecharts, including different productivity losses for each of these states: ‘infectedCP’ 
(costProductivityLossCP), ‘inHospital’ for chickenpox (costProductivityLossHospitalizedCP), 
‘infectedShingle’ (getCostProductivityLossShingleByAge), ‘PHN’ 
(getCostProductivityLossPHNByAge) and ‘inHospital’ for shingles 
(costPerDayHospitalizedShingle). These productivity losses included both the time spent taking 
care of the chickenpox case and any cost accrued for caregiving. The productivity costs for 
‘infectedShingle’, ‘PHN’ and ‘inHospital’ for shingles, partially depended on age. While deaths 
associated with chickenpox were captured in our model, we did not estimate their associated 
productivity loss, as the mortality rates were very low (<1 death per 500,000 person-years).  
Similarly to productivity loss, each agent had a quality of life (QoL) that depended on 
their disease and treatment state, as well as their age. QoL is calculated on a per day basis for 
each model agent (See Table 6.2). We included a base quality of life (qualityOfLifeBase) for any 
individual not in a disease state that impact their quality of life. Treatment states that impact 
quality of life included: ‘infectedCP’ (qualityOfLifeCPUnder15; qualityOfLifeCPOver15), 
‘weaklyInfectedCP’ (qualityOfLifeWeakUnder50, qualityOfLifeWeakOver50), ‘inHospital’ for 
chickenpox (qualityOfLifeHospitalizedCP), ‘infectedShingle’ (qualityOfLifeShingles), ‘PHN’ 
(qualityOfLifePHN) and ‘inHospital’ for shingles (qualityOfLifeHospitalizedShingle).  QoL 
estimates for a standard chickenpox [45] and shingles [32] case were based on primary quality of 
life studies, specifically the standard gamble and the Health Utilities Index mark 2 (HUI2) 
questionnaire for chickenpox, and the EuroQoL EQ-5D for shingles. The individuals QoL per 
day (depending on their current state) are then added up over the entire year and population to 
determine total QALYs per year in the population. Durations for QALYs were based on the time 
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spent in disease states (see Appendix G); for instance, durationCP determined the amount of 
time an individual had a chickenpox QoL. 
6.2.3. Main experiment 
In our main analysis we ran the model for 175 years. The first 100 years were to initialize 
the model (as described in Chapter 4), with costs and effects being measured over the last 75 
years. We include three comparators in our main analysis: 
- No vaccination: Disease outcomes, costs and QALYs were calculated for 75 years (year 
100-175) with no introduction of vaccination.  
- Schedule with long dosing interval (schedule LDI): Disease and vaccination outcomes, 
costs and QALYs were measured for 75 years (year 100-175) following introduction of 
vaccination at year 100, with children receiving 1st dose chickenpox vaccination at 12 
months and 2nd dose vaccination between 4 and 6 years.  
- Schedule with short dosing interval (schedule SDI): Disease and vaccination outcomes, 
costs and QALYs were measured for 75 years (year 100-175) following introduction of 
vaccination at year 100 with children receiving 1st dose chickenpox vaccination at 12 
months and 2nd dose vaccination at 18 months. 
We ran each comparator twice, once considering the impact of shingles on the overall costs and 
QALYs, and once ignoring the overall shingles impact. All other variables remained consistent 
across all three scenarios.  
The population size, total discounted costs and discounted QALYS for the 75 years 
following vaccination were summed for each run. All costs and QALYS are presented in 
medians per capita [95% predictive interval] across all simulation results. 95% predictive 
intervals represent the 2.5th and 97.5th percentiles from the sample of model runs. The costs and 
QALYs were presented per capita to account for differences in population size between model 
runs. For all model run sets (i.e. no vaccination, schedule LDI and schedule SDI) we conducted 
at least 30 paired runs. Pairing the model runs ensured that one set of runs for baseline, schedule 
LDI, and schedule SDI started with the same values for the transition probabilities, health 
utilization probabilities, as well as the cost and utility parameters and variables. Based on the 
previous sample size calculation describe in Chapter 4, and practical considerations (i.e. model 
run time) we decided to maintain our sample size at 30 runs minimum (90 non-paired runs). 
Running the model multiple times meant we could account for some of the stochastics in agent-
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based modelling and calculate an incremental cost utility ratio (ICUR) for each run, providing 
both a range of outcomes for cost-effectiveness, as well as a point estimate.  
6.2.4. Sensitivity analysis 
Using scenario analysis, we varied duration of boosting, discount rate for benefits, 
vaccination attitude, primary vaccine failure and secondary vaccine failure to see their relative 
impact on the cost-effectiveness of different chickenpox vaccine schedules. We tested the impact 
of a shorter duration of VZV boosting (duration of boosting= 2 years; waning of immunity 
coefficient= 0.5), as identified in Chapter 4, to observe its impact the cost-effectiveness of 
chickenpox vaccination. By shifting 15% of hesitant individuals to vaccine acceptors and then 
shifting 15% of hesitant individuals to vaccine rejectors, we tested the effects of higher and 
lower vaccination coverage. Furthermore, we used ranges in the literature to vary primary 
vaccine failure for first dose vaccine between 9% to 24%, while simultaneously varying the 
primary vaccine failure for second dose between 5% and 16% [2,51–54]. As the rate of 
secondary vaccine failure remains largely unknown we considered a wide range, between 0 and 
5%, in our sensitivity analysis. We also conducted a sensitivity analysis on one of our main 
economic evaluation assumptions, specifically the discount rate for the benefits, which we tested 
at 0%. 
6.3. Results 
6.3.1. Main experiment results 
Similar to our findings in Chapter 5, we discovered chickenpox vaccination lead to a 
significant decrease in chickenpox incidence. Furthermore, we found the 95% predictive 
intervals for chickenpox incidence overlapped between schedule SDI and schedule LDI; 
however, 100% of the paired runs found that schedule SDI had a lower chickenpox incidence 
rate than schedule LDI (Table 6.3). The decreased risk of chickenpox with vaccination 
contributed to a lower rate of chickenpox hospitalizations, as well as an increase in shingles 
cases, consistent with Chapter 4. From the healthcare perspective we found that both 
chickenpox vaccination strategies were more expensive than no vaccination, both when we 
considered and ignored the impact on shingles. Specifically, vaccination cost on average $0.47 
more per person-year than no vaccination when considering shingles, and $0.28 more per 
person-year when not considering shingles. However, chickenpox vaccination resulted in notable 
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savings in comparison to no vaccination from the societal perspective, reducing cost by an 
average of $1.83 per person-year with shingles and $2.15 per person-year without shingles 
(Table 6.3).  While schedule SDI was slightly cheaper than schedule LDI from the societal 
perspective, and more expensive from the healthcare perspective, the 95% predictive intervals 
for schedule SDI and LDI for these values overlapped, suggesting there was no significant 
difference.  
Table 6.3. Disease, healthcare, cost and QALY outcomes over 75 years post chickenpox 
vaccination (median and 95% predictive interval across 30 model runs).  
 Scenario (75 years post-vaccination) 
No vaccine Schedule LDI2 Schedule SDI2 
Chickenpox incidence 
(per 1,000 person-years) 
12.11 (12.0, 12.26) 
 
 
0.61 (0.50, 0.74) 0.49 (0.39, 0.64) 
Breakthrough 
(% of total cases)  
- 17.92%  
(14.55, 21.06) 
14.96%  
(11.13, 18.26) 
CP Hospitalization per 
capita (per 100,000 
person-years) 
6.09 
(5.89, 6.27) 
0.48 
(0.39, 0.58) 
0.39 
(0.35, 0.48) 
Healthcare costs ($ per 
capita)1 
$1.40 
(1.40, 1.41) 
$1.86 
(1.84,1.90) 
$1.88 
(1.86, 1.92) 
Societal costs ($ per 
person year) 
$5.65 
(5.58, 5.72) 
$3.82 
(3.76,3.92) 
$3.82 
(3.75, 3.91) 
QALY3  
(per 1,000,000 person-
years) 
854,748.42 
(854,745.63, 
854,750.08) 
854,746.99 
(854,744.89, 
854,748.33) 
854,746.85 
(854,745.85, 
854,748.58) 
Healthcare costs- no 
shingles4 
($ per person-years) 
$0.42 
(0.41, 0.44) 
$0.69 
(0.69, 0.71) 
$0.71 
(0.71,0.72) 
Societal costs- no 
shingles  
($ per person-years) 
$3.00 
(2.93, 3.07) 
$0.85 
(0.79,0.92) 
$0.84 
(0.84, 0.86) 
QALY- no shingles 
(per 1,000,000 person-
years) 
854,965.79 
(854,965.05, 
854,966.44) 
854,997.73 
(854,996.91, 
854,998.35) 
854,998.07 
(854,997.13, 
854,998.61) 
1All costs and QALYs were discounted at a rate of 1.5%  
2Schedule LDI is 1st dose MMRV at 12 months and 2nd dose at 4-6 years, and Schedule SDI is first dose of MMRV 
at 12 months and second dose at 18 months.  
3We represent QALY in person-years to account for differences in population size between model runs.  
4No shingles runs assumed there was no cost or loss of QALY associated shingles, therefore the differences 
between baseline, schedule LDI and schedule SDI were only based on differences in chickenpox incidence.   
Total societal costs per year under the no vaccination scenario were approximately 
$2,659,741, in comparison to the vaccination scenarios, which had a cost around $1,749,674 per 
year (median population across all runs= 470,424). Under the no vaccination scenario indirect 
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costs, including productivity loss chickenpox (37%), productivity loss shingles (26%), and the 
personal costs for chickenpox (8.2%) and shingles (3.7%), contributed far more to the total costs 
than direct costs (75% versus 25%) (Figure 6.1A). With chickenpox vaccination, for both 
schedule SDI and LDI vaccination, while productivity loss from shingles contributed to a larger 
proportion of the total costs (41%), the percentage of total costs attributed to chickenpox, 
including productivity, personal and hospital costs decreased dramatically (Figure 6.1B, Figure 
6.1C). Chickenpox vaccination had a notable impact on costs, accounting for 18% in schedule 
SDI and 17% in LDI of total societal costs, and costing between approximately $309,880 and 
$321,609 per year for a median population of 470,424 agents.  
Overall, we found that when not considering the impact on shingles QALYs were 
significantly greater with vaccination than without vaccination, with an increase of 3 QALY per 
100,000 person-years (Table 6.3). However, the opposite was true when we considered the 
impact of shingles, with QALY per person decreasing with chickenpox vaccination, most likely 
because of the associated rise in shingles incidence.  
Ignoring the impact on shingles, we ascertained that vaccination was cost-saving from the 
societal perspective (Table 6.4) and remained cost-saving across all runs and both schedules, as 
shown in Figure 6.2a. Moreover, from the healthcare perspective, without considering shingles 
we found that both schedules resulted in higher costs but significant gains in QALY, and 
therefore found vaccination was highly cost-effective based on cost-effectiveness thresholds 
reported in that literature, with ICURs less than 20,000 per QALY gained [55] (Figure 6.2b, 
Table 6.4). However, the ICUR outcomes change when we consider the impact on shingles, in 
these scenarios vaccination was either dominated by the no vaccination scenario, or highly cost 
ineffective at $1,184,999-$1,481,433 per QALY gained. As these are just point estimates based 
on multiple runs it is important to consider the distribution of ICURs as presented in Figure 6.2a 
and Figure 6.2b. For instance, while 79% of schedule LDI and schedule SDI runs found that 
vaccination would not be cost-effective from the societal perspective when considering shingles, 
21% of runs estimated vaccination would be cost-saving. This figure illustrates that vaccination 
is consistently cheaper than no vaccination from the societal perspective, but there are a range of 
QALY outcomes, with some showing QALY is higher with vaccination than no vaccination, and 
others showing contradictory results.  
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Figure 6.1. Type of costs as a percentage of the total costs, with (schedule SDI and schedule 
LDI) and without chickenpox vaccination.  
1Costs displayed in all three charts include: cost of a general practitioner for chickenpox (GP CP), emergency 
department visit chickenpox (ED Visit CP), cost of hospitalization chickenpox (Hosp. CP), productivity loss 
chickenpox (Prod. CP), personal costs chickenpox (Pers CP), medication cost for chickenpox (Med CP), cost of a 
general practitioner for shingles (GO Shingle), cost of hospitalization shingle (Hosp. Shingle), productivity loss 
shingles (Prod. Shingle), personal costs shingles (Pers. Shingle), medication costs shingle (Med. Shingle), cost 
chickenpox vaccination (Vacc. CP) and cost of adverse events from chickenpox vaccination (Vacc. AE) 
2Schedule LDI is 1st dose MMRV at 12 months and 2nd dose at 4-6 years, and Schedule SDI is first dose of MMRV 
at 12 months and second dose at 18 months.  
 
 
Table 6.4. Incremental cost utility ratios from healthcare and societal perspectives 
 Healthcare 
perspective 
Societal 
perspective1 
Healthcare (no 
shingles) 
perspective 
Societal (no 
shingles impact) 
perspective 
Schedule LDI vs.  
No Vaccine2 
Dominated $1,285,353 per 
QALY gained 
$8,447 per QALY 
gained 
Dominant 
Schedule SDI vs. 
No Vaccine2 
Dominated $1,170,209 per 
QALY gained 
$8,955 per QALY 
gained 
Dominant 
Schedule SDI vs. 
Schedule LDI2  
Dominated $23,177 per 
QALY gained 
$56,262 per 
QALY gained 
Dominant 
1All incremental cost-utility ratios are averaged over all model runs 
2Control Group 
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The point ICURs based on the comparison of vaccination schedule showed schedule SDI 
was dominant (i.e. lower costs and higher QALY than schedule LDI) from the societal 
perspective and cost-effective from the healthcare perspective ($59,381-62,992 per QALY 
gained). However, the distributions of runs in Figure 6.2a demonstrated a wide range of possible 
ICURs when comparing the vaccination schedules, with values from across the spectrum on the 
cost-effectiveness plane. Figure 6.2a illustrates the uncertainty around that estimate; with some 
runs showing schedule SDI as cost saving (32%), some as cost-effective (50%) and other 
showing schedule LDI dominating (18%).   
6.3.2. Sensitivity analysis 
Most of the scenario analyses did not show a significant difference from our baseline 
scenarios, with chickenpox vaccination cost-ineffective from the societal perspective considering 
shingles, and cost-saving when not considering shingles (Appendix H, Figure H-1 and H-2). 
However, no discounting of QALYs (i.e. one QALY lost in the present is worth the same as one 
QALY lost in the future) had a substantial impact on the benefits associated with chickenpox 
vaccination. Specifically, we found when we did not discount QALYs, the vaccination scenarios 
when considering shingles, had consistently higher QALYs per person-year than the no 
vaccination scenarios (Figure 6.3). Furthermore, lowering the duration of boosting to 2 years 
and using a waning immunity coefficient of 0.5 lead to a vast improvement in the cost-
effectiveness of chickenpox vaccination when considering shingles (Figure 6.3). In all scenario 
analyses, while schedule SDI was on average more cost-effective than schedule LDI there was a 
wide range of outcomes, particularly when considering shingles. For instance, when we moved 
15 % of vaccine hesitants to rejectors (low vaccine coverage) schedule SDI was more effective at 
preventing chickenpox infection on average but cost more than schedule LDI (Appendix H, 
Figure H-1 and Figure H-2).   
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Figure 6.2a. Cost-effectiveness plane for chickenpox vaccination with and without shingles (societal perspective) 
1
Schedule LDI is 1st dose MMRV at 12 months and 2nd dose at 4-6 years, and Schedule SDI is first dose of MMRV at 12 months and second dose at 18 months.  
2No shingles runs assumed there was no cost or loss of QALY associated shingles, therefore the differences between baseline, schedule LDI and schedule SDI 
were only based on differences in chickenpox incidence.   
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Figure 6.2b. Cost-effectiveness plane for chickenpox vaccination with and without shingles (healthcare perspective) 
1
Schedule LDI is 1st dose MMRV at 12 months and 2nd dose at 4-6 years, and Schedule SDI is first dose of MMRV at 12 months and second dose at 18 months.  
2
No shingles runs assumed there was no cost or loss of QALY associated shingles, therefore the differences between baseline, schedule LDI and schedule SDI 
were only based on differences in chickenpox incidence.   
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Figure 6.3. Scenario analysis cost-effectiveness plane: Median incremental costs and QALYs per capita with a shorter 
duration of exogenous boosting and no discounting of QALY, considering shingles (societal perspective) 
1Duration of boosting = 2 years and waning of immunity rate = 0.45 
2No discounting of quality adjusted life years; therefore, one QALY in the present is equal to one QALY in the future.  
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 6.4. Discussion 
This study is the first to use an ABM to conduct an economic evaluation of the 
chickenpox vaccine. Our ABM successfully estimated the cost-effectiveness of the chickenpox 
vaccination under a variety of scenarios (e.g. considering and ignoring the costs and benefits 
associated with shingles) in a 500,000-person population for 75 model-years. This is also the first 
study to compare the cost-effectiveness of different chickenpox vaccination schedules, a question 
particularly relevant to Canadian policy-makers [56].   
Our results demonstrate that chickenpox vaccine is cost-saving from the societal 
perspective when ignoring the impact on shingles vaccine. These findings are consistent with 
previous research both globally [7,8,57] and in Canada [10,11], which highlight the large indirect 
cost benefits of chickenpox vaccination. At the same time, our model predicted that chickenpox 
vaccination would be highly cost-effective from the healthcare perspective (ICURs < 20,000), 
while most previous models, including Canadian studies, predicted that if we only consider the 
costs to healthcare the vaccine would not be cost-effective [10,11,57]. For example, Getsios et al. 
[10] estimated routine chickenpox vaccination would save Canada approximately $4 million 
from the societal perspective but would lead to an increase of $2.2 million from the healthcare 
perspective. While Brisson et al. [11] estimated that a universal infant vaccination program 
would cost $44,503 per life-year gained from the healthcare perspective and be cost-saving from 
the societal perspective. 
The cost-savings from the societal perspective are largely due to the reduction in 
productivity losses, both from less time spent caregiving, as well as time off work due to illness.  
We estimated productivity losses accounted for a sizable percentage (75%) of the total costs for 
both shingles and chickenpox prior to vaccination. Hospitalization was the largest healthcare cost 
for shingles and chickenpox. However, recent research from Canada found shingles 
hospitalization rates were either declining and levelling over the past few years, while shingles 
medication costs were on the rise, up 37% from 1997/98 to 2011/12. These findings suggest drug 
costs may be a bigger factor in future cost-analyses. PHN also contributed to a substantial 
percentage of shingles healthcare costs in our model and in empirical studies [21]. Friesen et al. 
[21] estimate PHN was responsible for 41.6% of shingles hospital costs, 21.3% of medication 
costs and 49.7 % of drug costs, even though fewer than 10% of shingles cases got PHN.   
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When we incorporated shingles into our analysis, we found that vaccination was 
dominated by no vaccination (healthcare perspective) or was highly cost-ineffective (societal 
perspective). Again, these results were consistent with previous cost-effectiveness studies, which 
demonstrated that the increased severity of shingles infection, and the costs associated with 
treatment and productivity loss, generally outweighed the benefits of reducing chickenpox 
infection [11,57]. However, our model runs identified novel factors to consider when analysing 
chickenpox and shingles outcomes. First, while the point estimate for the ICUR of chickenpox 
vaccination considering shingles suggested vaccination was not cost-effective, even from the 
societal perspective, the range of values from the model runs tell a different story, as a 
substantial proportion of runs found that vaccination would be cost-saving. Second, the costs to 
society were consistently lower with vaccination than without. Therefore, while the point 
estimate ICURs suggested we should not vaccinate for chickenpox, policy-makers need to 
consider the overall picture of cost-effectiveness. For instance, there remains a large amount of 
uncertainty of the impact of chickenpox vaccine on shingles, which had a substantial effect on 
the cost-utility of the vaccine. Furthermore, most runs demonstrated that chickenpox vaccination 
would reduce overall costs, and many runs found chickenpox vaccination was cost-saving. All 
these factors may influence decision-making surrounding chickenpox vaccination.  
Second, our results suggest that discounting QALY by 1.5% per year, as recommended 
by CADTH had a substantial impact on the cost-effectiveness of vaccination when considering 
shingles. Similar to what we observed in Chapter 4, under chickenpox vaccination scenarios our 
model predicted an initial increase in shingles, due to vaccination reducing the natural boosting 
of VZV immunity [16,58–60]. At the same time, we also predicted an ultimate decrease in 
shingles cases, which we postulated in Chapter 4 was from the lowered risk of VZV latency 
following vaccination in comparison to natural infection, as observed in empirical studies 
[31,61,62].  With the increase of shingles occurring soon after the implementation of 
vaccination, and the overall decrease in shingles not occurring until many years into the model 
run, discounting QALY weighted the initial increase in shingles higher than the ultimate 
decrease in incidence. Discounting health effects have a particularly strong impact on public 
health interventions and prevention program, where effects, such as the reduction in shingles, are 
seen far in the future, but costs start to accrue immediately. Thereby leading to a bias against 
preventative measures [63]. It may be advisable to use a decreasing discount rate as 
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recommended by the World Health Organization [12] and NICE [64], to unsure we do not 
undervalue too heavily future benefits of vaccination.  However, it is also important to consider 
if an increase in shingles does occur it may have a profound impact on the health care system in 
the near future, both raising costs and lowering the QALYs of the population.  
Third, our sensitivity analysis further suggests, that if we assume a shorter duration of 
immunity following boosting and a faster waning of immunity rate, there is only a modest 
increase in shingles cases following vaccination, thereby drastically improving the cost-
effectiveness of the chickenpox vaccination when considering the impact on shingles (Figure 
6.3A). As we discussed in Chapter 4, there are many plausible values for boosting and waning 
of immunity, some of which lead to chickenpox vaccination being cost-saving and some of 
which result in high cost-effectiveness ratios. As the current empirical evidence suggests that the 
boosting of immunity may be short term and/or impact only a small percentage of the population, 
it is very possible the chickenpox vaccine may be cost-effective even when considering the 
impact of chickenpox vaccine on shingles [19,29,65]. As longer-term follow up data on shingles 
incidence following vaccination becomes available, it is essential we updated the assumptions in 
our model. 
It is important to consider the differences in our model to previous chickenpox 
transmission models, and how these deviations may affect the cost-effectiveness of chickenpox 
vaccination. The two previous Canadian cost-effectiveness of universal chickenpox vaccination 
used deterministic realistic age-structured population models, which like our ABMs can capture 
the indirect effects of vaccination, including age of infection and herd immunity. However, there 
are further benefits to using an ABM; including the ability to capture exogeneous infection and 
represent a pattern of small but sustained outbreaks in the vaccinated population, similar to what 
is seen in empirical data [66]. Furthermore, agent-based modelling gave us the ability to 
represent the detailed vaccine, disease and health services histories of agents, and as such 
allowed us to capture a wide variety of costs and QALY gains and losses, including differences 
in costs/QoL for weakly infected, PHN, age-specific QoL for chickenpox infection, along with a 
variety of health utilization costs (physician, hospitalization, emergency room and medication). 
ABMs can further represent detailed elements of vaccination, including vaccine attitudes, 
uncertainties in vaccine coverage and – critically for this study – continuous waning of vaccine 
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immunity. Finally, ABMs allow for probabilistic analysis, with each model run leading to a 
different ICUR, based on the stochastics in disease transmission inherent in ABMs.  
As our analysis took place several years following the implementation of the chickenpox 
within the Alberta childhood vaccine schedule, we could update prior parameter estimates. As 
such, this model provides a more accurate evaluation of the chickenpox vaccine’s real-world 
cost-effectiveness. There were a few differences between our ex-post analysis (i.e. post-
implementation) and the cost-effectiveness analyses conduct prior to vaccine implementation 
(ex-ante), both in terms of the inputs used, as well as the model outcomes. For instances, Brisson 
et al. [11] and Getsios et al. [10] both estimated the cost-effectiveness based one-dose 
vaccination, while most provinces and territories in Canada now have two dose schedules. 
Furthermore, the previous Canadian studies assumed only a certain percentage of individuals 
would be susceptible to vaccine waning of immunity and would wane at a relatively high rate 
[10,11]. These assumptions may account for the lower vaccine effectiveness and higher costs 
associated with infant vaccination described in Getsios et al. [10] and Brisson et al. [11]. 
Many of the assumptions made pre-vaccine implementation were similar to what we 
observed post-vaccine implementation, including assumptions about the costs of vaccination, 
coverage rates and primary vaccine failure. These assumptions resulted in some similar 
conclusions, including the cost-saving from the societal perspective and the impact of shingles 
on overall cost-effectiveness. Similar to our sensitivity analysis around coverage rates, Brisson et 
al. [11] found that varying the coverage of the chickenpox vaccine had little impact on the cost 
per life year gained for the infant vaccination strategy. These findings suggest that while cost-
effectiveness studies done ex-post are important and can improve our understanding of the costs 
and effects of a particular vaccine, the results from ex-ante studies can still provide meaningful 
policy-relevant results. 
Another element that may have altered the findings of our cost-effectiveness in 
comparison to the previous chickenpox vaccine cost-effectiveness studies, are changes to the 
CADTH guidelines outlining best-practices for economic evaluations in Canada [13,67]. For 
instance, neither Brisson et al. [11] (per life-year gained) or Getsios et al. [10] (per case avoided) 
conducted a cost-utility analysis, which CADTH recommends be the reference case analysis for 
all economic evaluations [13]. Type of economic evaluation is likely to make a significant 
difference in the cost-effectiveness of the vaccine, because while chickenpox and shingles may 
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not have a major impact on life years lost, they both can have major impacts on quality of life. 
Furthermore, as mentioned above we discounted QALY at a rate of 1.5% as recommend by 
CADTH, this had a significant impact on the cost-effectiveness of the chickenpox vaccine. In 
comparison, Brisson et al. [11] discounted both his costs and life years at a rate of 3% per year. 
Finally, Brisson et al. [11] only used a 30-year time horizon in their base case analysis. Currently 
CADTH recommends a time horizon long enough to capture all costs and benefits, which was 
the basis for running our model for 75-years post-vaccine implementation.  
To our knowledge, this was the first cost-effectiveness analysis to measure the costs and 
benefits associated with different vaccine schedules. As the childhood vaccine schedule expands 
and becomes progressively more complex (e.g. multiple doses, combination vaccines), knowing 
the most effective and cost-saving method of administering a vaccine may be invaluable to 
policy-makers. Furthermore, estimates of the cost-effectiveness of different schedules can help 
inform decision-making on chickenpox vaccine implementation in countries that do not currently 
have a universal chickenpox vaccine program.  While our point estimate ICUR suggests that 
schedule SDI was more cost-effective than schedule LDI from the societal perspective, some 
runs showed schedule SDI as more cost-effective and other suggested that LDI was the preferred 
strategy. The cost-effectiveness of schedule SDI is even less clear from the healthcare 
perspective, with an estimated ICUR at $$56,262 per QALY gained without shingles, and with 
LDI being the preferred strategy with shingles. However, healthcare costs for schedule SDI were 
artificially higher than schedule LDI due to the earlier start to 2nd dose vaccination, which meant 
there were a few years in the simulation where children were receiving 2nd dose vaccination in 
schedule SDI but not in schedule LDI. Furthermore, while schedule SDI was consistently more 
effective at decreasing chickenpox cases than schedule LDI, it also lead to a higher age of 
chickenpox infection and a slightly higher rate of shingles (see Chapter 5). These outcomes may 
have a negative impact on the cost-effectiveness of schedule SDI, as cases of chickenpox in 
adults and shingles are generally more severe (lower QoL) and costlier than the typical 
chickenpox case [14,17,20,21,28,57].  
Our study had some notable limitations. First, our estimates for costs associated with 
chickenpox disease, specifically, chickenpox hospitalization [28], personal costs [20] and 
productivity loss [39], were significantly older than the estimates for shingles. While we did 
account for inflation in our analysis, the costs estimates may have changed significantly since 
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these studies were published. The economic burden of chickenpox may be an area for future 
analysis, to see how chickenpox costs have changed over time, particularly with the advent of 
vaccination and the increase in breakthrough cases. Second, while we needed to make fewer 
parameter assumptions than previous economic evaluations, there still remain multiple 
unknowns, including the impact of vaccination on shingles incidence and the long-term risk of 
vaccine waning of immunity. Therefore, it is imperative we continue to update the ABM and the 
chickenpox vaccine cost-effectiveness analysis as the evidence-base grows. Third, while the use 
of cost-utility analysis, specifically QALYs, are recommended by CADTH the estimation of 
utilities is often a complicated and imprecise process [13,68]. Different methods to measure the 
utilities used to calculate the QALY, including Standard Gamble and Health Utility Index Mark 
II, can often lead to various outcomes. For instance, in a study conducted by Brisson & Edmunds 
they found two different methods to calculate utilities for chickenpox led to different QoL 
estimates [45]. Furthermore, the population surveyed for the utility analysis (e.g. patients, 
general population, country) can also affect the overall results [68]. Therefore, the utilities we 
used in this analysis are hard to validate [69]. Third, given the unknowns surrounding the costs 
and utilities associated with chickenpox and shingles used in this analysis, it may have been 
prudent to complete a probabilistic sensitivity analysis on these values. A probabilistic sensitivity 
analysis would have allowed us to determine the percentage of runs that were cost-effective or 
cost-saving based on a range of cost and utility estimates. However, as the model itself was 
already probabilistic and the stochastics in our model already provided a range of possible costs 
and outcomes for each run we did not want to input more uncertainty in the model by using 
distributions for the costs and effects. Furthermore, we did not test the impact of a 3% discount 
rate, which is a value commonly used in international literature. Finally, a cost-effectiveness 
analysis should be only one factor in decision-making, as it can only capture some of the benefits 
of a vaccination program. Therefore, it is imperative other evaluations are conducted on 
chickenpox vaccination, including equity evaluations (i.e. does the chickenpox vaccine benefit 
all population groups equally) and availability evaluations (is the vaccine reaching those who 
most need it?).  
Our ABM could be used for future cost-effectiveness; including testing a wider variety of 
chickenpox schedules, particularly those being used throughout Canada, for example in Ontario 
(V-15 months, MMRV 4-6 years) and Quebec (MMRV- 18 months, V- 4-6 years). We could 
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further use our ABM to simulate the cost-effectiveness of the new shingles vaccine, as policy-
maker will need to decide whether to include it in the publicly-funded vaccination program. In 
future analyses we aim to complete wider range of scenario analyses, including the impact of a 
higher rate of shingles following chickenpox vaccination, updated health and productivity costs 
for chickenpox disease, increased variation in vaccination costs, and potentially a threshold 
analysis to determine at what rate of primary and secondary vaccine failure there is an obvious 
preference for schedule LDI or schedule SDI.  
6.5. Conclusions 
Our findings suggest that chickenpox vaccination is cost-saving or cost-effective from the 
societal and healthcare perspective when not considering the impact on shingles. In fact, 
chickenpox vaccination may even be cost-effective when accounting for the additional costs 
associated with shingles. This is an important finding for countries which have delayed 
vaccination for fear of the impact on shingles incidence [15]. However, to fully understand the 
impact of the chickenpox vaccine on shingles and therefore its cost-effectiveness we need to 
continue to monitor VZV epidemiological and biological studies. Moreover, in this analysis we 
determined a chickenpox vaccination schedule with a reduced amount of time between 1st and 
2nd dose (schedule SDI) may lead to slightly lower costs and higher QALY than a longer time 
between doses (schedule LDI), and therefore may be the better choice for countries just setting 
up a chickenpox vaccination program. However, as the results were not conclusive, other 
contributing factors, such as the type of vaccine implemented (e.g. V versus MMRV), if the 
vaccine can be administered at the same time as other vaccines, public perception, vaccine 
coverage at different ages, should be considered and may play a larger role in the ultimate timing 
of chickenpox vaccination doses.  
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CHAPTER 7- CONCLUSIONS 
7.1. Overall findings and their relevance to research and policy 
This thesis aimed to address four research questions, (1) the scope of research available 
on economic evaluations of vaccines in Canada, (2) the impact of chickenpox vaccination on 
shingles disease outcomes under various theories of waning and boosting of varicella zoster virus 
(VZV) immunity, (3) the impact of two different chickenpox vaccination schedules on 
chickenpox and shingles disease outcomes in Alberta, and (4) the overall cost-effectiveness of 
chickenpox vaccine, as well as the cost-effectiveness of two different chickenpox vaccine 
schedules. 
Tackling these research questions can help improve shingles and chickenpox diseases 
control strategies, both in Alberta and internationally. This research can provide guidance to 
policy-makers interested in using agent-based modelling to inform decision-making; as well as 
improve the approach to, and reporting of, economic evaluations of vaccines in Canada. This 
chapter will highlight some of the key limitations of the research, including limitations with the 
two main methodological approaches used throughout this thesis, agent-based modelling and 
economic evaluation. Furthermore, this chapter will note key areas for future research, such as 
increasing the number of post-implementation economic evaluations and potential future 
applications for our chickenpox and shingles agent-based model (ABM). 
7.1.1. Shingles control 
Chapter 4 of this thesis presents novel findings relevant to chickenpox vaccination and 
shingles control. While previous models generally predicted a substantial increase in shingles 
incidence following chickenpox vaccination, this thesis inextricably linked the rise in shingles 
with the boosting and waning of VZV immunity assumptions in the model [1–3]. Chapter 4 
highlighted boosting and waning of VZV immunity scenarios that fit empirical data; while some 
of these scenarios predicted large increases in shingles cases following chickenpox vaccination, 
many of them predict only a small, potentially negligible rise in shingles incidence. Furthermore, 
current research suggests that individuals vaccinated with chickenpox have a significantly lower 
risk of VZV remaining latent in the body, and therefore a lower risk of the virus reactivating in 
the form of shingles. As such, our model predicted that chickenpox vaccination could ultimately 
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reduce shingles incidence to a very low rate. These results were validated in recent 
epidemiological studies [4,5].  
These findings may help inform decision-making surrounding the chickenpox vaccine. 
Many countries have resisted implementing the chickenpox vaccine due to concerns about its 
impact on shingles. Our model shows that the impact on shingles could be significantly smaller 
than originally estimated. Moreover, the benefits of reducing the population susceptible to 
shingles may ultimately outweigh the initial increase in cases. The results of this thesis highlight 
the need for better estimates of duration of VZV immunity following exogenous boosting (i.e. 
time gained in protection against shingles reactivation following a boosting event) and risk of 
reactivation in chickenpox vaccinees, so researchers can estimate the true impact of chickenpox 
vaccination on shingles.    
7.1.2. Chickenpox control  
While Chapter 4 focused on the impact of chickenpox vaccination on shingles, Chapters 
5 and 6 highlighted its effect on chickenpox control. Chapter 5 demonstrated that chickenpox 
vaccination is very effective at reducing the overall chickenpox incidence and predicted, based 
on current estimates of primary and secondary vaccine failure that it would continue to remain 
effective into the future. However, chickenpox was not eradicated in our population, likely due 
to the sustained transmission of VZV from shingles and due to cases being imported from 
outside the model (exogenous infection). These findings illustrate a more optimistic future to 
chickenpox than previous models that tested the impact of chickenpox vaccination over time, and 
commonly predicted a steady increase in chickenpox cases years following vaccine 
implementation [3]. 
In general, we found that chickenpox vaccination was likely cost-effective in Alberta over 
a 75-year time-period. While we did observe that an increase in shingles incidence following 
vaccination could drastically reduce the cost-effectiveness of the chickenpox vaccine, this was 
highly dependent on the duration of immunity following boosting and waning of immunity rate 
for VZV. As we demonstrated in Chapter 4, there are many plausible values for duration of 
immunity following boosting and waning of immunity that led to only a small increase in 
shingles cases and had a minimal impact on the cost-effectiveness of the vaccine. Furthermore, 
the majority of model runs found that chickenpox vaccination would be cost-effective from the 
societal perspective, even when considering the impact on shingles. Our results were also highly 
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sensitive to the discounting rate for the benefits of vaccination as a lot of the gains, including the 
ultimate decrease in shingles cases, were observed many years following the implementation of 
the vaccine. These findings demonstrate that chickenpox vaccine may be cost-effective even 
when accounting for the impact on shingles.  
Perhaps more relevant to Canadian policy were our findings on the optimal chickenpox 
vaccine schedule. Our study in Chapter 5 found that schedule SDI, which administered the 
second dose chickenpox vaccination shortly after first dose (18 months instead of at 4-6years in 
schedule long dosing interval- LDI), resulted in significantly fewer breakthrough cases. The 
impact of schedule on overall chickenpox cases was less clear; however, 100% of paired model 
runs showed a lower chickenpox incidence with schedule SDI than schedule LDI. These findings 
may be important for policy makers considering the most effective way to implement the 
chickenpox vaccine. However, while we found that schedule SDI had lower costs and higher 
quality-adjusted life-years from the societal perspective (with no shingles), this was not a 
consistent finding across all model runs, with some runs showing schedule LDI as dominant. 
Therefore, while schedule SDI may be the better choice for countries setting up new chickenpox 
vaccination programs, policy makers may want to consider other factors when scheduling the 
chickenpox vaccine, including public perception, ease of schedule implementation/change and 
the impact of the schedule on other antigens included in the combination vaccine (e.g. measles, 
mumps, rubella – MMR). 
7.1.3. ABMs to inform policy-making 
To conduct all the experiments described in this thesis, we constructed one of the first 
ABMs for chickenpox and shingles infection and vaccination. We have made this model open 
source (Chapter 4 – Data Reference 1) so future researchers can use it to answer their own 
research questions. Agent-based modelling is a relatively new technique used in economic 
evaluations. However, this modelling technique can overcome previous economic evaluation 
modelling limitations, including linearity (i.e. the inability to account for externalities, 
unintended consequences), homogeneity (i.e. lack of consideration of individual-level 
differences that impact population-level disease outcomes) and stationarity (i.e. the fact that how 
people interact and move through a population determines the spread of disease) [6].  With only 
a few examples of economic evaluations using ABMs in the literature [7–10], the description 
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presented in this thesis as to how to use an ABM to calculate cost-effectiveness may prove useful 
to researchers considering similar modelling techniques for their own economic studies.  
7.1.4. Economic evaluations of vaccines in Canada 
By outlining the gaps, the important trends, and the key strengths and weaknesses in the 
economic evaluation of vaccines literature in Canada, Chapter 2 can serve as a guiding 
document on economic evaluation of vaccines in Canada for policy makers. Prior to this thesis, 
Canada, like most countries, had not reviewed and synthesized the literature on economic 
evaluations of vaccines, meaning they had very little knowledge of the coverage or quality of this 
research. As other countries start to produce similar evidence, comparing reporting strategies, 
methods and results between countries could prompt an international discussion on the major 
gaps in the literature and the quality of economic evaluations, and in doing so lead to 
improvements in the standardization and transparency of these studies. Furthermore, Canadian 
researchers can use this review to build upon past economic evaluations by addressing some of 
the gaps and weaknesses in the literature. As illustrated in Chapter 2, the number of vaccine-
related economic evaluations has substantially increased in the last few years. Cost-effectiveness 
analyses are being used increasingly to make decisions and recommendations around the 
implementation of, and funding for, vaccines in Canada. Therefore, it is important to ensure 
economic evaluations produced in Canada are transparent and of high quality. By outlining the 
current state of the research, including limitations, we can promote improvement in the 
usefulness, quality and applicability of vaccine-related economic evaluations and the decisions 
they inform.  
7.2. Thesis limitations 
7.2.1. Limitations of agent-based modelling  
Building an ABM is a complicated process, as it is time-consuming to create and run the 
model, and it is data-consuming (i.e. wide variety of detailed data is required to input into the 
model). Individual-level data is often difficult to extract from the literature; for instance, in our 
model we estimated the individual probability of primary and secondary chickenpox vaccine 
failure and then compared our model findings to the more readily available empirical data on 
population-based vaccine effectiveness. To obtain appropriate values for a range of parameter 
estimates in our model, we conducted a review of a wide variety of literature, including data on 
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Canadian and Albertan demographics (i.e. age-distribution, mortality, birth rates), VZV 
immunology, chickenpox and shingles epidemiology and healthcare utilization, as well as 
chickenpox vaccine effectiveness and coverage. As described in Chapters 4 and 5, our model 
required substantial testing and validation to ensure it was providing results similar to what was 
observed in the empirical data. Furthermore, debugging problems in the agent-based 
environment is often difficult and time-consuming [11].  
Moreover, the intricacies of an ABM model may make presenting results to policy-
makers difficult. However, ABMs in Anylogic® include some useful graphical features, for 
example a network diagram showing disease transmission (Appendix I), which allows users to 
observe a disease spreading from agent-to-agent during an outbreak and identify which agents 
are protected through vaccination. It is important users of ABMs use these graphical capabilities 
to present the methods and results of their model in an informative and accessible way.   
7.2.2. Limitations of economic evaluations 
It is important to note some of the limitations of economic evaluations as a decision-
making tool, particularly as they only tell one side of the story. In many instances, it is 
imperative that policy makers undertake other forms evaluations, including those studying the 
efficacy (can it work?); effectiveness (does it work?); equality/equity (does it work on everyone? 
How does it affect the most vulnerable?); and the availability (is it reaching those in need?) of 
the intervention [12]. Economic evaluations often do not account for the fact that costs and 
consequences of diseases and interventions vary among population groups (e.g. stratifying the 
cost-effectiveness by risk group), making consideration of the equity of the intervention 
particularly important. Russell et al. [13] found in Alberta prior to adding chickenpox to the 
universal vaccination schedule, there were disparities in chickenpox disease; specifically, those 
with lower socio-economic status (based on a SES-proxy measure) and First Nations individuals 
had higher chickenpox incidence rates. Following vaccination, there was a dramatic decrease in 
the disparities between high and low SES-proxy, suggesting publicly-funded vaccination may 
help reduce disparities [13]. However, they discovered chickenpox rates in First Nations 
individuals remained higher than other groups following vaccination, suggesting a lack of equity 
in the delivery and/or the uptake of the vaccine [13]. There was no evidence of differences in 
shingles incidence by SES-proxy [13].  
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Furthermore, productivity loss is valued differently across groups. For instance, there is the 
tendency to undervalue the impact of the disease on older or unemployed individuals. In our 
analysis older individuals were less likely to be part of the labour force and therefore disease in 
these individuals, while typically more severe, was associated with smaller productivity losses. 
Furthermore, over-emphasizing the importance of the cost-effectiveness of an intervention may 
result in a focus on diseases that are economically expensive but do not have a large impact on 
morbidity or mortality [14]. One could argue this is the case with chickenpox, as the aim of 
chickenpox vaccination is to reduce the incidence of a generally minor infection in a large 
number of people.  
7.3. Future work 
7.3.1. Economic evaluations post-vaccine implementation 
In Chapter 2 of this thesis we identified a lack of economic evaluations conducting post-
vaccine implementation as a limitation in the Canadian vaccine cost-effectiveness literature. The 
results of Chapter 5 and 6 on the effectiveness and cost-effectiveness of different chickenpox 
schedules demonstrates post-implementation studies can provide valuable information for 
researchers and policy makers looking to run an effective vaccination program.  Policy-makers 
and researchers can use post-implementation economic evaluations to ensure the current 
vaccination programs are run efficiently and effectively. For instance, more research is needed 
on the cost-effectiveness of providing a booster dose at different ages for pertussis in Canada, or 
the cost-effectiveness of a catch-up dose off the MMR vaccine in individuals who only received 
one dose. However, it may be difficult to find the political will to support these types of studies, 
as there is often resistance, both politically and publicly, to discontinuing a health intervention 
that is already provided by the government.  
7.3.2. Future applications of the chickenpox ABM 
The ABM outlined in this thesis could be used to answer a variety of research questions, 
including how changing contact patterns between agents alters the number and type of VZV 
boosting events, and what other factors influence an individual’s chance of developing shingles. 
Furthermore, our model could help identify other reasons for the observed increase of shingles 
incidence in the past few years [15,16]. There are many theories for why we may see this 
increase, including changes in shingles reporting, increases in the number of 
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immunocompromised individuals, and fewer contacts with chickenpox cases; our model could 
provide a platform to test these theories. Moreover, our ABM can study the effectiveness and 
cost-effectiveness of a wider variety of chickenpox vaccine schedules, taking into account the 
impact of different types of vaccines (MMRV vs. V) and adverse events (e.g. febrile seizures 
[17]), as well as vaccine uptake at different age groups.   
Moreover, even though we did not use shingles vaccination in any of the thesis 
experiments, the ABM includes a shingles vaccination statechart and shingles protected state, 
and it therefore has the capability to measure the effectiveness and cost-effectiveness of 
implementing a universal shingles vaccination program in Alberta. An important next step would 
be to update the research on the cost-effectiveness of herpes zoster vaccine in Canada [18], 
including the cost-effectiveness of the new shingles vaccines [19,20]. 
A future goal is to make our model available for policy makers to ask their own ‘what-if’ 
questions and to test the impact of their decisions prior to implementation. Modifying our ABM 
so that it is more user-friendly with an easy to use interface would make it more accessible to 
policy-makers and program administrators alike. A similar project is currently underway for a 
pertussis ABM with Alberta Health Services, so policy-makers can enter their own parameter 
values into the ABM and test different pertussis outbreak immunization response strategies to 
see their effectiveness at reducing the length and size of the pertussis outbreak [21].  
 Although not appropriate for all economic evaluations, ABM is a valuable tool for 
conducting cost-effectiveness studies, particularly where there is the potential for multiple 
externalities and indirect consequences of vaccination [6]. It may also be valuable where the 
contact network plays a crucial role in how a disease spreads, for instance in sexual transmitted 
diseases and tuberculosis. The choice of model type and structure is an important one, as studies 
show that it can play a significant role in the cost-effectiveness of the vaccine and can drastically 
change the results of the analysis [22]. However, researchers should balance the usefulness of 
agent-based modelling with the time and data requirements needed to build these complex 
models. Researchers should generally follow the recommendation of the Canadian Agency for 
Drugs and Technologies in Health that the modelling approach should be “no more complex than 
is necessary to address the decision problem” [22, p.19]. It is particularly important that 
researchers work together to build and update these models, so that one model can be used to 
inform many research questions. It is our hope that researchers and research groups will continue 
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to use our chickenpox and shingles ABM to answer questions relevant to policy makers and 
scientists alike.  
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APPENDIX B 
ADDITIONAL FILES CHAPTER 2 
 
Table B.1. Keyword search strategy to identify peer-reviewed articles 
Immunization keywords Economic evaluation keywords Canadian keywords 
Immunization 
Immunizations 
Immunisation 
Immunisations 
Immunized 
Immuni* program 
Immuni* programs 
Immuni* schedule 
Immunization, Secondary 
Mass Immuni* 
Vaccine 
Vaccines 
Vaccination 
Vaccinations 
Vaccinating 
Mass vaccination 
Vaccin* program 
Vaccin* programs 
Economic evaluation 
Economic evaluations 
Cost benefit 
Cost effective 
Cost effectiveness 
Cost utility 
Cost* 
Cost benefit analysis 
Cost benefit analyses 
Cost effectiveness analysis 
Incremental cost effectiveness 
Incremental cost utility 
Incremental economic evaluation 
Models, economic 
Cost saving* 
Cost of illness 
Cost and cost analysis 
Cost minimization 
Canada 
British Columbia* 
Alberta* 
Saskatchewan* 
Manitoba* 
Ontario* 
Quebec* 
Maritimes 
New Brunswick 
Nova Scotia 
Prince Edward Island 
PEI 
Northwest Territories 
Nunavut 
Yukon 
Toront* 
Calgar* 
Edmonton* 
Vancouver* 
Winnipeg* 
Ottawa* 
Halifax* 
Saskatoon* 
Regina 
Victoria 
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APPENDIX C 
FULL LIST OF PARAMETER VALUES FOR CHAPTER 4 
Parameter Values 
Total Population 500,000 
Population Density- Urban 0.03 
Population Density- Rural 0.02 
1st dose chickenpox vaccination On 
2nd dose chickenpox vaccination On 
ProbabilityOf1stDoseVaccination 0.97,0.75,0.03 
ProbabilityOf2ndDoseVaccination 0.979,0.821,0.333 
ProbabitlityOf1stDoseEffective 1-uniform (0.16,0.24) 
ProbabilityOf2ndDoseEffective 1-uniform (0.05,0.16) 
ProbabilityCatchupGivenVacc 0.55 
Weight_vacc_acceptor 65 
Weight_vacc_hesitator 30 
Weight_vacc_rejector 5 
Shingles Vaccination Off 
Exogenous Infection Rate 17.83 
Pref. Mixing Age 1-9 
Duration of exogenous boosting See different calibration experiments below 
Shingles connection range modifier 0.124 
Shingles waning coefficient See different calibration experiments below 
Probability of shingles reactivation 0.05 
Initialization EQ_NoVacc 
Enable bimodal shingles immunizing timer Checked 
Min_ageForDosAccel 0 
Max_ageForDosAccel 19 
ProbabilityOrDosAcc 0.05 
DurationCP Uniform (5,9) 
durationCPweak Uniform (4,8) 
probCPDisease on Contact 0.781 
probCPDiseaseOnContactWithShingle 0.2343 
probCPDiseaseOnContactWithBreakthrough 0.2343 
probBreaktrhoughCPDiseaseOnExposure 0.03 
timeToRecoveryCP Uniform (0,4) *day 
timeToNotInfectiousShingles Uniform (7,20) * day 
WaningOfImmunityRateShingles 0.04*waningOfImmunityCoefficientShingles 
shinglesRecurrenceRate Uniform (0.0022,0.0076) 
connectionRange_Pref 21.245 
connectionRange_Norm 8.958 
baseContactRate_Pref 20 
baseContactRate_Norm 3 
burnPeriod 75 years 
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Total Model Run 175 years 
 
Main experiment 1: 
Parameter Values 
Duration of Exogenous Boosting 5 years 
Shingles waning coefficient 0.63 
 
Main experiment 2: 
Parameter Values 
Duration of Exogenous Boosting 4 years 
Shingles waning coefficient 0.6 
 
Main experiment 3: 
Parameter Values 
Duration of Exogenous Boosting 6 years 
Shingles waning coefficient 0.68 
 
Main experiment 4: 
Parameter Values 
Duration of Exogenous Boosting 2 years 
Shingles waning coefficient 0.5 
 
Main experiment 5: 
Parameter Values 
Duration of Exogenous Boosting 3 years 
Shingles waning coefficient 0.55 
 
Main experiment 6: 
Parameter Values 
Duration of Exogenous Boosting 7 years 
Shingles waning coefficient 0.74 
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APPENDIX D 
ADDITIONAL FILES CHAPTER 4 
Table of contents 
1. Figure D-1. Simulated and empirical age-specific incidence rate for scenarios that met 
calibration with various duration of boosting and waning of immunity rates.  
2. Figure D-2. Simulated and empirical age-specific incidence rate for scenarios that did not 
met calibration with various duration of boosting and waning of immunity rates.  
3. Figure D-3. Simulated and empirical age-specific chickenpox incidence for different 
duration of boosting and waning of immunity, all scenarios that met calibration. 
4. Figure D-4. Number of shingles cases by age at time 10, 25, 50 and 7 by experiment.  
5. Figure D-5: Age distribution of shingles cases in baseline scenario 
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(A) 
B) 
(C) 
(D) 
(E) 
(F)
Figure D.1. Simulated and empirical age-specific incidence rate for scenarios that met calibration with 
various duration of boostings and waning of immunity rates (A) DoB= 2 years, WoI= 0.5 (B) DoB= 3 
years, WoI= 0.55 (C) DoB= 4 years, WoI= 0.6 (D) DoB= 5 years, WoI= 0.63 (E) DoB= 6 years, WoI= 0.68 
(F) DoB= 7 years, WoI= 0.74. (Blue polygons represent the min and max of the 30 simulated runs) 
 
 
 168 
(A) 
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(C) 
 
(D) 
 
 
 
 
Figure D.2. Simulated and empirical age-specific incidence rate for scenarios that did 
not met calibration with various duration of boostings and waning of immunity rates 
(A) DoB= 0.42 years, WoI= 0.45 (B) DoB= 8 years, WoI= 0.79 (C) DoB= 9 years, WoI= 
0.85 (D) DoB= 10 years, WoI= 0.93. (Blue polygons represent the min and max of the 30 
simulated runs) 
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(A) 
(B) 
(C) 
 
 
(D) 
(E) 
(F) 
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(G) 
(H) 
 
 
 
 
 
 
 
(I) 
(J) 
 
 
 
Figure D.3. Simulated and empirical age-specific chickenpox incidence for different duration of 
boosting and waning of immunity, all scenarios that met calibration (A) DoB= 0.42 years, WoI= 
0.45 (B) DoB= 2 years, WoI= 0.5 (C) DoB= 3 years, WoI= 0.55 (D) DoB= 4 years, WoI= 0.6 (E) DoB= 
5 years, WoI= 0.63 (F) DoB= 6 years, WoI= 0.68 (G) DoB= 7 years, WoI= 0.74 (H) DoB= 8 years, 
WoI= 0.79 (I) DoB= 9 years, WoI= 0.85 (J) DoB= 10 years, WoI= 0.93. (Blue polygons represent the 
min and max of the 30 simulated runs) 
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(A) 
(B) 
(C) 
(D) 
(E) 
(F) 
Figure D.4. Number of shingles cases by age at time 10, 25, 50 and 75 years by scenario (A) 
DoB= 2 years, WoI= 0.5 (B) DoB= 3 years, WoI= 0.55 (C) DoB= 4 years, WoI= 0.6 (D) DoB= 5 
years, WoI= 0.63 (E) DoB= 6 years, WoI= 0.68 (F) DoB= 7 years, WoI= 0.74 
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Figure D.5. Age distribution of shingles cases in baseline 
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APPENDIX E 
STATISTICAL TEST RESULTS TO DETERMINE THE ADEQUATE 
NUMBER OF RUNS FOR EACH EXPERIMENT 
 
Table E.1. Chickenpox incidence comparing two sets of 15 runs 
 
 
 
 
 
 
 
 
 
 
  
 
Wilcoxon Scores (Rank Sums) for Variable CP_Incidence 
Classified by Variable Run1 
Run1 N 
Sum of 
Scores 
Expected 
Under H0 
Std Dev 
Under H0 
Mean 
Score 
1 15 229.0 232.50 24.106445 15.266667 
2 15 236.0 232.50 24.106445 15.733333 
Average scores were used for ties. 
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Wilcoxon Two-Sample Test 
Statistic 229.0000 
Normal Approximation  
Z -0.1244 
One-Sided Pr <  Z 0.4505 
Two-Sided Pr > |Z| 0.9010 
t Approximation  
One-Sided Pr <  Z 0.4509 
Two-Sided Pr > |Z| 0.9018 
Z includes a continuity correction of 0.5. 
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Kolmogorov-Smirnov Test for Variable CP_Incidence 
Classified by Variable Run1 
Run1 N 
EDF at 
Maximum 
Deviation from Mean 
at Maximum 
1 15 0.133333 -0.516398 
2 15 0.400000 0.516398 
Total 30 0.266667  
Maximum Deviation Occurred at Observation 23 
Value of CP_Incidence at Maximum = 0.010344 
 
Kolmogorov-Smirnov Two-Sample 
Test (Asymptotic) 
KS 0.13333
3 
D 0.26666
7 
KSa 0.73029
7 
Pr > KSa 0.6604 
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Table E.2. Shingles incidence comparing two sets of 15 runs 
 
 
  
 
 
Wilcoxon Scores (Rank Sums) for Variable Shingles_Incidence 
Classified by Variable Run2 
Run2 N 
Sum of 
Scores 
Expected 
Under H0 
Std Dev 
Under H0 
Mean 
Score 
1 15 223.0 232.50 24.106445 14.866667 
2 15 242.0 232.50 24.106445 16.133333 
Average scores were used for ties. 
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Wilcoxon Two-Sample Test 
Statistic 223.0000 
Normal Approximation  
Z -0.3733 
One-Sided Pr <  Z 0.3544 
Two-Sided Pr > |Z| 0.7089 
t Approximation  
One-Sided Pr <  Z 0.3558 
Two-Sided Pr > |Z| 0.7116 
Z includes a continuity correction of 0.5. 
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Kolmogorov-Smirnov Two-Sample 
Test (Asymptotic) 
KS 0.10000
0 
D 0.20000
0 
KSa 0.54772
3 
Pr > KSa 0.9251 
 
 
 
 
Kolmogorov-Smirnov Test for Variable Shingles_Incidence 
Classified by Variable Run2 
Run2 N 
EDF at 
Maximum 
Deviation from Mean 
at Maximum 
1 15 0.40 0.387298 
2 15 0.20 -0.387298 
Total 30 0.30  
Maximum Deviation Occurred at Observation 11 
Value of Shingles_Incidence at Maximum = 0.004063 
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APPENDIX F 
FULL LIST OF PARAMETER VALUES FOR CHAPTER 5 
Parameter Values 
Total Population 500,000 
Population Density- Urban 0.03 
Population Density- Rural 0.02 
1st dose chickenpox vaccination On at 100 years 
2nd dose chickenpox vaccination On at 100 years 
Shingles Vaccination  Off  
ProbabilityOf1stDoseVaccination 0.97,0.75,0.03 
ProbabilityOf2ndDoseVaccination 0.979,0.821,0.333 
ProbabitlityOf1stDoseEffective 1-uniform (0.16,0.24) 
ProbabilityOf2ndDoseEffective 1-uniform (0.05,0.16) 
ProbabilityCatchupGivenVacc 0 
Weight_vacc_acceptor 65 
Weight_vacc_hesitator 30 
Weight_vacc_rejector 5 
WaningOfImmunityRateCPVacc Uniform (0.01,0.03) 
WaningOfImmunityRateCPVacc2ndDose 0 
riskPossibilityShinglesfromCPVacc 0.05 
probFebrileSeizure 0.0006 
Shingles Vaccination Off 
ageToCheck1stDoseCoverage  2 years 
ageToCheck2ndDoseCoverage 7 years 
Exogenous Infection Rate 17.83 
Pref. Mixing Age 1-9 
Duration of exogenous boosting 5  
Shingles connection range modifier 0.124 
Shingles waning coefficient 0.63 
Probability of shingles reactivation 0.05 
Initialization EQ_NoVacc 
Enable bimodal shingles immunizing timer Checked 
Min_ageForDosAccel 0 
Max_ageForDosAccel 19 
ProbabilityOrDosAcc 0.05 
DurationCP Uniform (5,9) 
durationCPweak Uniform (4,8) 
probCPDisease on Contact 0.781 
probCPDiseaseOnContactWithShingle 0.2343 
probCPDiseaseOnContactWithBreakthrough 0.2343 
probFullDiseaseOnBreakthroughInfection 0.05 
timeToRecoveryCP Uniform (0,4) *day 
probabilityOfComplicationDeathCP 0.000128 
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timeToNotInfectiousShingles Uniform (7,20) * day 
timeToRecoveryShingles Triangular (7,14,70) 
waningOfImmunityCoefficientShingles 0.63 
DurationOfExogenousBoosting 5 years 
WaningOfImmunityRateShingles 0.04*waningOfImmunityCoefficientShingles 
shinglesRecurrenceRate Uniform (0.0022,0.0076) 
connectionRange_Pref 21.245 
connectionRange_Norm 8.958 
baseContactRate_Pref 20 
baseContactRate_Norm 3 
burnPeriod 75 years 
discountingBegins 100 years (whenever we start vaccination) 
Total Model Run 175 years 
Sensitivity 1: Vaccine attitude 1 (high coverage)  
Parameter Values 
Weight_vacc_acceptor 80 
Weight_vacc_hesitator 15 
Weight_vacc_rejector 5 
Sensitivity 2: Vaccine attitude 2 (low coverage) 
Parameter Values 
Weight_vacc_acceptor 65 
Weight_vacc_hesitator 15 
Weight_vacc_rejector 20 
Sensitivity 3: Vaccine waning of immunity rate 1 
Parameter Values 
waningOfImmunityRateCPVacc 0.0 
waningOfImmunityRateCP2ndDose 0.0 
  
Sensitivity 4: Vaccine waning of immunity rate 2 
Parameter Values 
waningOfImmunityRateCPVacc 0.05 
WaningOfImmunityRateCPVacc2ndDose 0.02 
Sensitivity 5: Primary vaccine failure 1 
Parameter Values 
ProbabitlityOf1stDoseEffective 1-0.09 
ProbabilityOf2ndDoseEffective 1-0.05 
Sensitivity 6: Primary vaccine failure 2 
Parameter Values 
ProbabitlityOf1stDoseEffective 1-0.24 
ProbabilityOf2ndDoseEffective 1-0.16 
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APPENDIX G 
FULL LIST OF PARAMETER VALUES FOR CHAPTER 6 
General parameter sets: 
Parameter Values 
Total Population 500,000 
Population Density- Urban 0.03 
Population Density- Rural 0.02 
1st dose chickenpox vaccination On at 100 years 
2nd dose chickenpox vaccination On at 100 years 
Shingles Vaccination  Off  
ProbabilityOf1stDoseVaccination 0.97,0.75,0.03 
ProbabilityOf2ndDoseVaccination 0.979,0.821,0.333 
ProbabitlityOf1stDoseEffective 1-uniform (0.16,0.24) 
ProbabilityOf2ndDoseEffective 1-uniform (0.05,0.16) 
ProbabilityCatchupGivenVacc 0 
Weight_vacc_acceptor 65 
Weight_vacc_hesitator 30 
Weight_vacc_rejector 5 
WaningOfImmunityRateCPVacc Uniform (0.01,0.03) 
WaningOfImmunityRateCPVacc2ndDose 0 
riskPossibilityShinglesfromCPVacc 0.05 
probFebrileSeizure 0.0006 
Shingles Vaccination Off 
ageToCheck1stDoseCoverage  2 years 
ageToCheck2ndDoseCoverage 7 years 
Exogenous Infection Rate 17.83 
Pref. Mixing Age 1-9 
Duration of exogenous boosting 5  
Shingles connection range modifier 0.124 
Shingles waning coefficient 0.63 
Probability of shingles reactivation 0.05 
Initialization EQ_NoVacc 
Enable bimodal shingles immunizing timer Checked 
Min_ageForDosAccel 0 
Max_ageForDosAccel 19 
ProbabilityOrDosAcc 0.05 
DurationCP Uniform (5,9) 
durationCPweak Uniform (4,8) 
probCPDisease on Contact 0.781 
probCPDiseaseOnContactWithShingle 0.2343 
probCPDiseaseOnContactWithBreakthrough 0.2343 
probFullDiseaseOnBreakthroughInfection 0.05 
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timeToRecoveryCP Uniform(0,4) *day 
probabilityOfComplicationDeathCP 0.000128 
timeToNotInfectiousShingles Uniform (7,20) * day 
timeToRecoveryShingles Triangular (7,14,70) 
waningOfImmunityCoefficientShingles 0.63 
DurationOfExogenousBoosting 5 years 
WaningOfImmunityRateShingles 0.04*waningOfImmunityCoefficientShingles 
shinglesRecurrenceRate Uniform (0.0022,0.0076) 
connectionRange_Pref 21.245 
connectionRange_Norm 8.958 
baseContactRate_Pref 20 
baseContactRate_Norm 3 
burnPeriod 75 years 
discountingBegins 100 years (whenever we start vaccination) 
Total Model Run 175 years 
 
Cost Effectiveness Parameters Sets: 
Parameter Values 
qualityOfLifeBaseUnder50 0.855 
qualityOfLifeCPUnder15 0.76 
qualityOfLifeCPOver15 0.67 
qualityOfLifeWeakUnder50 0.83 
qualityOfLifeWeakOver50 0.76 
qualityOfLifeShingles 0.59 
qualityOfLifePHN 0.67 
qualityOfLifeHospitalizedCP 0.36 
qualityOfLifeHospitalizedShingle 0.32 
probGPVisitCP 0.4 
probGPVisitCPWeak 0.4 
probGPVisitShingles 1.0 
probEDVisitCP 0.035 
probEDVisitShingle 0 
tableFunctionChanceOfPHNByAge 0-48: 5% 
49-60: 14.6% 
61-70: 20.5% 
70+: 33.8% 
CustomDistributionPHNDuration 90-120 days: 25% 
120-356 days:  50% 
356-700 days: 25% 
 
probabilityOfComplicationDeathShingle 0.000154 
costProductivityLossCP 280.84 
costProductivityLossHospitalized 224.1 
costProductivityLossShinglesUnder50 666.44 
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costProductivityLossHospitalizedShinglesUnder50 147.01 
costProductivityLossPHNUnder50 1720.99 
costProductivityLossShinglesOver50 345.41 
costProductivityLossHospitalizedShinglesOver50 76.19 
costProductivityLossPHNOver50 891.98 
costPersonalExpenseCPUnder4 105.60 
costPersonalExpenseCPOver4 43.84 
costPersonalExpenseShingle 84.86 
costGPVisitCP 40.96 
costEDVisitCP 139 
costGPVisitShingle 84.95 
costEDVisitShingle 139 
costPerPrescriptionMedCP 0.75 
costPerPrescriptionMedShingle 58.31 
CostShingleVacc 0 
CostCPVaccDose1 55.22 
CostCPVaccDose2 55.22 
costPerDayHospitalizedCP 1523 
costPerDayHospitalizedShingle 929.81 
tfFracHospitalizedCPbyAge 0-1 = 1.8% 
2-4 = 0.4% 
5-11 = 0.2% 
12-18= 0.4% 
19-24 = 0.5% 
25-44 = 1.4% 
45-64 = 1.9% 
65+ = 7% 
tfLOSHospitalizedbyAge <1 = 2.92 
1-4 = 3.23 
5-9 = 4.30 
10-14 = 5.13 
15-19 = 8.86 
20+ = 5.70 
tfFracHospitalizedShinglebyAge 0-4: 0.0055 
5-14: 0 .0035 
15-44: 0.0028 
45-64: 0.007 
65+: 0.0265 
tfLOSHospitalizedShinglebyAge 0-4: 5.1 days 
5-14: 4.6 days 
15-44: 8 days 
45-64: 11.6 days 
65+: 20 days 
costFebrileSeizures 139 
DiscountRateQALY 1.5 
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DiscountRateCosts 1.5 
 
 
Sensitivity 1: Vaccine attitude 1 (high coverage)  
Parameter Values 
Weight_vacc_acceptor 80 
Weight_vacc_hesitator 15 
Weight_vacc_rejector 5 
Sensitivity 2: Vaccine attitude 2 (low coverage) 
Parameter Values 
Weight_vacc_acceptor 65 
Weight_vacc_hesitator 15 
Weight_vacc_rejector 20 
Sensitivity 3: Low vaccine waning of immunity rate  
Parameter Values 
waningOfImmunityRateCPVacc 0.0 
Sensitivity 4: Low vaccine waning of immunity rate  
Parameter Values 
waningOfImmunityRateCPVacc 0.05 
WaningOfImmunityRateCPVacc2ndDose 0.02 
Sensitivity 5: Primary vaccine failure low 
Parameter Values 
ProbabitlityOf1stDoseEffective 1-0.09 
ProbabilityOf2ndDoseEffective 1-0.05 
Sensitivity 6: Primary vaccine failure high 
Parameter Values 
ProbabitlityOf1stDoseEffective 1-0.24 
ProbabilityOf2ndDoseEffective 1-0.16 
Sensitivity 7: No discounting the benefits 
Parameter Values 
ProbabitlityOf1stDoseEffective 1-0.09 
Sensitivity 8: Shorter duration of boosting 
Parameter Values 
Duration of Exogenous Boosting 2 years 
Shingles waning coefficient 0.5 
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APPENDIX H 
FIGURES FROM SCENARIO ANALYSES CHAPTER 6 
 
 
1Low attitude= shifting 15% of vaccine hesitant individuals to rejectors (low coverage); High attitude= shifting 15% of vaccine hesitant individuals to acceptors 
high coverage) 
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1No waning= 0% waning of chickenpox vaccine immunity; high waning= 5% waning of chickenpox vaccine immunity 
1Low primary vaccine failure 1st dose= 9 and 2nd dose= 5%; high primary vaccine failure 1st dose= 24% and 2nd dose= 16%.  
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1Duration of boosting = 2 years and waning of immunity rate = 0.45; 2No discounting of quality adjusted life years; therefore one QALY in the present is equal to 
one QALY in the future.  
 
Figure H.1. Scenario analysis cost-effectiveness plane -Median incremental costs and QALYs per capita by scenario with 
shingles (societal perspective) 
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1Low attitude shifting 15% of vaccine hesitant individuals to rejectors (low coverage); High attitude shifting 15% of vaccine hesitant individuals to acceptors 
(high coverage)
 
1No waning= 0% waning of chickenpox vaccine immunity; high waning= 5% waning of chickenpox vaccine immunity 
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1Low primary vaccine failure 1st dose= 9 and 2nd dose= 5%; high primary vaccine failure 1st dose= 24% and 2nd dose= 16%.  
Figure H-2. Scenario analysis cost-effectiveness plane -Median incremental costs and QALYs per capita by scenario without 
shingles (societal perspective) 
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APPENDIX I 
NETWORK DIAGRAM 
 
 
 
Centre Colour 
Green= Susceptible 
Light Blue= Recovered 
Red= Infected 
Outside Colour 
Blue= Protected through 1st dose vaccination 
Dark Green= Protected through 2nd dose vaccination 
Yellow= Not protected 
 
*Black lines between agents signify connections 
